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 Opioid use and dependence have increased dramatically since the early 2000s. As of 2013, an 
estimated 2.4 million people were considered to be dependent on opioids. Medication assisted 
treatment (MAT), such as methadone and buprenorphine, is the most effective form of treatment for 
opioid dependence; yet, since 2002, MAT use has decreased steadily.  
 Medicaid is the largest purchaser of MAT in the United States; however, Medicaid coverage of MAT 
varies by state. As of 2008, fourteen states did not cover either methadone or buprenorphine, or both. 
This dissertation examines the factors associated with Medicaid coverage of methadone and 
buprenorphine, and explores the impact of this coverage on the length of time individuals waited to 
enter substance use treatment, and the extent to which Medicaid coverage of methadone is associated 
with MAT utilization. 
This dissertation utilized a combination of individual-level, program-level and state-level data. 
Individual-level data came from the Treatment Episodes Data Set-Admissions (TEDS-A). Program-level 
data were obtained from the Uniform Facility Data Set (UFDS) and the National Survey of Substance 
Abuse Treatment Services (N-SSATS). State-level data regarding Medicaid coverage of MAT were 
obtained from three sources: (1) McCarty et al’s study, “Methadone Maintenance and State Medicaid 
Managed Care Programs”; (2) Ducharme at al’s study, “State policy influence on the early diffusion of 
buprenorphine in community treatment programs”; and, (3) the State Financing for Medication Assisted 
Treatment study.  
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The main findings of this study indicate that state wealth is correlated with Medicaid coverage of 
MAT, Medicaid coverage of MAT is associated with an increase in treatment wait time and Medicaid 
coverage of methadone is associated with greater odds of MAT use. This dissertation did not include any 
analyses since the passage of the Patient Protection and Affordable Care Act (PPACA), which in 2014, 
required that all public and private health insurance programs cover substance use treatment services. 
While this prioritization will undoubtedly increase access to substance use treatment, not all services 
must be covered. Given this, variability in the accessibility of treatment will likely persist. Further 
research should continue to monitor the accessibility and utilization of substance use treatment, with 
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Chapter 1: Introduction and Objectives 
 Dependence on opioids, including heroin and prescription pain relievers, has increased significantly 
in the United States over the last decade.1 Between 2002 and 2013, the number of individuals 
considered to be opioid dependent grew 41% from approximately 1.7 million to 2.4 million people.2,3 As 
opioid dependence has increased, so has the utilization of substance use treatment services. Between 
2002 and 2012, the proportion of admission to substance use treatment programs for individuals 
reporting opioid use increased from 18% to 26%.1  
 Broadly speaking, there are two types of treatment for opioid dependence: (1) drug-free 
inpatient/outpatient, which includes inpatient hospitalization and rehabilitation programs, as well as 
outpatient programs such as 12-step programs; and, (2) medication assisted treatment (MAT), which 
included methadone and buprenorphine. MAT is the most effective form of substance use treatment for 
opioid dependence.4,5 MAT, such as methadone and buprenorphine, suppresses the analgesic effect that 
opioids produce, as well as reduces withdrawal symptoms associated with opioid dependence.6 Despite 
evidence supporting MAT as the most effective form of treatment for opioid dependence, only 28% of 
heroin dependent individuals and 18% of other opioid dependent individuals used MAT in 2012.1  
 In the United States, Medicaid beneficiaries represent the largest group of opioid dependent 
individuals, and Medicaid is the largest purchaser of buprenorphine and methadone.7,8 As a result, 
Medicaid coverage of opioid treatment services has the potential to impact a large proportion of 
individuals with opioid dependence in the United States.  As a combined state/federal program, state 
Medicaid programs have significant latitude in determining coverage for optional benefits, including 
some types of substance use treatment. As a result, Medicaid coverage of substance use treatment 
services varies significantly by state.  For MAT, state variability ranges from full, unrestricted coverage, 
to partial coverage which includes restrictions such as pre-authorization requirements or lifetime limits 
on MAT use, and in some states, neither methadone nor buprenorphine are covered at all.9   
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This study seeks to gain a better understanding of the factors that influence Medicaid coverage of 
MAT, and whether coverage of MAT is associated with increased access to methadone and 
buprenorphine treatment. To understand the factors that influence Medicaid coverage of MAT, I 
examine two main categories of predictors: economic and need factors. Examples of economic factors 
include: state Federal Medical Assistance Percentages (FMAP) rate, percent of total residents that are 
Medicaid beneficiaries, per capita income, state expenditures, and the amount of funding that is 
received through federal block grants for substance use treatment services. Need factors include the 
number of substance use treatment facilities and the number of opioid dependent individuals in each 
state.  
To gain a better understanding of the relationship between Medicaid coverage of MAT and the 
accessibility of substance use treatment for opioid dependent individuals, I examine the associations 
between Medicaid coverage of methadone and buprenorphine and the amount of time individuals 
seeking treatment are required to wait prior to treatment entry, as well as Medicaid coverage of 





Dissertation Specific Aims 
The specific aims for this dissertation project are:   
 
Aim 1:  Identify state-level factors that are correlated with Medicaid coverage of methadone and 
buprenorphine   
 Aim 1a:   
Assess whether state-level economic factors such as Federal Medical Assistance Percentages 
(FMAP), percent of total residents that are Medicaid beneficiaries, per capita income, and 
amount of funding received through federal block grants for substance use treatment services 
are correlated with Medicaid coverage of methadone and buprenorphine. 
 Aim 1b:   
Assess whether the need for opioid treatment, measured by the number of substance use 
treatment facilities and the number of opioid dependent individuals, is correlated with Medicaid 
coverage of methadone and buprenorphine.  
 
Aim 2: Determine whether individuals enrolled in substance use treatment in states with Medicaid 
coverage of methadone or buprenorphine experience decreased wait times for substance use 
treatment entry, as compared with individuals enrolled in substance use treatment in states 
with no Medicaid coverage of methadone or buprenorphine. 
 
Aim 3: Determine whether opioid dependent individuals seeking substance use treatment in states with 
Medicaid coverage of methadone are more likely to utilize medication assisted treatment, as 
compared to opioid dependent individuals seeking substance use treatment in states without 




The following paragraph provides an overview of the chapters included in this dissertation. 
In Chapter 2, Background and Significance, I provide a review of the literature related to each study 
aim. I also include an overview of the public health burden of opioid dependence, current treatments for 
opioid dependence and Medicaid coverage of MAT. In Chapter 3, Data and Measures, I describe the data 
sources used in each aim of this study, the methods for creating the analytic samples and the methods 
used to handle missing data. In Chapter 4, I review the theoretical framework used to guide the 
construction of Aim 1 and the addition of state-level predictor variables utilized in Aims 2 and 3. In 
Chapters 5, 6 and 7, I describe the findings from each of the three analyses. Finally, in Chapter 8, I 
review the limitations of the study, synthesize the findings across study aims and discuss the relevance 
of these findings within the policy context of current day Medicaid coverage of substance use treatment 




Chapter 2: Background and Significance 
 This dissertation has two primary objectives: (1) to understand the factors associated with state 
Medicaid coverage of methadone and buprenorphine, the primary medications used to treat opioid 
dependent individuals; and, (2) to demonstrate the impact of this coverage on the accessibility of 
substance use treatment. To achieve this, three separate analyses have been conducted. The first 
analysis, described in greater detail in Chapter 5, examines the association between state-level factors 
representing the economic situation of the state and the need for treatment within a state, and 
Medicaid coverage of methadone and buprenorphine. The remaining two analyses focuses on 
understanding the impact of Medicaid coverage of methadone and buprenorphine on individuals 
seeking substance use treatment. The first of these two analyses, described in detail in Chapter 6, 
investigates the association between Medicaid coverage of methadone and buprenorphine (examined 
separately) and the amount of time individuals wait to enter substance use treatment. The second 
analysis, detailed in Chapter 7, explores the association between Medicaid coverage of methadone and 
the utilization of MAT. 
 This chapter provides an overview of the literature related to these analyses, including the public 
health significance of opioid dependence in the United States, a review of treatment for opioid 
dependence, with a detailed description of MAT, and a review of the current literature regarding 
utilization of MAT in the United States. 
 
Public Health Burden of Opioid Dependence 
Opioid dependence, whether the result of nonmedical use of prescription opioids such as 
Oxycodone and Hydrocodone, or heroin use, poses a significant public health problem in the United 
States as it has been linked to drug overdose, polydrug use, sexual risk behaviors for HIV and other 
infectious diseases, and injection drug use.10–15 In 2013, 4.5 million Americans reported nonmedical use 
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of prescription opioids within the previous twelve months, the second most frequently used illicit drug 
category behind marijuana.16  
While nonmedical use of prescription opioids remains significant, recent trend data indicate that it is 
decreasing in the United States.16 Heroin use, however, has been steadily increasing.17–20 Between 2007 
and 2013, there was a consistent increase in heroin use (within the past year) among persons 12 years 
or older.16 Evidence suggests that the concurrent increase in heroin use and decrease in nonmedical 
prescription opioid use is the result of two factors: changes to the formulation of prescription opioids 
that made it more difficult to crush, and therefore inject and/or inhale prescription opioids, and the 
transition from nonmedical prescription opioid use to heroin use among prescription opioid dependent 
individuals.21–23 Similar to prescription opioids, heroin dependence has significant health consequences, 
including HIV and hepatitis C infection, drug overdose, injection drug use, bacterial and soft tissue 
infections such as endocarditis and cellulitis, as well as unsafe sex and drug behaviors.24–31  
Opioid dependence, whether the result of prescription opioid or heroin use, carries a significant 
monetary cost. Health care costs associated with opioid dependence are considerable, at approximately 
$25 billion, and the overall societal costs due to opioid dependence, including health care costs, 
incarceration and workplace costs such as lost employment, are estimated at $55.7 billion.32  
 
Treatment for Opioid Dependence 
The increase in heroin use and continued high rate of nonmedical use of opioids in the United States 
has resulted in a substantial increase in the use of substance use treatment. Between 2002 and 2013, 
the number of individuals seeking treatment for heroin increased from 277,000 to 526,000 and from 
360,000 to 746,000 for prescription opioid users.16  
Broadly speaking, there are two main categories of treatment currently available for opioid 
dependence: drug-free inpatient/outpatient treatment, which includes inpatient therapeutic 
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communities and outpatient support groups (primarily focused on abstinence); and medication-assisted 
treatment (MAT), which includes methadone, buprenorphine and naltrexone. Of these forms of 
treatment, methadone and buprenorphine are the most effective approach to treating opioid addiction. 
These two treatments are the focus of this dissertation.4,5  
 
Medication Assisted Treatment 
Opioids stimulate feelings of euphoria, drowsiness and decreased anxiety by binding to and 
activating opioid receptors in the body.33 Medications used to treat opioid dependence are classified by 
their effect on these receptors. Opioid agonists, such as heroin, codeine and methadone, both bind to 
and activate these receptors, allowing users to experience feelings of euphoria.33 Opioid antagonists 
such as naloxone also bind to these receptors, but they block the euphoric effects of these drugs, and 
have the potential to reverse the effects altogether.34 Naloxone, for example, is used to reverse opioid 
overdoses by removing opioid agonists from these receptor sites, effectively putting the patient in a 
state of withdrawal. Finally, between the categories of agonists and antagonists are partial agonists, 
such as buprenorphine. Partial opioid agonists bind to opioid receptors, providing some agonist effects 
but these effects are limited by the antagonist properties.34  
Methadone and buprenorphine are particularly effective at suppressing withdrawal symptoms, due 
to their agonist properties, while simultaneously creating blocking effects for other opioids, such as 
heroin.35 These medications create a tolerance to opioids which, over time, lessens the effect of other 
opioids.36 This quality is an important benefit for the treatment of opioid dependence because it can 
reduce the likelihood of sustained or increased use of other opioids.  
Methadone and buprenorphine have long half-lives, or lasting effects, making them ideal for the 
treatment of opioid dependence. Heroin has a half-life of approximately two to three hours, at which 
point opioid receptors begin to empty and the user begins to feel symptoms of withdrawal. In contrast, 
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the half-life of methadone ranges from 16-48 hours and approximately 24 hours for 
buprenorphine.33,36,37 The extended half-lives of these medications make them particularly effective at 
reducing cravings by staving off withdrawal symptoms between doses. 
Both methadone and buprenorphine can be used in detoxification and maintenance treatment. 
Methadone maintenance, as compared with inpatient detoxification, has been shown to retain patients 
for longer durations and is associated with significantly less heroin use than individuals utilizing inpatient 
detoxification.5 Additionally, methadone maintenance treatment has been associated with reductions in 
HIV incidence, mortality, injection drug use, syringe sharing, and slower progression of HIV disease, and 
is safe for treating opioid dependence in pregnant women.38–46 Buprenorphine, while not as effective as 
methadone treatment overall, is more effective at retaining heroin users in substance use treatment 
than users receiving a placebo.4,47,48 
 
MAT Provision and Utilization 
In the United States, methadone is administered through opioid treatment programs (OTPs) that are 
certified and regulated by the Substance Abuse and Mental Health Services Administration (SAMHSA).49 
OTP regulations are strict, particularly regarding the frequency of methadone dosing, requiring most 
patients to report to the clinic for dosing five to six days per week.50 This highly regulated environment is 
considered, by some, to be stigmatizing and a barrier to recovery.51–53 
 Given the restrictive nature of methadone provision in the United States, the approval of 
buprenorphine for the treatment of opioid dependence in office-based settings was ground-breaking. In 
2000, President Bill Clinton signed the Drug Addiction Treatment Act of 2000 (DATA 2000), a bill that 
allowed for the expansion of medication assisted treatments to outpatient settings beyond methadone 
maintenance treatment programs. Two years later, buprenorphine was approved by the Food and Drug 
Administration for the treatment of opioid dependence. In addition to office-based settings, 
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buprenorphine can also be provided at methadone clinics and community based treatment programs by 
qualified physicians.54 Evidence suggests that buprenorphine users are demographically different than 
methadone users, and include individuals residing in rural areas and users of prescription opioids, two 
factors which may help to expand the reach of MAT.55  
Both the provision of MAT by substance use treatment programs and providers and the utilization of 
MAT by opioid dependent individuals is limited in the United States.9,49,55–58 In 2010, 8% of all substance 
use treatment facilities in the United States provided MAT, and these programs served approximately 
one-quarter of all individuals attending substance use treatment.59 Further, despite the increase in the 
use of substance use treatment among opioid dependent individuals over the last decade, MAT use 
decreased by 7%.1  
Low MAT utilization is influenced by factors at several levels, including those related to individuals, 
organizations/providers as well as systems-level factors. At the individual-level, cocaine injecting or 
crack smoking60,61, homelessness62, recent or previous incarceration61,62, injection drug use60–62, previous 
negative experiences with MAT63–65, stigma associated with MAT, particularly methadone65–69 and the 
punitive treatment structure of methadone programs70 have been negatively associated with MAT 
utilization. Individual-level factors found to be positively associated with MAT use include being 
female61,62,71, married71, having Medicaid coverage62, heroin use60,62,64, older age61,62 and having 
previously been in substance use treatment60,71. 
The literature regarding the factors associated with the availability of MAT is largely focused on 
organizational-level factors of substance use treatment facilities. Factors positively associated with MAT 
provision include large organizational size54,72,73, receipt of public funding54,58,72, awareness of Medicaid 
and/or state contract policies regarding coverage74, having a physician on staff58,72, public versus private 
ownership54,72, and whether the program is located within a hospital setting54,73,75.  In contrast, negative 
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staff perceptions of methadone and/or buprenorphine and treatment ideology, particularly those that 
follow 12-step philosophy, have been negatively associated with MAT provision.76–78  
Provider-level barriers regarding the dispensing of MAT in the United States are focused on 
buprenorphine given that methadone can only be dispensed in certified substance use treatment 
facilities. Barriers to providing buprenorphine, as cited by potential or actual buprenorphine providers, 
include: insurance coverage/reimbursement concerns79–81, negative perceptions of substance users 
and/or buprenorphine81–83, lack of expertise or necessary training79–81,84–86, lack of time79,81,83,85and lack 
of support79–81,84,85,87.  
Finally, the perspective least explored is the role of systems or state-level factors in methadone or 
buprenorphine provision, which is part of the focus of this dissertation. Factors such as local zoning 
restrictions that prohibit mobile dispensing of methadone and/or buprenorphine88,  lack of support by 
state agencies for methadone and/or buprenorphine74,88, lack of state Medicaid coverage of methadone 
and/or buprenorphine54,89 and buprenorphine prescribing regulations that require pre-authorization by 
some insurance companies88 have all been found to be negatively associated with MAT provision. Two 
important positive associations must be noted, both of which have been found in research investigating 
the adoption of naltrexone. Both higher state public assistance expenditures (per capita) and the 
prevalence of alcohol abuse or dependence were positively associated with naltrexone adoption.89 
These findings suggest that states with a greater need for substance use treatment and those that are 
more invested in safety net programs are more likely to adopt naltrexone. These findings are novel and 
have yet to be explored with respect to methadone and buprenorphine provision.  
The findings regarding state-level barriers and facilitators of methadone and buprenorphine 
demonstrate the important role that states play in setting the tone for the way these treatments are 
perceived. States have the authority to direct public funds toward or away from treatment programs; 
therefore, a state’s endorsement (or rejection) of a given treatment modality or approach  can have 
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significant impact on the extent to which substance use treatment programs adopt treatment options 
such as methadone and buprenorphine. To date, we are unaware of any research that has investigated 
the relationship between structural factors such as Medicaid coverage of MAT, and the use of MAT by 
opioid dependent individuals. 
 
Treatment Wait Time 
Chapter 6 describes the findings from an analysis of the factors associated with substance use 
treatment wait time entrance and Medicaid coverage of methadone and buprenorphine. This analysis 
was not limited to individuals receiving treatment in programs providing MAT; rather, this association 
was explored among individuals across all modalities of substance use treatment. Therefore, this section 
provides a review of the literature related to wait time across substance use treatment modalities. 
  Treatment wait time is often reported as one of the most significant barriers to enrolling in 
substance use treatment.90–94 The average time individuals wait to enter substance use treatment 
ranges from zero days, particularly in cities such as San Francisco and Baltimore that employ a treatment 
on demand model95, to one week96–99, 3 weeks100,101 and over one month91,96,102,103. Delays in treatment 
entry have been associated with a lack of treatment enrollment91,104,105, shorter periods of treatment 
engagement98, an increased risk of mortality106, arrest107, untreated psychiatric problems108, HIV109, and 
a return to or initiation of injection drug use (IDU)110. Finally, an inverse relationship between wait time 
and treatment entry has been observed in several studies, such that the longer a person waits to enter 
treatment, the less likely they are to enroll in it.92,95,111–113  
Methadone, in particular, has been associated with an increase in waiting time for treatment 
entry.114–116 Andrews et al found that individuals initiating methadone treatment were three times more 
likely to wait one month or more to enter treatment as compared with individuals waiting to enter other 
outpatient programs.116 Gryczynski et al also found significant delays for individuals seeking methadone 
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treatment, as compared with other treatment modalities. In their study, less than one quarter of 
individuals enrolling in methadone treatment were able to begin treatment within four months of 
initiating contact with a program.103  
The literature regarding substance use treatment wait time is largely focused on factors related to 
individuals and organizations. Individual-level factors such as unemployment96, homelessness96, being 
African American103,116, cocaine use103,106 and psychiatric problems103 have all been associated with 
longer wait times for treatment entry. The associations between age96,106,117 and gender 100,102,105 and 
treatment wait time have been inconsistent. 
Organizational factors, particularly regarding program inefficiencies, are believed to contribute most 
significantly to wait times.90,98,118–121 In fact, in the Treatment Episodes Data Set (TEDS), which was the 
main dataset utilized for the analysis of wait time, substance use treatment programs were directed to 
calculate treatment wait times as “the number of days the client must wait to begin treatment because 
of program capacity, treatment availability, admissions requirements, or other program requirements. It 
should not include time delays caused by client unavailability or client failure to meet any requirement 
or obligation”.122 Specific organizational factors associated with delays to treatment entry include larger 
client caseload96,123, staff shortages,92 provision of methadone116, inefficient phone scheduling systems99, 
central intake units94 and increased proportion of clients receiving public assistance123; whereas for-
profit programs117, programs with an increased number of patients attending daily96 and programs with 
performance contracting101, or financial incentives for improvement in patient outcomes or 
organizational efficiencies, have been associated with reduced treatment wait times. 
Structural level factors have been the least explored with regard to treatment wait times. Factors 
such as bureaucratic delays related to processing court-ordered treatments94,96 and a lack of insurance94 




Medicaid Coverage of Methadone and Buprenorphine 
Medicaid is a combined federal/state program that provides health insurance for low-income 
individuals and families. The federal government offers guidelines to states regarding the extent to 
which medical services and medications should be covered by Medicaid. Ultimately, however, each state 
creates their own eligibility requirements, as well as coverage parameters for medical care and 
medications.124 Prior to 2014, substance use treatment was considered an optional benefit under 
federal Medicaid guidelines, meaning that states were not required to cover it beyond detoxification. As 
a result, there was significant state variability in the extent to which substance use treatment was 
covered, particularly regarding methadone and buprenorphine. In some states, for example, neither 
buprenorphine nor methadone was covered by Medicaid; however, in other states Medicaid covered 
one or both medications as long as they were provided in specific settings or after physicians obtain pre-
approval. As of 2008, the most recent year utilized in the analyses for this dissertation, 19 states had 
some form of restriction on the coverage of buprenorphine and/or methadone.9  
Medicaid is the largest purchaser of both buprenorphine and methadone and Medicaid beneficiaries 
represent the largest group of opioid dependent individuals in the United States.7,8 According to the 
National Survey on Drug Use and Health (NSDUH), approximately 14% of Medicaid beneficiaries have a 
substance use disorder, as compared with 10% of the general population.125 Given this, Medicaid 
coverage of substance use treatment services has the potential to impact a significant number of 
individuals in the United States. In the remaining chapters of this dissertation, the results of three 
analyses will be presented related to Medicaid coverage of MAT, including (1) the factors correlated 
with Medicaid coverage of MAT, (2) the association between Medicaid coverage of methadone and 
buprenorphine and treatment wait time, and (3) the association between Medicaid coverage of 




Chapter 3: Data and Methods 
 This dissertation includes both state-level (Aim 1) and individual-level (Aims 2 and 3) analyses of 
datasets that were compiled using multiple sources. In this chapter, I provide a description of each 
dataset, including a detailed explanation of each data source and the variables contained within, a 
description of how each analytical sample was created and the techniques used to handle missing data 
and the validation of study findings. 
 
Data Sources and Variable Description 
Individual-level Data 
 The primary data source for this dissertation was the Treatment Episodes Dataset-Admissions 
(TEDS-A). The TEDS-A is an administrative data set composed of annual admissions of individuals 12 
years of age and older to substance use treatment programs in the United States that are licensed or 
certified by State agencies.126 TEDS-A is primarily composed of admissions to substance use treatment 
programs that receive public funds; however, some states also require non-publicly-funded programs to 
report demographic and treatment-related data, and therefore may be included in TEDS-A. Substance 
use treatment programs that are not likely to be contained within TEDS-A include programs that are not 
licensed by the State, including some hospitals, private-for-profit programs and programs operated by 
the Bureau of Prisons, the Department of Defense and the Veterans Administration.126 
 TEDS-A data are publicly available for download through the Substance Abuse and Mental Health 
Data Archive (SAMHDA), which is maintained by SAMHSA and available through the Institute for Social 
Research (ISR) website at the University of Michigan.127  TEDS-A includes a mixture of self-reported and 
program-reported demographic characteristics such as gender, age group, race/ethnicity, among other 
variables, and treatment-related variables such as substances of abuse, substance use treatment history 
and treatment program type. While TEDS-A provides individual-level data for substance use treatment 
15 
 
episodes, these data describe encounters with substance use treatment, rather than individual clients. 
For example, if the same individual has entered substance use treatment four times within a calendar 
year, there will be four separate treatment episodes counted in TEDS-A, not one.  
 
 TEDS-A Variables 
 All individual-level variables in Aims 2 and 3 came from the TEDS-A. Below is a description of each 
variable, as well as an explanation of any recodes that were made to them. 
 
TEDS-A – Independent Variables 
Age: When initially collected by programs, age was a continuous variable. However, when the TEDS-A is 
cleaned for public use, SAMHDA recodes age into a categorical variable in order to protect the ages of 
the youngest and oldest individuals in substance use treatment.  The resulting age categories by years 
are: 12-14, 15-17, 18-20, 21-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55 and over.  
 In Aim 2, based on the age distribution of the sample, age was recoded and dummy coded in the 
following manner: Less than 18, 18-24, 25-34, 35-44 and 45 and over. In Aim 3, based on the distribution 
of the sample, which had fewer very young individuals, age was recoded and dummy coded as: Less 
than 25, 25-34, 35-44 and 45 and over. 
Male: In the original dataset, sex was coded as 1 for males and 2 for females. Sex was recoded for all 
analyses in this dissertation to female=0 (referent group) and male=1. 
Race: The original race variable included 9 categories: Alaska Native, American Indian, Asian or Pacific 
Islander, Black or African American, White, Asian, Other single race, Two or more races (only for 2006 
and 2008 TEDS-A), Native Hawaiian or other Pacific Islander. Based on the distribution of the sample, 
race was dummy coded into three main categories: White (referent group), Black and Other Race(s). 
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Hispanic: TEDS-A provided 6 options for ethnicity: Puerto Rican, Mexican, Cuban, Other specific 
Hispanic, Not of Hispanic Origin and Hispanic, specific origin not specified. Ethnicity was dummy coded 
into a binary variable where Puerto Rican, Mexican, Cuban, Other specific Hispanic and Hispanic, specific 
origin not specified became Hispanic=1, and individuals not of Hispanic origin were coded as Hispanic=0 
(referent group).  
Married: Marital status contained 4 original categories: never married, now married, separated and 
divorced/widowed. Based on the distribution of these categories, marital status was recoded into a 
binary variable where never married and divorced/widowed became married=0 (referent group) and 
married and separated individuals became married=1. 
 Marital status was a supplemental variable in TEDS-A, and therefore was not reported by every 
program. In the final Aim 2 dataset, before any missing data techniques were used, the largest amount 
of missing data for marital status in any one year or combined year, for either methadone or 
buprenorphine, was 27%. In the final Aim 3 dataset, before any missing data techniques were employed, 
the largest amount of missing data for marital status in any of the methadone analyses was 23%. 
High School Ed: The original TEDS-A variable education contained 5 categories: 8 years or less, 9-11 
years, 12 years, 13-15 years and 16 or more years. Education was recoded into a binary variable where 
12 or more years of education became high school education=1 and less than 12 years became high 
school education=0 (referent group). 
Employed: This variable reflects the employment status of individuals at the time of enrollment in a 
treatment program. The original employment categories were: full-time, part-time, unemployed and not 
in labor force. This variable was recoded into a binary variable where individuals working full or part-
time were recoded as 1 and those individuals that were unemployed or not in the labor force were 
recoded as 0 (referent group). 
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Unstable Housing: This variable describes the living arrangement of individuals at the time of treatment 
entry. The original variable contained 3 categories: homeless, dependent living (individuals living in a 
residential facility, halfway house, group home or children less than 18 years of age who are living with 
parents, relatives, guardians or in foster care), and independent living (individuals living alone or with 
others without any supervision, including individuals 18 and older who live with their parents). Living 
arrangement was recoded to reflect unstable housing, where homeless and dependent living individuals 
were coded as 1 for unstably housed and individuals who were living independently were coded as 0 for 
unstably housed (referent group).  
 Living arrangement was a supplemental variable, and therefore not reported by every program. In 
the Aim 2 analyses before any missing data techniques were used, the largest amount of missing data 
for this variable in any one year or combined year, for either methadone or buprenorphine, was 12%. In 
the Aim 3 analyses before any missing data techniques were employed, the largest amount of missing 
data for this variable in any of the methadone analyses was 32%. 
Primary Source of Income/Support: This variable describes the primary source of income, and for 
individuals under 18 years of age, the parent’s primary source of income at the time of treatment 
admission. This variable was dummy coded using the original categories: wages/salary (referent group), 
public assistance, retirement/pension, disability, other and none. The primary source of income/support 
variable was also a supplemental variable, and therefore not reported by every program. In the final Aim 
2 dataset, before any missing data techniques were used, the largest amount of missing data for any 
category of primary source of income in any one year or combined year, for either methadone or 
buprenorphine, was 45%. In the final Aim 3 dataset, before any missing data techniques were employed, 
the largest amount of missing data for any category of primary source of income in any of the 
methadone analyses was 60%. 
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Treatment Program Type: This variable describes 8 treatment types and/or settings in which treatment 
was provided. A description of each category follows, as well as an explanation of the recoded variable. 
1. Detoxification/24 hour service/Hospital inpatient – Hospital settings in which acute care medical 
detoxification services were provided 24 hours per day for persons who might experience 
withdrawal complications.  
2. Detoxification/24 hour service/Free-standing Residential – Non-hospital settings in which 24 
hour per day care is provided for safe withdrawal and transition to ongoing treatment. 
3. Rehabilitation/Residential-Hospital (Other than Detox) – Treatment services for alcohol or drugs 
that were provided within a hospital setting and included 24 hour per day medical care. 
4. Rehabilitation/Residential-Short Term (30 days or fewer) – Non-acute care treatment services 
for alcohol or drugs for 30 days or less. 
5. Rehabilitation/Residential-Long Term (More than 30 days) – Non-acute care treatment services 
for alcohol or drugs for longer than 30 days. This category includes programs such as halfway 
houses. 
6. Ambulatory-Intensive Outpatient – Outpatient programs in which clients received at least two 
hours of treatment per day, for at least three days per week. 
7. Ambulatory-Non-Intensive Outpatient – Outpatient programs in which clients received 
individual, family or group services. This category includes programs that provided MAT. 
8. Ambulatory-Detoxification – Outpatient treatment programs in which clients received services 
and/or MAT to withdraw from alcohol or drugs.  
 
 In the Aim 2 dataset, treatment program type was recoded into three main categories of programs: 
detoxification, outpatient and rehab (referent). Detoxification/24 hour service/Hospital inpatient, 
Detoxification/24 hour service/Free-standing Residential and Ambulatory-Detoxification were recoded 
to detox=1 (all others=0). Rehabilitation/Residential-Hospital (Other than Detox), 
Rehabilitation/Residential-Short Term (30 days or fewer) and Rehabilitation/Residential-Long Term 
(more than 30 days) were recoded to rehab=1 (all others=0). Ambulatory-Intensive Outpatient and 
Ambulatory-Non-Intensive Outpatient were recoded to outpatient=1 (all others=0).   
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 In the Aim 3 dataset, because of the distribution of programs, treatment program type was recoded 
so that Rehabilitation/Residential-Short Term (30 days or fewer) and Rehabilitation/Residential-Long 
Term (More than 30 days) became rehab=1 and all other programs were rehab=0. 
Number of Substances Using: This variable indicates the number of substances that a person reported 
using at the time of treatment admission. The original variable had 4 categories, ranging from 0-3, to 
reflect the primary, secondary and tertiary substances used. This variable was dummy coded with 3 
substances as the referent category. In the Aim 2 buprenorphine analysis and the Aim 3 analysis, there 
were no individuals reporting 0 substances of abuse during each of the study years so only one, two and 
three substances of abuse were used in these analyses. 
IDU: This binary variable reflects whether a person reported injecting either their primary, secondary or 
tertiary substance of abuse at the time of admission.  
Cocaine: This binary variable reflects whether cocaine was reported as the primary, secondary or 
tertiary substance of abuse at admission. 
Heroin: This binary variable reflects whether heroin was reported as the primary, secondary or tertiary 
substance of abuse at admission. 
Non-prescription Methadone: This binary variable reflects whether non-prescription methadone was 
reported as the primary, secondary or tertiary substance of abuse at admission. 
Synthetic Opioids: This binary variable reflects whether synthetic opioids were reported as the primary, 
secondary or tertiary substance of abuse at admission. 
Benzodiazepines: This binary variable reflects whether benzodiazepines were reported as the primary, 
secondary or tertiary substance of abuse at admission. 
Any opioid use: This binary variable was created by combining the heroin, synthetic opioid and non-
prescription methadone use variables, so that if a person reported using any of these drugs, opioids was 
coded as 1, and if they did not report using any one of them, opioids was coded as 0. 
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Psychiatric Problem: This binary variable indicates whether an individual has a psychiatric problem, as 
identified through self-report and/or program report. The psychiatric problem variable was a 
supplemental variable, and therefore was not reported by every program.  In the final Aim 2 dataset, 
before any missing data techniques were used, the largest amount of missing data for psychiatric 
problem in any one year or combined year, for either methadone or buprenorphine, was 26%. In the 
final Aim 3 dataset, before any missing data techniques were employed, the largest amount of missing 
data for any category of primary source of income in any of the methadone analyses was 29%. 
Primary Health Insurance Type: This variable indicates the primary type of health insurance coverage a 
person had at the time of treatment admission. The original variable was categorical but was dummy 
coded for these analyses using the original categories: private insurance (referent group), Medicaid, 
Medicare and none. Health insurance was a supplemental variable, and therefore was not reported by 
every program.  In the final Aim 2 dataset, before any missing data techniques were used, the largest 
amount of missing data for any category of client insurance coverage in any one year or combined year, 
for either methadone or buprenorphine, was 50%. In the final Aim 3 dataset, before any missing data 
techniques were employed, the largest amount of missing data for any category of client insurance 
coverage in any of the methadone analyses was 54%. 
 
TEDS-A – Dependent Variables 
Days Waiting to Enter Treatment: This continuous variable was the outcome variable used in Aim 2. 
Treatment wait time reflects the number of days between a person’s first contact with a program and 
their date of admission or receipt of their first clinical service. Treatment wait time reflects delays in 
treatment entry due to program capacity, treatment availability, admission requirements or other 
requirements related to the program. Programs are directed to not report any delays in treatment entry 
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that are caused by the unavailability of the client. The range of possible values for treatment wait time 
was 0 to 996 days. 
 Days waiting to enter treatment was a supplemental variable, and therefore was not reported by 
every program. In the final Aim 2 dataset, before any missing data techniques were used, the largest 
amount of missing data for treatment wait time in any one year or combined year, for either methadone 
or buprenorphine, was 24%.  
Enrolled in MAT: For the Aim 3 analyses, the TEDS-A Medication Assisted Treatment variable was the 
outcome variable of interest. This binary variable indicated whether methadone or buprenorphine were 
part of an individual’s treatment plan. This variable does not, however, specify which of the two MATs, 
methadone or buprenorphine, was used. The variable was coded as yes=1 and no=2 and was recoded to 
enrolled in MAT=1 and not enrolled in MAT=0.  
 
Structural Variables 
 Variables representing the state economic environment and need for substance use treatment 
within a state were utilized in Aim 1 of this study to investigate the correlation between two sets of 
factors, economic and need, and Medicaid coverage of methadone and buprenorphine. Some of the 
state-level factors from the Aim 1 analyses were included in the analyses for Aims 2 and 3 as fixed 
effects estimators to help account for the unobserved heterogeneity of the state environment. A 
description of each structural variable follows.  
 
Federal Medical Assistance Percentages (FMAP): The Federal Medical Assistance Percentage is the 
proportion of funds that the federal government contributes to each state’s Medicaid program. The 
FMAP varies by state and is largely based on the per capita income of the state.128 On average, the FMAP 
rate is 57%, meaning that the federal government pays 57% of Medicaid costs. While the FMAP rate is 
22 
 
never lower than 50%, in 2013 it was over 70% for Arkansas, the District of Columbia, Idaho, Kentucky, 
Mississippi, South Carolina and West Virginia.129 The FMAP rate is reassessed every three years in order 
to account for changes in a state’s overall wealth.  FMAP rates for this study were obtained for fiscal 
years 1998, 2006 and 2008 from the Department of Health and Human Services.130 The fiscal year covers 
the period of October 1, 1997 – September 30, 1998, October 1, 2005 – September 30, 2006 and 
October 1, 2007 – September 30, 2008. 
State Expenditures: State expenditure data were obtained from the National Association of State Budget 
Officers.131–133 Some of the broad expense categories that are included in the annual state expenditure 
total are: education, public assistance, Medicaid, corrections, transportation and capital expenses. State 
expenditure totals were obtained for fiscal years (July 1-June 30) 1998, 2006 and 2008. 
Percent of Residents Receiving Medicaid: Data regarding Medicaid beneficiaries were obtained from the 
Centers for Medicaid and Medicare (CMS), Medicaid Statistical Information System.134–136  The total 
number of beneficiaries was obtained for each state and was then divided by each state’s estimated 
population total (data obtained from the United States Census Bureau137), and then multiplied by 100. 
Medicaid beneficiary data were obtained for 1999 (1998 Medicaid beneficiary data were not available), 
2006 and 2008. 
Per Capita Income: Per capita income data were obtained from the United States Department of 
Commerce, Bureau of Economic Analysis for 1998, 2006 and 2008.138 The per capita income in each 
state is calculated by summing the total personal income for all state residents, divided by the total 
midyear population, as estimated by the United States Census Bureau. 
Substance Abuse Prevention and Treatment Block Grant (SABG) funding: SABG funds provide states with 
the opportunity to address their substance use prevention and treatment needs in ways that are unique 
to their individual communities. The amount each state receives is dependent upon population size, the 
total personal income for state residents and the amount of taxable resources in a state.139 SABG data 
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were obtained from the Substance Abuse and Mental Health Services Administration for fiscal years 
2006 and 2008 (1998 data were not available).140 Data used for this study were limited to substance use 
treatment block grant funds, excluding state funding that was obtained for substance use prevention. 
Rate of Individuals in Opioid Treatment: To calculate the opioid treatment rate, the number of opioid 
dependent individuals in 1998, 2006 and 2008 were obtained from the TEDS-A. TEDS-A data were 
limited to individuals reporting opioids as their primary, secondary or tertiary substance of abuse. To 
standardize the number of opioid dependent individuals seeking treatment across states, an opioid 
treatment rate of opioid dependent individuals per 10,000 population was calculated based on the 
number of opioid dependent individuals and the population of each state. 
Methadone and Buprenorphine Program Rate: The number of opioid treatment programs were 
obtained from the Uniform Facility Data Set (UFDS) for 1998, and the National Survey of Substance 
Abuse Treatment Services (N-SSATS), formerly known as the UFDS, for 2006 and 2008.141 The UFDS and 
N-SSATS include all private and publicly funded substance use treatment programs in the United States. 
The UFDS and N-SSATS data used for this study were limited to the total number of programs providing 
methadone in 1998 or 2008 and buprenorphine in 2006 and 2008. In order to standardize the number of 
programs per state, a program rate of programs per one million population was calculated based on the 
number of methadone and buprenorphine programs (calculated separately) and population of each 
state.  
Medicaid Coverage of Methadone: State Medicaid coverage of methadone for 1998 and 2008 was 
obtained from two sources. For 1998, data were obtained from McCarty et al’s article, “Methadone 
Maintenance and State Medicaid Managed Care Programs”.142  This article describes the results of a 
cross-sectional study of Medicaid coverage restrictions for methadone in each state in the U.S. in 1998.  
For 2008, state Medicaid coverage of methadone was obtained from the State Financing for 
Medication Assisted Treatment study, which includes cross-sectional data on Medicaid coverage of both 
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methadone and buprenorphine.9 For both study years, Medicaid coverage of methadone was 
dichotomized as yes/no. 
Medicaid Coverage of Buprenorphine: State Medicaid coverage of buprenorphine in 2006 was gathered 
from Ducharme at al’s article, “State Policy Influence on the Early Diffusion of Buprenorphine in 
Community Treatment Programs”, which describes the results of a cross-sectional investigation of the 
organizational factors associated with state policy restrictions of Medicaid coverage of buprenorphine.54 
Similar to the 2008 data used for methadone, data for Medicaid coverage of buprenorphine in 2008 
were obtained from the State Financing for Medication Assisted Treatment study. Similar to methadone, 
Medicaid coverage of buprenorphine was dichotomized as yes/no for both 2006 and 2008. 
 
Construction of Analytic Samples 
 Each study aim utilized a different sample based on available data for the predictors and outcome of 
interest in the study analyses. This section describes how each analytic sample was derived. 
 
Aim 1 
The Aim 1 dataset was developed by gathering state-level data for Medicaid coverage of methadone 
and buprenorphine, FMAP rates, percent of residents receiving Medicaid, per capita income, total state 
expenditures, SABG, rate of opioid dependent individuals in treatment and rate of methadone and 
buprenorphine programs. These data were entered into Microsoft Excel and were matched based on 
the state indicator variable. Matching was done for each state per study year. The final dataset was then 
exported to SAS 9.3 for analyses. 
 As a state-level exploration, the potential analytic sample for each analysis in Aim 1 began with 
N=50. Due to missing data on the outcome and/or main predictors of interest, the sample was then 
reduced in each study year and in the combined year analyses for both treatment types. As displayed in 
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Figure 1.3, the 1998 methadone analysis was reduced to N=48, excluding Nevada and West Virginia due 
to missing data. In 2008, the methadone sample was reduced to N=44 due to missing data, excluding the 
District of Columbia, Mississippi, North Carolina, North Dakota, Rhode Island and Texas. Finally, in the 
combined year analysis for methadone, the final sample was N=92 after excluding the District of 
Columbia, Mississippi, North Carolina, North Dakota, Nevada, Rhode Island, Texas and West Virginia due 
to missing data in one or both study years. The unit of analysis for the combined year sample was state-
year. 
 Due to missing data on either the outcome variable or one of the predictor variables of interest, the 
2006 buprenorphine sample was reduced to N=48, with Alaska and Georgia excluded from the analyses. 
The 2008 buprenorphine sample was limited to N=45 due to missing data from the District of Columbia, 
Mississippi, North Carolina, Rhode Island and South Carolina. Finally, the combined 2006-2008 
buprenorphine sample, after excluding Alaska, the District of Columbia, Georgia, Mississippi, North 
Carolina, Rhode Island and South Carolina due to missing data, was limited to N=93. The unit of analysis 
for the combined year sample was state-year. 
 
Aim 2 
Two datasets were constructed for the Aim 2 analyses, one dataset for the 1998, 2008 and 
combined 1998-2008 methadone analyses, and one dataset for the 2006, 2008 and combined 2006-
2008 buprenorphine analyses. Each dataset was primarily composed of individual-level data from the 
TEDS-A, as well as state-level predictors utilized in the Aim 1 analyses. Both datasets included the 
following individual-level variables: sex, race, ethnicity, education, marital status, employment status, 
living arrangement, age, treatment program type, MAT use, psychiatric problems, reported drug use, 
including: heroin, cocaine, methamphetamines, non-prescription methadone, synthetic opioids, 
benzodiazepines, any opioids, the total number of substances reported at treatment admission, IDU, 
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health insurance type and primary source of income. In addition to the aforementioned individual-level 
data from TEDS-A, the methadone dataset included the following structural factors: Medicaid coverage 
of methadone, state per capita income, state methadone program treatment rate, percent of individuals 
receiving Medicaid and rate of opioid dependent individuals engaged in substance use treatment. The 
buprenorphine dataset included the following structural predictors: Medicaid coverage of 
buprenorphine, per capita income, SABG, percent of individuals receiving Medicaid, buprenorphine 
program treatment rate, and rate of opioid dependent individuals engaged in substance use treatment. 
TEDS-A data were matched with these structural variables based on the state indicator variable. For 
instance, if the methadone treatment rate for NJ was 40.5, every individual receiving treatment in NJ 
would have 40.5 for the methadone treatment rate variable in the final dataset. This matching was done 
for each study year and the data were then merged into a final dataset that contained both study years. 
In the final combined dataset, the unit of analysis was person-year. 
 
Methadone dataset 
 Figure 2A.1 describes the analytic sample sizes for the methadone analyses performed for Aim 2, as 
well as the steps in which the sample was restricted. The initial methadone dataset contained a total of 
3,721,278 individuals for the combined 1998-2008 period, with 1,704,606 individuals for 1998 and 
2,016,672 for 2008. Each sample year was restricted to fourteen states in which there were sufficient 
data available for the outcome of interest, main predictor variables and the combined year analyses. 
These fourteen states included: Arizona, Colorado, Florida, Hawaii, Idaho, Iowa, Kansas, Louisiana, 
Montana, New Hampshire, New Mexico, Ohio, South Carolina and Wyoming. The largest amount of 
missing data for any one variable retained in the methadone dataset was 54%. Once the methadone 
sample was restricted to these fourteen states, there were 357,031 individuals in the 1998 dataset and 
432,993 in the 2008 dataset. 
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  Two different approaches, multiple imputation (MI) and listwise deletion (LD), were utilized to 
handle missing data in Aims 2 and 3 of this study [a more in-depth explanation of MI and LD is included 
later in this chapter]. MI was performed for each single study year (the combined study year sample size 
was too large). The MI sample, which was drawn from the fourteen state sample, was N= 1,364,735 for 
1998 and N= 2,034,778 for 2008. For the LD analyses, each year and the combined year sample was 
restricted to only those individuals in which there were complete case data. The final LD sample was 
N=98,183 for 1998, N=162,242 for 2008 and a combined 1998-2008 sample of N=260,425.  
  Bootstrap Analysis (BA) was also conducted for each year and combined year dataset because it is 
known to produce stable, unbiased estimates that demonstrate good internal validity, which is crucial in 
large sample sizes143 [a more in-depth explanation of MI and LD is included later in this chapter]. The BA 
models are presented as the final models for Aims 2 and 3.  
  Each BA consisted of an unrestricted random sample of individuals selected from each LD dataset. 
The initial BA samples were N=290 for 1998, N=243 for 2008 and N=259 for the 1998-2008 dataset. As 
part of the BA procedure, each sample was replicated in 100 separate datasets which were then 
combined to form a final sample. The final BA samples for the methadone analyses were N=29,500 for 
1998, N=24,400 for 2008 and N=26,100 for the combined 1998-2008 dataset.  
  
Buprenorphine Dataset 
 Figure 2B.1 depicts the various sample sizes for the buprenorphine analyses. The main, 2006-2008 
combined year dataset contained 3,721,278 individuals, 1,914,338 from 2006 and 2,016,672. A similar 
process was used to subset the buprenorphine data as was used for the methadone dataset. For the 
buprenorphine analyses, there were 24 states with sufficient data available for the outcome of interest, 
main predictor variables and the combined year analyses. These states included: Arizona, Arkansas, 
California, Colorado, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maryland, Michigan, 
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Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, South 
Dakota, Utah and Wyoming. The largest amount of missing data for any one variable retained in the 
buprenorphine dataset was 50%. The sample size, after restricting the analyses to these twenty four 
states, was N=883,207 for 2006 and N=968,237 for 2008. This sample, based on individuals representing 
24 states, was then utilized as the basis for MI. The MI sample was N= 4,258,996 for 2006 and N= 
4,698,055 for 2008 (the combined study year sample size was too large to perform MI). 
 The next step was to restrict the sample for the LD analyses, or to only those individuals with 
complete case data. The LD sample was N=240,757 for 2006, N=320,656 for 2008 and N=561,413 for the 
combined 2006-2008. Similar to the methadone analyses, BA was performed on the LD sample. The 
buprenorphine BA analyses consisted of three initial unrestricted random samples for each study year, 
N=241 for 2006, N=257 for 2008 and N=253 for the combined 2006-2008 dataset. Each of these samples 
was replicated in 100 separate datasets which were then combined to form a final sample. The final BA 
samples for the buprenorphine analyses were N=24,100 for 2006, N=25,700 for 2008 and N=25,300 for 
the combined 2006-2008 dataset.  
 
 Aim 3 
The Aim 3 analyses utilized the primary methadone dataset described in Aim 2; however, the Aim 3 
sample was restricted differently. Figure 3.1 provides an overview of the various analytic samples 
utilized in Aim 3, including the steps that were taken to restrict the sample for each analysis. 
 As shown in Figure 3.1, similar to Aim 2, the initial 1998-2008 combined methadone sample 
contained 3,721,278 individuals, 1,704,606 from 1998 and 2,016,672 from 2008. The main outcome for 
Aim 3 was use of medication assisted treatment, a treatment that is only appropriate for opioid users; 
therefore, the next step restricted the sample to only those individuals that reported opioids (including 
heroin, synthetic opioid or non-prescription methadone) as their primary, secondary or tertiary drug of 
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abuse at admission. Once the sample was restricted to opioid users, the 1998 sample was N=327,647 
and N=511,448 for 2008.  
 Thirty-eight states had sufficient data available in both 1998 and 2008 for the outcome of interest 
and main predictor variables. The 38 states were: Alaska, California, Colorado, Connecticut, Delaware, 
Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New 
Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, 
Utah, Vermont, Virginia, Wisconsin and Wyoming.  The largest amount of missing data for any one 
variable included in the sample was 60%. Once the remaining twelve states were excluded from the 
dataset, the 1998 sample was N=299,452 and the 2008 sample was N=461,004.  
 The 1998 and 2008 samples of opioid users from 38 states were then used as the basis for MI. The 
MI sample for 1998 was N=1,497,260 and the 2008 MI sample was N= 2,305,020. The next step was to 
restrict the 38 state sample for the LD analyses. The LD samples, once all cases with any missing data 
were removed, were N=8,311 for 1998, N=81,584 for 2008 and N=89,895 for the combined 1998-2008 
sample.  
 Similar to Aim 2, bootstrapping was performed on each year’s LD sample. The Aim 3 BA consisted of 
three unrestricted random samples for each of the study years, N=250 from the 1998 LD dataset, N=246 
from the 2008 LD dataset and N=253 from the combined 1998-2008 dataset. Each of these samples was 
replicated in 100 separate datasets which were then combined to form final BA samples. The final BA 








As an administrative dataset, the TEDS contains several variables that substance use treatment 
programs are required to report, as per state law. However, the TEDS also includes supplemental 
variables that are not mandatory for programs to report, such as treatment wait time, psychiatric 
problems, health insurance type, veteran status, source of income, marital status, criminal justice 
referral and payment source. Several of these variables were included in the analyses for Aims 2 and 3, 
and treatment waiting time was the outcome of interest in Aim 2. Because these variables were optional 
for programs to report, there was a significant amount of missing data to contend with. This section 
provides an overview the types of missing data and describes the techniques used to handle missing 
data in this dissertation.  
 
Types of Missing Data 
Several methods have been developed to address missing data. Choosing the most appropriate 
method requires an understanding of the types of and/or reasons for missing data in order to minimize 
bias.144,145 The three main types of missing data are: missing completely at random (MCAR), missing at 
random (MAR) and missing not at random (MNAR). When data are MCAR, there are no distinguishable 
patterns of variables leading the data to be missing.146–148 For example, in a randomized controlled trial, 
data would be MCAR if participants in both the treatment and control arms drop out of the study 
because they had relocated. These data are MCAR because study arm assignment is unrelated to study 
participation and an individual’s relocation. Data that are MCAR are considered “harmless” because they 
will not bias the mean or standard deviation estimated from the dataset, and will not impact the 
estimated relationships among other variables in the dataset given the fact that missingness occurs 
because of random events.144,149  
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While the extent of missing data and the way in which missing data are handled are not often 
explained in publications, when missing data are reported, they are most frequently described as 
missing at random (MAR).150 When data are MAR, the probability that the data are missing is based on 
observable characteristics within a study population but are not related to the outcome of interest.147,148 
For example, if a larger proportion of Hispanics, as compared with other racial/ethnic groups, are less 
likely to report their income on a survey, their data are considered MAR as long as the Hispanics in the 
sample include sufficient representation of Hispanics in all income strata. In other words, the missing 
data are conditional on being Hispanic but not on the dependent variable of income. Therefore, when 
data that are MAR take into account the variable on which they are conditional (such as including the 
conditional variable in a regression equation), bias can be minimized.151 
Despite the fact that researchers usually report missing data as MAR, some researchers argue that 
missing data are usually missing not at random (MNAR).150 Data that are MNAR occur when the 
probability that an item is missing is dependent upon unobserved information among a subset of 
participants.147,148 Utilizing the previous income example, data would be considered MNAR if low income 
Hispanics were less likely to report their income on a questionnaire. In this case, the reason for 
missingness is a characteristic of the outcome of interest and is therefore not a random event. This is 
particularly problematic because any estimates produced from such a sample will be biased, in this case 
producing an inflated overall income for the sample due to fewer responses among lower income 
Hispanics.144 Data that are MNAR weaken the generalizability of the findings because the pattern of the 






Missing Data Methods 
This dissertation employed two techniques to address missing data: Listwise Deletion and Multiple 
Imputation. The following section provides an overview of each technique, as well as a discussion of 
other methods used to handle missing data. 
 
Listwise Deletion (LD) 
The most common method for analyzing missing data is listwise deletion, or excluding cases from 
analysis if any item within that case is missing. The underlying assumption of listwise deletion is that the 
data are MCAR; therefore, utilizing listwise deletion with data that are MCAR would not introduce bias 
because the data that are deleted do not have a systematic pattern of missingness.152 However, when 
listwise deletion is applied to data that are MAR or MNAR, bias is likely to be introduced due to a 
potential overestimation of the certainty of the results. 153 For instance, if a sample of Americans were 
asked about their annual household income, and low income participants were less likely to report their 
income, the resulting mean income would be larger than the true mean income had the lower income 
individuals responded to that question. The standard error would be smaller than is accurate because 
the assumption is that the sample was randomly selected. However, when data are MAR or MNAR, and 
are excluded via listwise deletion, the retained sample no longer reflects a random sample of the 
population and therefore selection bias may be introduced. Some researchers, however, argue that 
utilizing listwise deletion with data that are MAR, particularly when the missing data for predictor 
variables are independent of the dependent variable, will yield unbiased results because it is similar to 
stratified sampling.154 
A general drawback of listwise deletion, regardless of the type of missing data, is the impact that 
listwise deletion can have on statistical power. Because listwise deletion removes all cases from the 
dataset that have any missing data, this method poses a threat to external validity, particularly in studies 
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with small sample sizes. However, in large sample surveys, such as the TEDS-A, particularly when data 
are MCAR, listwise deletion is not likely to impact results due to the large sample size.144 
Pairwise Deletion 
Pairwise deletion is similar to listwise deletion, in that missing data are excluded from analysis; 
however, with pairwise deletion, only the missing item is excluded while the rest of the case is 
retained.152 The ability to preserve a majority of the items for each case is advantageous because it 
results in a larger sample size (as compared with listwise deletion), thereby increasing statistical power.  
Similar to listwise deletion, utilizing pairwise deletion for data that are MCAR will likely produce 
unbiased results because of the ability to retain the entire sample minus the missing items. However, 
when using pairwise deletion for data that are MAR or MNAR, it is difficult to produce accurate 
estimates of the standard error due to fluctuations in the sample size.155,156  
For example, when assessing the relationship between several independent variables via a correlation 
matrix, utilizing a dataset in which pairwise deletion has been performed can be problematic because 
each correlation may include a different set of cases, making comparisons difficult and potentially 
prohibiting the use of these correlations in multivariate analyses.157 
 
Imputation 
As a general category, imputation refers to the act of replacing missing values from a dataset with 
estimated values. Because imputation allows for the analysis of a complete dataset, threats to external 
validity may be minimized. There are several imputation methods, but the most widely utilized methods 
include: mean substitution, hot deck imputation, regression imputation, and multiple imputation. This 
section reviews each method, with a more in-depth description of MI, the imputation method used to 





Mean substitution is the process of substituting a missing value with the mean of non-missing 
values.158 Similar to both listwise and pairwise deletion methods, the main assumption underlying mean 
substitution is that the data are MCAR and normally distributed. When this is the case, substituting the 
mean for this missing data will likely lead to unbiased results. However, when mean substitution is used 
with data that are not MAR, it can lead to an under- or over-estimation of the true value of the item 
because the reason the item is missing may be associated with the outcome. For example, individuals 
with higher incomes may be less willing to report their income than individuals with lower incomes; 
therefore, by replacing missing income with the mean income, the result will be an underestimate of the 
true value of income.  Similarly, mean substitution may also weaken variance estimates because by 
substituting the mean, the true variability of the data are compromised. 
 
Hot Deck Imputation 
Hot deck imputation is a useful tool for imputing missing data because this approach uses non-
missing values from characteristically similar respondents, called donors, to impute missing values.159 
This imputation process is carried out through the creation of a matrix of variables that a researcher 
deems are related to the missing item to be imputed.160 For example, if occupational status 
(unemployed, employed, etc.) is missing from a survey, a researcher with in-depth knowledge of the 
study can identify a set of variables that may be associated with occupational status, such as occupation 
and annual income. The data then form a deck where respondents with complete data on each of these 
variables are sorted.161 Then, respondents who match the donee, or the respondent with missing data, 
then form a donor pool of potential imputes.152 The donor may be randomly selected from the pool, 
called random hot deck methods, or the donor may be the “nearest neighbor” meaning that it most 
closely resembles the missing data characteristics (called deterministic hot deck methods).162  
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Hot deck imputation is widely utilized in the analysis of large surveys conducted by organizations 
such as the United States Census Bureau and the Substance Abuse and Mental Health Services 
Administration. National surveys with large sample sizes are most appropriate for hot deck procedures 
because of the increased likelihood of finding a similar donor due to the large sample size. Hot deck 
imputation is not as useful when it is applied to data sets with large amounts of missing data, or when 
used in the analysis of data sets with a small sample size. In these cases, the validity of hot deck 
imputation is threatened due to the need to identify matching donors for several respondents (in 
datasets with large amounts of missing data), or the need to find matching donors with a limited 
number of respondents (in small datasets that may yield few donors).158,163–165 Finally, in order to 
accurately identify similar donors in the hot deck procedure, researchers must be able to determine a 
set of variables that are predictive of the missing data. The hot deck procedure hinges on this 
identification, yet it is subjective, and as such introduces the potential for bias. 
 
Regression Based Single Imputation 
Similar to hot deck imputation, single regression imputation draws on what is known about cases 
with missing data, as well as cases with non-missing data, and uses this information to predict a missing 
value via a regression equation.166 Using the same example as above, if we wanted to impute missing 
values for occupational status, we would first calculate the correlation between variables that we think 
might be associated with occupational status, such as annual income, occupation and several others, 
and those variables with the highest correlations would then be used as predictors in a regression 
equation in which employment status was the outcome variable. Then, all of the variables (with 
complete data) that were associated with the outcome are used to predict the missing values for 
employment status.150  
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Single regression imputation affords researchers the ability to “recover” missing data through 
estimates, a benefit that can increase statistical power and generalizability of the findings. Additionally, 
the ability to include random error in the regression equation helps to account for the uncertainty of the 
imputation procedure. Despite these advantages, there are also some noted drawbacks. In particular, 
similar to hot deck imputation, special attention must be paid to the variables chosen as predictors for 
the imputation. If there is multicollinearity among these variables, the variance of the missing data 
variable may be artificially high.146 Finally, single regression imputation assumes a linear relationship 
between variables; however, when this is not the case, the model may produce artificially low 
significance values, leading to a falsely conclusion of statistical significance.  
 
Multiple Imputation (MI) 
Multiple imputation (MI) is similar to hot deck and single regression imputation, in that this 
procedure also utilizes existing data to help inform imputed values. However, with MI, the process of 
creating imputed values for missing data is carried out several times.167 More specifically, similar to 
single regression imputation, a predictive statistical model is developed based on a set of independent 
variables that are correlated with the missing variable, an error term is added and then an imputed 
value is computed.168  This process is then repeated, usually between five and ten times, resulting in the 
creation of five to ten complete data sets. Once these data sets are created, analyses can then be 
performed (analyses are run separately on each dataset), and the results are then pooled in order to 
create a single set of statistics, including parameter estimates and standard errors.  
The main advantage of MI is that through these multiple steps in the procedure, and the inclusion of 
an error term at each step, the uncertainty inherent in imputation is accounted for because the 
variability of the data is considered. The ability to account for the fluctuations in standard error across 
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each imputed data set can help reduce type I error, or the wrongful conclusion that there is an effect 
when none is present.152  
The creation of several distinct data sets in the MI procedure is a critical strength to this technique. 
Because each data set is generated randomly, the potentially imputed values may vary slightly from one 
another. The randomness and repeated process of MI help to increase the likelihood of making valid 
inferences based on these imputed data by increasing the random variability that is inherent in non-
imputed data.168  
MI has been used to impute missing data in research on sensitive topics, such as substance use and 
sexually transmitted infection status. For example, MI was used in a study investigating the factors 
associated with severe liver disease among HCV-infected PWIDs.169 The predictive model contained 8 
variables, 6 of which had varying amounts of missing data. Researchers used both listwise deletion and 
MI to determine which of the eight factors were associated with severe liver disease. When comparing 
the two methods, listwise deletion found that male sex, age over 40, HCV infection of 18 years or more, 
excessive alcohol consumption and HCV genotype 3 were all associated with severe liver disease. The 
MI-enhanced model found the same five variables to be associated with severe liver disease, as well as 
the addition of HIV infection. Though the findings from the listwise deletion model are similar to the MI-
enhanced model, the increase in power provided by MI allowed for additional associations, affirming the 
current evidence base regarding the role of HIV co-infection in advancing liver disease, 170–173  
MI and listwise deletion methods were also utilized in a study predicting factors associated with 
Chlamydia infection among teenage and young adult men.174 Laboratory data confirming Chlamydia 
status were missing for 28% of the young adult sample and 18% of the teenage sample. Researchers first 
assessed whether missing data were due to a nonresponse bias and determined that males in both 
samples with missing Chlamydia status were not significantly different than males with complete data. 
Researchers then imputed missing Chlamydia status for both samples utilizing MI and compared the 
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results to those achieved through listwise deletion. There was little difference in the findings between 
the missing data methods so the researchers chose to report the listwise deletion model results in their 
paper. This study demonstrates that in certain circumstances, such as datasets with large sample sizes 
and when there is a lack of association between the missing data and the outcome of interest, listwise 
deletion can be as effective as multiple imputation.144  
A main drawback of MI is the accurate specification of predictor variables.168,175 Researchers using 
MI must have a distinct sense of the variables that predict missingness because these variables must be 
included in the imputation model in order to reduce bias and potentially invalid conclusions. For 
example, Hippisley-Cox developed an algorithm to predict cardiovascular risk among UK residents and, 
after using MI to account for missing data, found that cholesterol was not associated with cardiovascular 
risk.176 This finding drew a fair amount of criticism given that it defied conventional wisdom about 
cardiovascular risk.177–179 Due to these criticisms, the authors re-ran their analyses using listwise 
deletion, and found a strong association between cholesterol and cardiovascular risk.180 The authors 
then developed new MI models that included additional predictor variables that might help to inform 
the missing values. When the revised MI-enhanced dataset was used to run the cardiovascular risk 
model, the researchers found an association between cholesterol and cardiovascular risk. Given this, the 
authors concluded that they had not used a sufficient number of independent variables in the initial MI 
model to accurately predict the imputed values, which then led to an underestimation of the association 
between cholesterol and cardiovascular risk.180  
To explore missingness in this dissertation, cases that contained missing data were compared to 
those without missing data on all variables of interest in this study. The results of these comparisons 
indicate that for both Aims 2 and 3, the two samples were significantly different on nearly every study 
variable, indicating that the data are not likely MCAR.  
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Because this dissertation utilized very large datasets, concerns regarding a reduction in sample size 
when considering missing data methods were minimized. For this reason, and the fact that retaining the 
same sample size across analyses was preferable, LD was chosen as one method for handling missing 
data in this dissertation. However, given the large amount of missing data in both of the Aim 2 and 3 
datasets, MI was also chosen so that complete case analyses could be performed, and any bias 
associated with excluding cases with missing data would be reduced. Both methods were performed for 
each Aim and study year and the findings across these methods were compared for the main outcomes 
in Aims 2 and 3. Due to the very large dataset for the combined year analyses, only LD was carried out. 
Listwise Deletion was carried out by eliminating all cases from each dataset that contained at least 
one missing value. A dummy variable indicating missing data in any one of the variables of interest was 
created and the sample was then restricted based on those cases in which there were no missing data. 
Multiple imputation was performed using the ProcMI function and Markov Chain Monte Carlo method 
in SAS 9.3 (SAS Institute, Cary, NC). While there is some disagreement in the literature regarding the 
inclusion of outcome variables in MI procedures181–183, the dependent variable was included in all MI 
procedures. All study variables, including the dependent variables, were included in the imputation 
models. Each single year dataset in Aims 2 and 3 were imputed five times. Regression analyses were 
then performed on each dataset and the results were pooled using the ProcMIAnalyze function. 
 
Validating Findings Derived from Large Samples 
  The final samples used in the analyses for Aims 2 and 3 were very large, even after restricting them 
by study criteria and to those individuals with complete data. An important issue to consider when 
analyzing large datasets such as these is that the increased power due to the large size of the sample 
can result in an increase in the amount of significant associations.184 These associations, while 
statistically significant, may have very small effect sizes, reducing the utility of the p-value as the sole 
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basis for interpreting study findings.185 One way to address this limitation is to present the effect sizes 
and confidence intervals along with the p-value so that readers have a better understanding of the 
extent of the relationship between variables.184 Another way to address this concern is to utilize a 
validation procedure to augment significance testing.143 The most commonly used validation procedures 
are bootstrapping and jackknifing. The bootstrap and jackknife procedures are resampling techniques 
that can be used with non-normally distributed data to estimate parameters, standard errors and 
confidence intervals. These techniques are particularly useful when there is uncertainty regarding the 
generalizability of study findings. The following section provides a brief overview of each method. 
 
Jackknife 
 As a resampling procedure, the jackknife technique, also known as the “leave one out” procedure, 
utilizes an entire sample, without replacement, to estimate a given parameter.186 To do this, a single 
case is eliminated from the original sample one step at a time, and a “pseudo-value” is computed to 
estimate the parameter of interest at each step.185 This procedure is repeated over a specified number 
of times as each observation is dropped from the sample. Once the iterative estimate process is 
complete, the “pseudo-values” are averaged to create an overall estimate of the parameter of 
interest.187  
 In addition to parameter estimates, the jackknife procedure can be used to create confidence 
intervals and estimate standard errors. Because observations or cases are removed from the original 
dataset one at a time, the jackknife procedure is particular sensitive to outliers and can reduce bias 






Similar to the jackknife procedure, bootstrapping involves the creation of a new set of samples via 
repeated resampling from an original, representative sample. Unlike the jackknife procedure, 
bootstrapping allows for random sampling with replacement, meaning that each time an observation is 
selected for bootstrapping, it is returned to the original dataset, allowing for it and all other 
observations to have an equal chance of being drawn at each selection step.188  This procedure is 
repeated until a set number of cases is achieved for a set number of samples. The target sample size is 
determined prior to the start of the procedure and usually equals the size of the main sample, unless 
bootstrap subsampling is performed, in which case a fraction of the original sample is selected.189 
Bootstrap subsampling is often utilized with large datasets and when traditional bootstrapping 
procedures fail. The number of replications, or the number of times a new sample is created, is also 
determined a priori and usually ranges from 100-1000, or more.143,190 Similar to MI, the bootstrap 
samples are pooled, which creates a sampling distribution and facilitates the computation of parameter 
estimates, standard errors and confidence intervals.191 
Bootstrapping has been found to provide more stable estimates than the jackknife 
procedure.143,186,192 While the jackknife procedure is particularly effective at reducing bias through the 
identification of outliers, bootstrapping can provide more comprehensive and accurate estimates for a 
given sample or set of samples. In Aims 2 and 3 of this dissertation bootstrapping was utilized as a 
validation technique to ensure that model results were consistent when performed on smaller and 
different samples.   
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Chapter 4: Conceptual Framework 
 The first aim of this study is guided by a theoretical framework developed by Schneider and Jacoby 
that sought to explicate the impact of external influences on bureaucratic policy making.193  The findings 
from this analysis provided a theoretical foundation for the selection of state-level factors utilized in the 
development of models for Aims 2 and 3 of this study.  
 Medicaid is a combined federal/state program, with the federal government and state governments 
sharing the costs of Medicaid services, depending upon the per capita income of the state, among other 
factors.128 The federal government issues guidelines on “mandatory services” that states must cover, 
such as inpatient hospital stays, physician visits, as well as several other services; however, states can 
choose whether to cover “optional services”, which include prescription drugs and dental services, 
among other services.194 The decision regarding what optional services state Medicaid programs will 
cover ultimately lies with state Medicaid administrators. Given the magnitude of this decision and the 
variability in coverage across states, Schneider and Jacoby sought to understand the factors that 
influence the number of optional services covered by states. To do this, Schneider and Jacoby developed 
and tested a theory that posited four levels of influence on Medicaid policy making: elected officials, 
interest groups, structural influences and state-level environmental conditions.193 Schneider and Jacoby 
believed that elected officials have the potential to influence Medicaid decision-making due to the fact 
that governors and/or legislatures are responsible for appointing state Medicaid directors. 195  Because 
of this, Schneider and Jacoby tested the influence of two variables at the elected officials’ level that have 
been found to be influential in other relevant research: legislative partisanship, which they defined as 
the percent of Democrats in both the Senate and the House of Representatives or Assembly; and, the 
incumbent governor’s party affiliation.  
 At the interest group level, Schneider and Jacoby included four variables to assess the influence of 
interest groups on the inclusion of Medicaid optional services: the proportion of physicians, dentists, 
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hospital beds and nursing home beds within a state. These variables were chosen because they 
represented a wide cross-section of parties that might be interested in and lobby for specific optional 
services. 
 Structural influences, Schneider and Jacoby posited, may also play a significant role in influencing 
decisions regarding the coverage of Medicaid optional services. They operationalized these structural 
influences through the inclusion of the previous year’s Medicaid expenditures, given that these 
expenses may impact decisions about future spending. Additionally, they believed the FMAP rate may 
also influence the extent to which states include optional services given that it is an indication of the 
payment contribution of the federal government. The final structural influence included in their model 
was whether Medicaid programs are controlled by state or local administrations. In some states, 
decision making regarding Medicaid lies solely at the state level, whereas in other states, Medicaid 
decision making has devolved to county officials as well. Schneider and Jacoby hypothesized that in 
states with local administration involved in the decision making, bureaucrats may have a better handle 
on the needs of their communities and therefore be more likely to include optional services that reflect 
the need of the population. 
 The final group of potential influences in their model was environmental factors. These factors were 
chosen to account for the conditions within a state that may influence Medicaid directors’ decision 
making, including need, economics and ideology. Schneider and Jacoby operationalized need through 
the use of state infant mortality rate as an indicator of the overall health of the population. Per capita 
income was chosen to reflect the economic condition of the state, and the ideological leaning of the 
state was operationalized through the use of survey data measuring the extent to which state residents 
lean conservative or liberal. 
 Schneider and Jacoby assessed the strength of their framework by testing the extent to which the 
aforementioned independent variables explained the variability across states regarding the total 
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number of optional services adopted. Schneider and Jacoby found that per capita state income, FMAP 
rate, the proportion of physicians and dentists, state versus local Medicaid administrators and infant 
mortality rate were all significant factors that influenced the adoption of Medicaid optional services 
across states.193  
Schneider and Jacoby were interested in understanding the influences on the volume of optional 
services states covered; however, this study is focused on the influences for two specific optional 
services, methadone and buprenorphine treatment. While some forms of substance use treatment are 
considered mandatory under federal Medicaid guidelines, such as inpatient detoxification, methadone 
and buprenorphine are optional. Given the fact that methadone and buprenorphine are the two most 
effective treatments for opioid dependence, it is unclear why only a portion of states provide coverage 
for these treatments.  
Due to limitations on the availability of relevant factors, this study utilizes an adapted version of 
Schneider and Jacoby’s framework to test the correlation of two levels of influence on Medicaid 
restrictions of methadone and buprenorphine coverage: economic and need. Economic factors will be 
operationalized through the use of the following state-level variables: FMAP rate, percent of residents 
receiving Medicaid, per capita income, annual state expenditures and the amount of federal block grant 
funding for substance use treatment. Finally, need factors will be operationalized through the following 
state-level indicator: the number of substance use treatment facilities in each state and the number of 




Chapter 5: State-level Analysis of Economic and Need Factors and Medicaid Coverage of Methadone 




Substance use treatment admissions for opioid dependence have increased 71% between 1998 and 
2012, due to a large increase in the nonmedical use of prescription opioids and heroin.1,126,196 By 2013, 
4.5 million Americans reported nonmedical use of prescription opioids within the previous month and 
close to 300,000 people reported heroin use within the previous month.16 Both nonmedical prescription 
opioid use and heroin use have been associated with dramatic increases in the number of fatal drug 
overdose deaths in the United States. Between 2001 and 2013, fatal drug overdoses that were that 
result of nonmedical use of prescription opioids tripled and those associated with heroin increased by 
fivefold.197  
  Expanding access to evidence based treatments for opioid dependence, particularly methadone 
and buprenorphine, is a critical step in stemming the growing tide of opioid dependence and the 
negative health consequences associated with it.198  While methadone and buprenorphine are 
considered to be the most effective forms of treatment for opioid dependence, public and private 
insurance programs are not required to cover these treatments. This study examines the association 
between two sets of factors, economic and need, and state Medicaid coverage or methadone and 
buprenorphine. 
 
Medicaid Coverage of Methadone and Buprenorphine 
Medicaid is a combined federal/state program that provides health insurance for low-income 
individuals and families. The federal government offers guidelines to states regarding the extent to 
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which medical services and medications should be covered under Medicaid. Ultimately, however, each 
state develops their own eligibility requirements, as well as coverage parameters for medical care and 
medications.124 As a result of state autonomy, there is substantial variability in substance use treatment 
coverage across states, particularly for methadone and buprenorphine. In some states, for example, 
Medicaid covers either buprenorphine or methadone; however, in other states, Medicaid covers both 
medications as long as they are provided in specific settings or after physicians have obtained pre-
approval. As of 2008, 19 states had some form of restriction on the coverage of buprenorphine and/or 
methadone.9 
In 2014, substance use treatment became an Essential Health Benefit (EHB) under the Patient 
Protection and Affordable Care Act (PPACA). An EHB is a required set of health care services that every 
insurance plan sold in the Health Insurance Marketplace must cover. Additionally, new Medicaid 
beneficiaries now covered in states that have opted to expand their Medicaid programs will be entitled 
to receive substance use treatment as part of their essential benefits. This new EHB status provides 
significant hope for increased access to substance use treatment services; however, these changes are 
not likely to decrease the variability in Medicaid coverage of methadone and buprenorphine. State 
Medicaid programs will continue to have great latitude in choosing the types of substance use 
treatment services that will be covered. Additionally, while Medicaid expansion has the potential to 
increase access to substance use treatment, the expansion in services in some states will only apply to 
new Medicaid beneficiaries and not those that were receiving Medicaid prior to January 1, 2014.199,200  
 This study sought to gain a better understanding of Medicaid coverage variability for methadone 
and buprenorphine in the United States, focusing on two main categories of predictors: the need for 
treatment and the economic environment of the state. To guide the selection of relevant independent 
variables, we utilized an adapted framework from a study investigating factors associated with state 




An historical analysis of publicly available data was conducted using a variety of sources. An 
explanation of study variables and sources follow. 
 
Independent Variables 
The independent variables chosen as economic predictors in this study include: state Federal 
Medical Assistance Percentages (FMAP) rate, percent of residents in each state receiving Medicaid, per 
capita income of each state, state expenditures and the amount of substance abuse block grant funding. 
The need predictor variables used in this study include: the rate of people seeking opioid treatment in 
each state and the rate of methadone and buprenorphine programs in each state. Each variable was 
examined separately to determine whether it was correlated with state Medicaid coverage of 
methadone in 1998, 2008 and 1998-2008 combined, and Medicaid coverage of buprenorphine in 2006, 
2008 and 2006-2008 combined.  
 
Federal Medical Assistance Percentages (FMAP)  
 The Federal Medical Assistance Percentage is the proportion of funds that the federal government 
contributes to each state’s Medicaid program. The FMAP rate varies by state, however, the average 
FMAP rate is 57%, meaning that the federal government pays 57% of Medicaid costs. While the FMAP 
rate is never lower than 50%, in 2013 it was over 70% for Arkansas, the District of Columbia, Idaho, 
Kentucky, Mississippi, South Carolina and West Virginia.129 FMAP rates for this study were obtained for 






Residents receiving Medicaid 
 Data regarding Medicaid beneficiaries were obtained from the Centers for Medicaid and Medicare 
(CMS), Medicaid Statistical Information System.  The total number of beneficiaries was obtained for 
each state and then the proportion of residents receiving Medicaid was calculated using population 
totals obtained from the United States Census. Data were obtained for 1999 (1998 Medicaid beneficiary 
data were not available), 2006 and 2008. 
 
State Per Capita Income 
 Per capita income was obtained from the US Department of Commerce, Bureau of Economic 
Analysis for 1998, 2006 and 2008, and was based on the total personal income in each state, divided by 
the total midyear population. 
 
State Expenditures 
 State expenditure data include expenses paid by states for education, public assistance, Medicaid, 
corrections, transportation and capital expenses, among other categories. Expenditure data were 
obtained from the National Association of State Budget Officers for fiscal years 1998, 2006 and 2008. 
 
Substance Abuse Prevention and Treatment Block Grant (SABG) funding 
 SABG funds provide states with the opportunity to address their substance use prevention and 
treatment needs in ways that are unique to their communities. The services funded by SABG vary by 
state, as does the amount each state receives. SABG data were obtained from the Substance Abuse and 
Mental Health Services Administration for fiscal years 2006 and 2008 (1998 data were not available). 
Data used for this study was limited to substance use treatment block grant funds, and excluded the 
total amount awarded for substance use prevention. 
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Rate of Individuals Seeking Opioid Treatment 
 The number of individuals seeking opioid treatment in 1998, 2006 and 2008 was obtained from the 
Treatment Episodes Data Set – Admission (TEDS-A). TEDS-A data include all drug treatment admissions 
from public and private substance use treatment programs that receive public funding. TEDS-A data are 
based on encounters in substance use treatment, rather than distinct individuals. For these analyses, 
TEDS-A data were limited to individuals seeking substance use treatment services with heroin or 
prescription opioids reported as their primary, secondary or tertiary substance of abuse. In order to 
standardize the number of opioid dependent individuals across states, a treatment rate of opioid 
dependent individuals per 10,000 population was calculated based on the number of opioid dependent 
individuals and population of each state. 
 
Rate of Methadone and Buprenorphine Programs 
 The number of opioid treatment programs were obtained from the Uniform Facility Data Set (UFDS) 
for 1998, and the National Survey of Substance Abuse Treatment Services (N-SSATS), formerly known as 
the UFDS, for 2006 and 2008. The UFDS and N-SSATS include all private and publicly funded substance 
use treatment programs in the United States. The UFDS and N-SSATS data used for this study were 
limited to the total number of programs providing methadone in 1998 or 2008 and buprenorphine in 
2006 and 2008. In order to standardize the number of programs per state, a program rate of programs 
per one million population was calculated based on the number of methadone and buprenorphine 






Medicaid Coverage of Methadone and Buprenorphine 
State Medicaid coverage of methadone for 1998 and 2008 was obtained from two sources. For 
1998, data were obtained from McCarty et al’s study, “Methadone Maintenance and State Medicaid 
Managed Care Programs”.142  For 2008, Medicaid coverage of methadone by state was obtained from 
the State Financing for Medication Assisted Treatment study.9  
 State Medicaid coverage of buprenorphine in 2006 was gathered from Ducharme at al’s study, 
“State policy influence on the early diffusion of buprenorphine in community treatment programs”.54 
Data for Medicaid coverage of buprenorphine in 2008 were obtained from the State Financing for 
Medication Assisted Treatment study.  
 
Analytic Approach  
 Bivariate logistic regression was used to assess the relationship between economic and need factors 
and Medicaid coverage of methadone in 1998, 2008 and 1998-2008 combined and buprenorphine in 
2006, 2008 and 2006-2008 combined. The study timeframe was determined based on the availability of 
state-level Medicaid coverage of methadone and buprenorphine. The analyses included combined years 
for each treatment as well as analyses separated by study year in order to determine whether 
associations between the predictor variables and Medicaid coverage of each treatment remained 
significant when study years were assessed separately.  
 Predictor variables were standardized by dividing each mean score by the standard deviation in 
order to create a common scale. Economic and need factors were then assessed in separate bivariate 
analyses by predictor variable, year and type of treatment (methadone and buprenorphine). For all 
study years, Medicaid coverage of methadone and buprenorphine were dichotomized as yes/no. The 
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final sample for each analysis year was confined to only those states with data available for all of the 
independent and dependent variables in the given year. The analytic samples are depicted in Figure 1.3. 
 All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). The study was 
determined exempt by the City University of New York’s Human Research Protections Program Office 
due to the use of publicly available data. 
 
Results 
Table 1.1 displays Medicaid coverage by state for methadone in 1998 and 2008 and buprenorphine 
in 2006 and 2008. In 1998, 25 states provided Medicaid coverage of methadone, as compared with 34 
states in 2008. In 2006, 28 states provided coverage of buprenorphine for Medicaid beneficiaries, as 
compared with 38 states in 2008. A total of eleven states did not cover methadone for Medicaid 
beneficiaries in either 1998 or 2008 and six states did not cover buprenorphine for Medicaid 
beneficiaries in either 2006 or 2008. Finally, five states did not cover either methadone or 
buprenorphine for Medicaid beneficiaries in 2008.  
The results of the bivariate logistic regression models for both treatments across study years are 
presented in Table 1.2. 
 
Economic Factors 
State FMAP rate was negatively associated with Medicaid coverage of both methadone and 
buprenorphine across all study years. In 1998, for every one standard deviation increase (8.34%) in the 
FMAP rate, the odds of a state providing Medicaid coverage of methadone decreased by 64%. 
Comparable negative relationships were noted across all study years for methadone. Similarly, in 2006, 
for every one standard deviation increase (7.86%) in the FMAP rate, the odds of a state providing 
Medicaid coverage of buprenorphine decreased by 62%.  
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 Per capita income was also significantly associated with Medicaid coverage of methadone and 
buprenorphine across all study periods. In 1998, the odds of a state providing Medicaid coverage of 
methadone increased by a factor of two for every one standard deviation ($3,623) increase in per capita 
income, and in 2006, for every one standard deviation increase ($5,261) in per capita income, the odds 
of a state providing coverage of buprenorphine more than doubled (OR=2.11).  
 The association between annual state expenditures and methadone and buprenorphine was 
inconsistent across study time periods for both methadone and buprenorphine. While state 
expenditures were associated with Medicaid coverage of methadone in 1998 (p=0.016) and in 1998-
2008 (p=0.001), the relationship was not significant in 2008. For buprenorphine, annual state 
expenditures were associated with buprenorphine coverage in the combined 2006-2008 analysis 
(P=0.048), but not in 2006 or 2008. 
  The relationship between Substance Abuse Block Grant funding (SABG) and Medicaid coverage of 
methadone and buprenorphine was assessed for 2006 and 2008 (1998 data were not available) but was 
not found to be significant in any of the analyses. Finally, the percent of residents receiving Medicaid 
was not associated with Medicaid coverage of methadone or buprenorphine in any study time period.  
 
Need Factors 
 The rate of individuals in opioid treatment was only associated Medicaid coverage of methadone in 
the 1998-2008 analysis. This finding suggests that for every 18 additional individuals/10,000 population 
being treated for opioid dependence, a state was 9.68 times more likely to cover methadone treatment 
for Medicaid beneficiaries.  
 Finally, the rate of methadone programs per one million population and Medicaid coverage of 
methadone were significantly associated in all three time periods (no associations were observed for 
buprenorphine). In 1998, for example, for every 2 additional methadone programs per one million 
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The main finding of this study is the significant associations observed between two measures of 
state wealth, FMAP rate and per capita income, and Medicaid coverage of methadone and 
buprenorphine. A negative relationship between FMAP rate and Medicaid coverage of methadone and 
buprenorphine was noted across all study time periods, demonstrating that states with greater financial 
need were less likely to provide Medicaid coverage of methadone and buprenorphine. Similarly, a 
positive association was found between per capita income across all study time periods, demonstrating 
that states with greater financial resources were more likely to cover methadone treatment than states 
with less financial resources.  
The associations between annual state expenditures and Medicaid coverage of methadone and 
buprenorphine are difficult to interpret given their lack of consistency across study years and treatment 
type; however, the lack of association found for both percent of residents receiving Medicaid and the 
total amount of funding received from SABG have an interesting commonality. These two measures are 
both very specific; one regarding Medicaid itself and the other regarding substance use funding. Unlike 
per capita income and annual state expenditures, which are measures that include input from all 
members and sectors of the state, and the FMAP rate which is calculated in part based on per capita 
income, the percent of Medicaid recipients is not a broad based measure of a state’s economy, but 
rather an economic indicator of a portion of a state’s economy. As such, the percent of residents 
receiving Medicaid may not have a significant impact on the overall financial standing of the state.  For 
instance, it is feasible for a state to have a large disparity in the wealth of its residents, which may result 
in a moderately large percentage of residents receiving Medicaid, but may not impact the overall 
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economy of the state if there is an equally sizeable segment of the state population with above average 
wealth. Similarly, the SABG funding proxy measure provides a very narrow measure of the wealth of a 
state, with its only use being for those programs and services that are specifically related to substance 
use treatment. Again, such a narrow economic indicator may not be broad enough to impact the overall 
financial standing of a state. Additionally, if a state receives an above average amount of SABG funding, 
this may actually serve as marker of a greater need for substance use treatment rather than an indicator 
of economic need. Given this possibility, future analyses may consider using SABG as an indicator of 
need rather than as an economic factor. 
The findings regarding need factors were inconsistent both within and across treatments. While 
there was evidence of a significant relationship between the rate of methadone programs and Medicaid 
coverage of methadone, the confidence intervals associated with these odds ratios were large. Similarly, 
the confidence intervals regarding the rate of individuals in treatment for opioid dependence and 
Medicaid coverage of methadone, which may indicate that the relationship between these variables is 
weak. While the need factors and buprenorphine findings are somewhat consistent with those observed 
in the methadone analyses, the N-SSATS data did not include private physicians that are not affiliated 
with substance use treatment programs, which undoubtedly impacted the significance of these 
analyses. It is not known, however, whether these associations would become significant if the dataset 
were to include private physicians that prescribe buprenorphine. Future research in this area might 
utilize a dataset that provides a better indicator of the proportion of buprenorphine programs and 
providers.  
 Each annual analysis conducted in this paper (1998, 2006 and 2008) contained a sample of less than 
fifty states. The small sample size undoubtedly impacted the strength of the associations because when 
study years were combined, and therefore the sample size increased, nearly every association increased 
in significance. This may provide further evidence that a larger sample size could increase the strength 
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of the relationships between each of the economic variables, and reduce the confidence intervals; 
however, this limitation is in inherent in state-level analyses. 
While these analyses are historical, and do not include any time period since the PPACA was 
enacted, the findings of this study remain significant within the context of PPACA implementation. As 
mentioned previously, the PPACA has not changed the accessibility of methadone and buprenorphine 
directly. While substance use treatment has become an essential health benefit under the PPACA, states 
continue to choose the types of treatments their Medicaid programs will cover. Given this, it is very 
likely that the variability in Medicaid coverage of substance use treatment services that was observed in 
this study will persist post-PPACA implementation, resulting in inconsistent access to these evidence-
based treatments. 
Finally, this study investigated Medicaid coverage of methadone and buprenorphine as a 
dichotomous outcome. Other studies have investigated the accessibility of these treatments in terms of 
degrees.9 For instance, in some states Medicaid coverage of methadone and buprenorphine is 
unrestricted, while in other states Medicaid programs put limits on the length of time a patient can be 
covered, require prior authorization for these treatments, and delay reimbursement to practitioners and 
programs by not putting these treatments on Medicaid formulary lists. Such restrictions are permissible 
under the PPACA, but may create additional barriers to both the provision and utilization of these 
treatments. Future research should investigate the extent to which environmental factors within a state 
are associated with different types of Medicaid restrictions of methadone and buprenorphine, and 








Data regarding Medicaid coverage of methadone and buprenorphine by state were not available for 
consecutive years. This limited my ability to detect the direct impact when a policy changed. Given this 
limitation, particularly for need factors, it is not possible to determine whether Medicaid policy 
regarding coverage of methadone and buprenorphine led to an increase or decrease in the number of 
methadone and buprenorphine programs or individuals seeking treatment for opioid dependence. The 
findings presented in this paper simply indicate that some of the factors examined were associated. 
Future studies on this topic might investigate Medicaid coverage of methadone and buprenorphine over 
multiple, consecutive years in order to detect distinct changes in policy that could help to isolate causal 
factors.  
This study utilized data from the TEDS-A, which includes only those individuals enrolled in substance 
use treatment, to investigate the association between the need for treatment and Medicaid coverage of 
these treatments. The number of people enrolled in treatment was used as one proxy measure for 
need, but the associations observed were weak. A better proxy measure for future research might 
include the rate of opioid dependence derived from a population-based sample so that individuals in 
and out of substance use treatment can be captured.  
The majority of privately owned treatment facilities, which according to SAMHSA account for 
approximately twenty-nine percent of outpatient methadone programs in the United States, are not 
included in the TEDS data.201 Additionally, individuals treated through private physicians that are not 
contained within a substance use treatment facility are not included in TEDS.202 The exclusion of 
treatment programs not receiving public funds and private physicians may provide an under-
representation of the rate of methadone and/or buprenorphine programs and therefore bias the results 





Although methadone and buprenorphine are the two most effective treatments for opioid 
dependence, their use in the United States is limited. Previous research has investigated the influence of 
health insurance coverage, regulatory issues governing these treatments and physician training, among 
other factors, as potential reasons for the limited use of these treatments. This study expanded on 
previous research regarding the role of health insurance coverage by investigating the extent to which 
the economic condition of states and the significance of opioid dependence in states was associated 
with differences in Medicaid coverage of methadone and buprenorphine. This study provides evidence 
that states with increased wealth are more likely to provide Medicaid coverage of methadone and 
buprenorphine than states with less overall wealth.  While the findings regarding the need for treatment 
were inconsistent, future research should investigate these associations utilizing additional variables 
that may serve as better proxy measures for the significance of opioid dependence in a state.  
Finally, given the sustained increase in opioid use and associated mortality in the United States over 
the last decade, it is critical to ensure that evidence based treatments are accessible to all individuals in 
need. While passage of the PPACA and the inclusion of substance use treatment as an EHB provide hope 
for the expansion and increased accessibility of substance use treatment, states will continue to have 
the authority to choose the types of treatments covered under their Medicaid programs. Identifying the 
factors that are associated with states that cover these treatments, and those that do not, is an 
important step toward increasing the accessibility of these evidence based treatments. 
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Chapter 6: Medicaid Coverage of Methadone and Buprenorphine and Waiting Time to Enter 
Substance Use Treatment (Aim 2 Analysis) 
 
Background 
Opioid use has increased significantly over the last decade.3,203 As of 2013, an estimated 2.4 million 
people were considered to be dependent on opioids; however, according to current estimates, only 20-
25% of opioid dependent individuals receive some form of treatment.204 Untreated opioid dependence 
is associated with significant health consequences, including HIV and hepatitis C infection, drug 
overdose, injection drug use, and unsafe sex and drug behaviors.24–31 Medication assisted treatments 
(MAT), such as methadone and buprenorphine, are the most effective form of treatment for opioid 
dependence.4,5,47,48 MAT have been associated with reductions in HIV infection, mortality, crime, 
injection drug use, heroin use,  and syringe sharing.38–40,43,205,206 In order to address the epidemic of 
opioid use and reduce the public health consequences associated with it, experts have called for an 
increase in access to MAT.198  
Substance use treatment that is readily accessible can have a significant impact on both engagement 
and retention in treatment. When individuals are required to wait to enter treatment, they are at 
increased risk for treatment dropout,104 mortality,106  arrest,107 untreated psychiatric problems,108 new 
HIV infection,109 and a return to or initiation in injection drug use (IDU).110 Further, an inverse 
relationship between the time a person waits to enter treatment and treatment entry has been 
observed in several studies, such that the longer a person waits to enter treatment, the less likely they 
are to enroll in it.92,95,111–113 Research suggests that the first twenty four hours following a client’s initial 
contact with a substance use treatment program is the most critical period as it results in the largest 




Factors Associated with Treatment Wait Time 
Treatment wait time, which is defined here as the lag between when a person attempts to enter 
substance use treatment and actual treatment entry, is frequently cited as a primary barrier to initiating 
substance use treatment.90–93 Factors contributing to treatment wait time may be the result of delays 
related to individuals, organizations or structural factors. Individual-level factors such as 
unemployment96, homelessness96, being African American103,116, cocaine use103,106, lack of insurance94 
and psychiatric problems103 have all been associated with longer wait times for treatment entry. The 
associations between age96,106,117 and gender 100,102,105 and treatment wait time have been inconsistent. 
While individual-level factors may contribute to delays in treatment entry, they are not believed to 
have a significant impact on treatment wait time.90,98 Rather, organizational factors, particularly 
regarding program inefficiencies, are believed to contribute most significantly to wait times.118–121 
Specific organizational factors associated with delays to treatment entry include larger client 
caseload96,123, staff shortages,92 provision of methadone116, inefficient phone scheduling systems99, 
central intake units94 and increased proportion of clients receiving public assistance123; whereas for-
profit programs117, programs with an increased number of patients attending daily96 and programs with 
performance contracting101, or financial incentives for improvement in patient outcomes or 
organizational efficiencies, have been associated with reduced treatment wait times. 
 There is scant literature regarding the influence of structural factors on treatment wait time. The 
only study that we found was an investigation of systems-level and individual-level characteristics by 
Carr et al.96 This study found that bureaucratic delays related to processing court-ordered treatment 
resulted in increased wait times for substance use treatment entry.37  
 The main purpose of this study is to investigate the association between state Medicaid coverage of 
methadone and buprenorphine and the length of time individuals wait to enter substance use 
treatment. This study includes individual-level demographic variables and program-level characteristics 
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that have been observed in the literature. In addition, this study explores the contribution of several 
other structural factors in addition to Medicaid coverage of methadone and buprenorphine. Utilizing an 
adapted framework from a study investigating the factors associated with state coverage of Medicaid 
optional services, this study includes structural factors related to the economic environment and the 
need for treatment within states.193 These variables include the percent of residents receiving Medicaid 
in each state, per capita income of each state, the rate of opioid dependent individuals enrolled in 
substance use treatment and the rate of methadone or buprenorphine programs in each state.  
 
Methods 
 The primary objective of this study is to provide an individual-level investigation of the association 
between Medicaid coverage of methadone and buprenorphine and treatment wait times. We 
hypothesize that individuals enrolled in substance use treatment programs in states with Medicaid 
coverage of methadone and buprenorphine will experience shorter wait times to enter treatment. 
 The main predictor of interest in this study is whether the state in which a person sought treatment 
provided Medicaid coverage for methadone or buprenorphine (examined separately) in 1998 and 2008 
for the methadone analysis and 2006 and 2008 for the buprenorphine analysis. Additional independent 
variables include both individual-level demographic variables, program-level characteristics and 
structural variables. The structural variables served as state-level fixed effects estimators in order to 
help account for the unobserved heterogeneity of the state environment when examining the effect of 
state Medicaid policy. A detailed description of each of these variables is provided below. Finally, the 







 Individual level data regarding admission to substance use treatment in 1998, 2006 and 2008 were 
obtained from the Treatment Episodes Data Set-Admissions (TEDS-A), an administrative data set 
containing annual admissions of individuals 12 years of age and older to licensed substance use 
treatment programs in the United States.126 TEDS-A data are publicly available through the Substance 
Abuse and Mental Health Data Archive (SAMHDA).127  The TEDS-A data represent annual encounters in 
substance use treatment, rather than individual clients, such that if a single individual had multiple 
episodes in substance use treatment programs in a given year, each treatment episode is counted 
separately.  
 Once TEDS-A data were obtained, separate methadone and buprenorphine datasets were created 
by matching structural variables with the state indicator variable representing the state in which a 
person sought substance use treatment. State matching was carried out for each study year and then 
merged into a final dataset for each treatment type containing both study years. The final methadone 
dataset contained data for 1998 and 2008 and the final buprenorphine dataset contained 2006 and 
2008 data. The unit of analysis in each final dataset was person-year.  
 A description of the analytic sample is provided in Figure 2A.1. For the methadone analyses, the 
sample for each study year was restricted to individuals enrolled in any type of substance use treatment 
in 1998 and 2008 in the following fourteen states for which there were sufficient data available for the 
outcome of interest, main predictor variables and the combined year analyses: Arizona, Colorado, 
Florida, Hawaii, Idaho, Iowa, Kansas, Louisiana, Montana, New Hampshire, New Mexico, Ohio, South 
Carolina and Wyoming.  
For the buprenorphine analyses, there were 24 states with sufficient data available for the outcome 
of interest, main predictor variables and the combined year analyses. The buprenorphine sample 
included individuals enrolled in any type of substance use treatment in 2006 and 2008 in Arizona, 
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Arkansas, California, Colorado, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maryland, 
Michigan, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, 
South Dakota, Utah and Wyoming.  
 
Independent Variables  
Individual and Program-Level Variables 
Individual and program-level variables obtained from the TEDS-A for both the methadone and 
buprenorphine analyses included sex, age, race, gender, education, marital status, income, unstable 
housing, drug use, psychiatric problems, treatment type, provider type and insurance coverage.  
 
Structural variables 
 Structural variables included the percent of residents in each state receiving Medicaid, per capita 
income of each state, rate of opioid dependent individuals enrolled in substance use treatment, rate of 
methadone or buprenorphine programs in each state and state Medicaid coverage of methadone and 
buprenorphine. Each continuous structural variable (percent of residents in receiving Medicaid, per 
capita income, rate of opioid dependent individuals enrolled in treatment and the rate of methadone or 
buprenorphine programs) was standardized by dividing the mean score by the standard deviation in 
order to create a common scale. A description of each structural variable follows. 
 
Percent of Residents Receiving Medicaid 
 Data regarding Medicaid beneficiaries were obtained from the Centers for Medicaid and Medicare 
(CMS), Medicaid Statistical Information System.  The total number of beneficiaries was obtained for 
each state and then the proportion of residents receiving Medicaid was calculated using population 
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totals obtained from the United States Census. Data were obtained for 1999 (1998 Medicaid beneficiary 
data were not available), 2006 and 2008. 
 
State Per Capita Income 
 Per capita income was obtained from the US Department of Commerce, Bureau of Economic 
Analysis for 1998, 2006 and 2008, and was based on the total personal income in each state, divided by 
the total midyear population. 
 
Rate of Opioid Dependent Individuals Enrolled in Substance Use Treatment 
 The number of opioid dependent individuals receiving substance use treatment was gathered from 
the TEDS-A data set for the years 1998, 2006 and 2008. In order to standardize the number of 
individuals per state, a treatment rate of individuals per 1 million population was calculated based on 
the number of opioid dependent individuals in any type of substance use treatment each year and the 
population of each state.  
 
Rate of Methadone and Buprenorphine Programs 
 The number of opioid treatment programs was obtained from the Uniform Facility Data Set (UFDS) 
for 1998, and the National Survey of Substance Abuse Treatment Services (N-SSATS), formerly known as 
the UFDS, for 2006 and 2008. The UFDS and N-SSATS include all private and publicly funded substance 
use treatment programs in the United States. The UFDS and N-SSATS data used for this study were 
limited to the total number of programs providing methadone in 1998 or 2008 and buprenorphine in 
2006 and 2008. In order to standardize the number of programs per state, a program rate of programs 
per 10,000 population was calculated based on the number of methadone and buprenorphine programs 
(calculated separately) and the population of each state.  
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Medicaid Coverage of Methadone and Buprenorphine 
State Medicaid coverage of methadone for 1998 and 2008 was obtained from two sources. For 
1998, data were obtained from McCarty et al’s study, “Methadone Maintenance and State Medicaid 
Managed Care Programs”.142  For 2008, Medicaid coverage of methadone by state was obtained from 
the State Financing for Medication Assisted Treatment study. 9 For both study years, Medicaid coverage 
of methadone was dichotomized as yes/no. 
 State Medicaid coverage of buprenorphine in 2006 was gathered from Ducharme at al’s study, 
“State policy influence on the early diffusion of buprenorphine in community treatment programs”.54 
Similar to the 2008 data used for methadone, data for Medicaid coverage of buprenorphine in 2008 
were obtained from the State Financing for Medication Assisted Treatment study. Finally, similar to 
methadone, Medicaid coverage of buprenorphine was dichotomized as yes/no for both 2006 and 2008. 
 
Dependent variable 
 Wait time for entrance into substance use treatment was gathered from TEDS-A for 1998, 2006 and 
2008. The TEDS-A defines wait time as the number of days a person waited to enter a treatment facility, 
based on the time of their initial request for treatment entry and the time that they were admitted to 
the program. The TEDS-A definition is based solely on delays due to treatment capacity, availability, or 
requirements due to admission or other programmatic factors. This wait time variable includes only 
successful admissions to treatment and does not reflect delays that were the result of individual factors, 
such as unavailability or failure to meet an obligation.  
 
Analytic Approach  
 Descriptive statistics were calculated to determine the distribution of the outcome variable, 
treatment wait time. Univariate analysis indicated that treatment wait time was heavily skewed towards 
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zero (range=0-996; mean=5.13, median=0, mode=0, variance=608). Poisson Regression (PR), Negative 
Binomial Regression (NBR) and Zero-Inflated Negative Binomial Regression (ZINBR) were all considered 
for modeling the relationship between the predictor variables and treatment wait time. Given the 
overdispersion of the treatment wait time variable, and the fact that PR could lead to false significance 
when overdispersion is evident, PR was ruled out.207,208 While ZINBR can be utilized for models with an 
excess of zeros, it assumes that the zeros come from two sources, sampling (those that occur by 
randomly) and structural (those that occur through systematic error); thus, the zeros are modeled 
differently based on these assumptions.209 The zeros reported for treatment wait time in the TEDS 
dataset are not believed to be subject to any systematic bias and therefore should not be modeled 
separately. Given the inappropriateness of both PR and ZINBR for these analyses, and the fact that NBR 
has more flexibility in handling overdispersion, NBR was selected. 
 Bivariate NBR was used to assess the unadjusted association between the main predictor of interest, 
Medicaid coverage of methadone and buprenorphine, and the amount of time individuals waited to 
enter substance use treatment. Multivariable NBR was then used to model the relationship between the 
remaining predictor variables and wait time for treatment entry in a stepwise fashion. Models were 
developed for each treatment type by single study year and combined study years (only the combined 
year analyses are presented here). An interaction term of Medicaid coverage and time (Medicaid 
coverage*time) was added to each combined year model to account for the combined effects of these 
variables on treatment waiting times. To assist with the interpretation of the NBR estimates, 
coefficients in each model were transformed using the formula: (e-1)(100) to provide the percent 
change in the number of days spent waiting to enter treatment, given a one unit difference in the 
predictor variable.  
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 All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Associations were 
considered statistically significant at the p<.05 level. The City University of New York’s Human Research 
Protections Program Office approved this study. 
  
Missing Data 
Missing data can be categorized in three ways: missing completely at random (MCAR), missing at 
random (MAR) and missing not at random (MNAR). When data are MCAR, there are no distinguishable 
patterns of variables leading the data to be missing; thus, these data will not bias the estimated 
relationships given the fact that missingness occurs because of random events.144,146–149  When data are 
MAR, the probability that the data are missing is based on observable characteristics within a study 
population but are not related to the outcome of interest.147,148 Finally, when data that are MNAR occur 
when the probability that an item is missing is dependent upon unobserved information among a subset 
of participants.147,148  
To explore missingness in this study, cases containing missing data were compared to those without 
missing data on all variables for each study year. The results of these comparisons revealed that the 
samples were significantly different on nearly every study variable, indicating that the data are not likely 
MCAR (Tables 2A.1, 2A.2, 2B.1 and 2B.2). While there is no test to determine whether data are MAR or 
MNAR, most missing data are treated as MAR.150 Data in this study were treated as MAR and two 
missing data techniques were employed prior to analyses: Listwise Deletion (LD) and Multiple 
Imputation (MI). An a priori cutoff of no more than 55% missing data on any one variable served as the 
criteria for the inclusion of cases in this study. This criteria was chosen in order to balance geographic 
representation, sufficient variability in Medicaid coverage of methadone and buprenorphine and the 
inclusion of relevant covariates. 
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Listwise Deletion was carried out by eliminating all cases from each dataset that contained at least 
one missing value for any study variable. A dummy variable indicating missing data for any one of the 
variables of interest was created and the sample was then restricted based on those cases in which 
there were no missing data. Multiple imputation was performed using the Markov Chain Monte Carlo 
method in SAS 9.3 (SAS Institute, Cary, NC). While there is some disagreement regarding the inclusion of 
outcome variables in MI181–183, the dependent variable, along with all other study variables, were 
included in the MI procedures in this study. Each single year dataset was imputed five times. LD and MI 
were performed for each single study year; however, only LD could be performed in the combined year 
analyses due to the very large sample size.  
 
Resampling 
The samples used for the methadone and buprenorphine analyses were very large, even after 
restricting by study criteria and to those individuals with complete case data. With such large data sets, 
the number of significant associations are likely to increase.184 These associations, while statistically 
significant, may have very small effect sizes, reducing the utility of the p-value as the sole basis for 
interpreting study findings.185 To address this potential limitation, effect sizes and confidence intervals 
are presented alongside p-values in each model.184  
Bootstrapping, a resampling technique used to validate non-normally distributed data, was 
performed on all LD samples to ensure that model results were consistent when performed on smaller 
and different samples. Bootstrapping was chosen because it is known to produce stable, unbiased 
estimates that demonstrate good internal validity, which is critical with large samples. Bootstrapping 
was employed using an unrestricted random sample of individuals from each single year and combined 
year LD dataset for each treatment type. Each sample was replicated in 100 separate datasets which 
were then combined to form a final sample for each study year and treatment. 
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The final models presented in this paper are from the combined year (1998-2008 for methadone 
and 2006-2008 for buprenorphine) bootstrapped LD analyses. The reader is referred to Tables 2A.6-
2A.12 for the remaining combined year and single year methadone analyses, and Tables 2B.6-2B.12 for 
the remaining combined year and single year buprenorphine analyses. 
 
Results 
 Figures 2A.1 and 2B.1 describe how the final analytic samples for the methadone and 
buprenorphine analyses were obtained. The demographic characteristics of the final combined 1998-
2008 methadone and 2006-2008 buprenorphine LD bootstrapped samples that are presented in this 
paper are displayed in Tables 2A.3 and 2B.3, respectively.   
 
Methadone Sample 
 A total of 26,100 people were included in the methadone sample. The sample was predominantly 
male (71%), white (73%) and non-Hispanic (88%). Almost two-thirds of the sample completed high 
school (63%), one-quarter were married, 40% were employed and 40% were living in an unstable 
housing situation at the time of treatment entry. The majority of the sample was attending outpatient 
treatment (64%), 1% were receiving medication assisted treatment and 9% reported some form opioid 
use at admission. Finally, slightly less than half of the sample (43%) was enrolled in substance use 
treatment in states that provided Medicaid coverage of methadone. As shown in Table 2A.4, individuals 
receiving treatment in states with Medicaid coverage of methadone were more likely to be older, male, 
white, Hispanic, have a high school education, unstably housed, enrolled in a detoxification program, 
utilizing MAT, using heroin, using one drug at the time of admission, have private insurance, a pension, 
and seeking treatment in a state with greater per capita income and an increased number of methadone 
programs per 10,000 population.  
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 Table 2A.5 describes the findings from the unadjusted and adjusted NBR models investigating the 
association between Medicaid coverage of methadone and the number of days a person waited to enter 
substance use treatment. Given the large number of significant findings across the models, only the 
main predictor variable of interest, Medicaid coverage of methadone, and those significant predictors 
with a percent change of 50% or greater are explored in detail.  
 Model 1 describes the results of the bivariate association between Medicaid coverage of methadone 
and the number of days a person waited to enter substance use treatment. This unadjusted association 
indicated that Medicaid coverage of methadone was associated with an 11% decrease in the number of 
days that individuals waited to enter treatment (p=<0.001).  
 Model 2 explored the relationship between Medicaid coverage of methadone and treatment wait 
time with the addition of demographic variables including sex, race, ethnicity, education, marital status, 
employment, unstable housing and age. Medicaid coverage of methadone was not significant in this 
model (p=0.14); however, both being Hispanic and less than 18 years of age, as compared with being 
over 45, were associated with treatment wait time. Hispanics experienced a 53% decrease in the mean 
number of days they waited to enter treatment, as compared with non-Hispanics (p=<0.0001), and 
individuals that were less than 18 years of age experienced a 78% increase in the mean number of days 
they waited to enter treatment, as compared with individuals 45 years of age and over (p=<0.0001).  
 Model 3 included all significant and non-significant variables from Model 2, as well as predictors 
related to substance use and treatment, including treatment program type, MAT use, psychological 
problems, the total number and type substances used at the time of treatment admission and whether 
the person was injecting drugs at the time of admission. The results of Model 3 indicate that, when 
controlling for demographic and drug-related variables, Medicaid coverage of methadone was 
negatively associated with treatment wait time, with individuals receiving treatment in states with 
Medicaid coverage of methadone experiencing a 15% decrease in the number of days they waited to 
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enter treatment, as compared with individuals in states without Medicaid coverage of methadone 
(p=<0.0001). In addition to Medicaid coverage of methadone, Hispanic ethnicity remained negatively 
associated with treatment wait time (57% decrease in mean days; p=<0.0001), and being less than 18 
years of age, as compared to individuals aged 45 and older, continued to be associated with an increase 
in treatment wait time (58% increase in mean days; p=<0.0001). Being enrolled in a detoxification 
program, as compared to a rehabilitation program, was associated with a 88% decrease in the mean 
number of days a person waited for treatment (p=<0.0001), and individuals receiving MAT experienced 
a 68% decrease in treatment waiting time, as compared to individuals not using MAT (p=<0.0001). 
Finally, individuals reporting benzodiazepine use experienced a 60% increase in the mean number of 
days they waited to enter treatment, as compared with non-benzodiazepine users (p=<0.001). 
 Model 4 contained all of demographic and substance use variables from Models 2 and 3, in addition 
to health insurance coverage and primary source of income. Similar to Models 2 and 3, Medicaid 
coverage of methadone was associated with a 16% decrease in the mean number of days individuals 
waited to enter treatment, as compared to individuals in states without Medicaid coverage of 
methadone (p=<0.0001). Hispanic ethnicity (56% decrease; p=<0.0001), enrollment in detoxification, as 
compared to rehabilitation (89% decrease; p=<0.0001), and MAT use (66% decrease; p=<0.0001), all 
continued to be associated with a reduction in the mean number of days waiting to enter treatment 
wait time. Being less than 18 years of age, as compared with individuals 45 and over (61% increase; 
p=<0.0001), using benzodiazepines (52% increase; p<0.05), having Medicaid, as compared to private 
insurance (63% increase; p=<0.0001), and having a retirement or pension as the primary source, as 
compared with a salary (72% increase; p=<0.0001), were all associated with increased wait time. 
 In Model 5, structural variables related to the state environment, including per capita income, rate 
of methadone programs, rate of opioid dependent individuals in substance use treatment and the 
percent of Medicaid beneficiaries were added as fixed effects estimators to the demographic, substance 
71 
 
use, health insurance and income variables included in Model 4. The addition of these state-level 
variables resulted in a change in the direction of the association between Medicaid coverage of 
methadone and treatment wait time. In Model 5, individuals receiving treatment in states with Medicaid 
coverage of methadone experienced a 90% increase in the mean number of days they waited to enter 
treatment, as compared with individuals receiving treatment in states without Medicaid coverage of 
methadone (p=<0.0001). This was the only significant variable in which the direction of the association 
changed in Model 5. Enrollment in a detoxification program, as compared to rehabilitation (92% 
decrease, p=<0.0001), and MAT use (67% decrease, p=<0.0001) remained negatively associated with 
treatment wait times, and reporting zero substances of abuse at treatment entry, as compared to three 
substances, was also associated with a decrease in treatment wait time (55% decrease, p=<0.0001). 
Finally, being under the age of 18, as compared to being 45 years of age or older (84% increase, 
p=<0.0001), and having a retirement or pension, as compared to a salary as the primary source of 
income (57% increase, p=<0.0001) were all associated with an increase in treatment wait time. 
 In Model 6, time was added to account for differences between 1998 and 2008. In this model, time 
was associated with an increase in treatment wait time, with individuals receiving treatment in 2008 
experiencing a 239% increase in the mean number of days they waited for treatment, as compared with 
individuals in 1998 (p=<0.0001). The addition of time also strengthened the association between 
Medicaid coverage of methadone (123% increase, p=<0.0001), being under 18 years of age, as 
compared to being over 45 (99% increase, p=<0.0001), enrollment in detoxification, as compared to 
rehabilitation (92% decrease, p=<0.0001) and having no insurance, as compared to private insurance 
(60% increase, p=<0.0001) and treatment wait time. The associations between enrollment in MAT (67% 
decrease, p=<0.0001) and individuals whose primary source of income was retirement or pension, as 
compared to salary (57% increase, p=<0.0001) remained similar to the associations observed in Model 5. 
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 Model 7 included all of the predictor variables used in Model 6, as well as the addition of an 
interaction term for Medicaid coverage and time. The interaction term was negatively associated with 
treatment wait time in this model, suggesting that Medicaid coverage of methadone impacted 
treatment wait time differently in 1998 than in 2008 (50% decrease, p=<0.0001). The addition of the 
interaction term to Model 7 increased the association between Medicaid coverage of methadone and 
treatment wait time, with individuals receiving treatment in states with Medicaid coverage experiencing 
a 219% increase in the amount of time they waited to enter treatment, as compared with individuals in 
states without Medicaid coverage of methadone (p=<0.0001). The interaction term also strengthened 
the association between time and treatment wait time, with individuals in the 2008 sample experiencing 
a 410% increase in the amount of time they waited to enter treatment, as compared with individuals in 
1998 (p=<0.0001). Additionally, being under 18 years of age (92% increase, (p=<0.0001) as compared 
with individuals 45 and over, having no insurance, as compared to having private insurance (57% 
increase, p=<0.0001) and having a retirement or pension as your primary source of income, as compared 
with a salary (55% increase, p=<0.0001), were all associated with increased treatment wait times. 
Finally, being enrolled in a detoxification program, as compared with rehabilitation (92% decrease, 
p=<0.0001), utilizing MAT (67% decrease, p=<0.0001), and reported no substances of abuse at 
treatment admission, as compared to individuals reporting three substances (51% decrease, p=<0.001), 
were all associated with reduced treatment wait times. 
 
Buprenorphine Sample 
 As described in Table 2B.3, a total of 25,300 individuals were included in the buprenorphine sample. 
The sample was predominantly male (69%), white (66%) and non-Hispanic (89%). Almost two-thirds of 
the sample (64%) were high school educated and close to one-half (45%) reported an unstable housing 
situation at the time of treatment enrollment. Outpatient treatment was the most common form of 
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treatment (59%), 5% of the sample was receiving either methadone or buprenorphine, and 20% of the 
sample reported using some form of opioids at the time of treatment enrollment.  
 As detailed in 2B.4, individuals who attended treatment programs in states with Medicaid coverage 
of buprenorphine were more likely to be black, other race, unstably housed, less than 18 years of age 
and over 34 years of age, be enrolled in an outpatient treatment program, utilize MAT, use heroin, 
opioids and crack, report two or fewer substances of abuse at the time of treatment admission, be 
covered by Medicaid, Medicare and private insurance, report public assistance, retirement/pension, 
other income and salary as their primary source of income, wait longer to enter substance use 
treatment and seek treatment in states with higher per capita income, an increased number of 
buprenorphine programs and a higher rate of individuals in substance use treatment.  
 Table 2B.5 presents the results from the unadjusted and adjusted NBR models investigating the 
association between Medicaid coverage of buprenorphine and treatment wait time. Similar to the 
methadone results, only the main predictor variable of interest, Medicaid coverage of buprenorphine, 
and those significant predictors with a percent change of 50% or greater will be explored in detail.  
 In the unadjusted analysis presented in Model 1, individuals receiving treatment in states with 
Medicaid coverage of buprenorphine experienced a 75% increase in the mean number of days they 
waited to enter substance use treatment, as compared to individuals in states without Medicaid 
coverage of buprenorphine (p=<0.001).  
 Model 2 contained Medicaid coverage of buprenorphine along with the addition of demographic 
variables, including sex, race, ethnicity, education, marital status, employment, unstable housing and 
age. Medicaid coverage of buprenorphine continued to be associated with an increase in treatment wait 
time, as compared to individuals in states without Medicaid coverage of buprenorphine (82% increase, 
p=<0.001). In addition, being less than 18 (80% increase, p=<0.001), 18-24 (65% increase, p=<0.001) and 
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25-34 years of age (57% increase, p=<0.001) were all associated with an increase in the mean number of 
days individuals waited to enter substance use treatment, as compared to individuals over 44 years old. 
 Model 3 contained Medicaid coverage of buprenorphine and demographic variables that were 
included in Model 2, as well as variables related to substance use and treatment, including treatment 
program type, MAT use, psychological problems, the total number and type of substances used at the 
time of treatment admission and whether the person was injecting drugs at the time of admission. 
Medicaid coverage of buprenorphine remained associated with an increase in treatment wait time (67% 
increase, p=<0.001). Additionally, attending detoxification programs, as compared with rehabilitation, 
was associated with a 70% decrease in treatment wait time (p=<0.001). 
 Model 4 contained all of the demographic and substance use and treatment variables from Models 
2 and 3, in addition to health insurance coverage and primary source of income. In Model 4, Medicaid 
coverage of buprenorphine was associated with a 63% increase in the mean number of days individuals 
waited to enter treatment, as compared with individuals in states without Medicaid coverage of 
buprenorphine (p=<0.001). Similar to Model 3, detoxification program enrollment was associated with a 
70% decrease in the mean number of days individuals waited to enter treatment, as compared to 
rehabilitation programs (p=<0.001). Finally, having Medicare was associated with a 54% increase in 
treatment wait time (p=<0.001). 
 Model 5 contained all variables included in the previous models, with the addition of the following 
state fixed effects estimators: per capita income, rate of buprenorphine programs, rate of opioid 
dependent individuals in substance use treatment and the percent of Medicaid beneficiaries. The 
addition of the state-level fixed effects strengthened the association between Medicaid coverage of 
buprenorphine and treatment wait time, such that individuals receiving treatment in states with 
Medicaid coverage of buprenorphine experienced a 260% increase in the mean number of days they 
waited to enter substance use treatment, as compared with individuals in states without Medicaid 
75 
 
coverage of buprenorphine (p=<0.001). In addition, the association between use of detoxification 
programs, as compared to rehabilitation programs, strengthened (82% decrease in wait time, p=<0.001), 
and the positive association between Medicare coverage and treatment wait time also became stronger 
(79% increase in wait time, p=<0.001). Finally heroin use was associated with a 67% increase in 
treatment wait time (p=<0.05). 
 In Model 6, time was added to the variables used as predictors in Model 5. Unlike the methadone 
analysis, time was not significant. The association between Medicaid coverage of buprenorphine and 
wait time remained significant in Model 6, with individuals receiving treatment in states with Medicaid 
coverage of buprenorphine experiencing a 267% increase in the mean number of days they waited to 
enter treatment, as compared with individuals in states without Medicaid coverage of buprenorphine. 
Finally, detoxification, as compared with rehabilitation, remained associated with a reduction in 
treatment wait time (82% decrease, p=<0.001) and heroin use (67% increase, p=<0.05) and Medicare 
coverage (79% increase, p=<0.001) were associated with an increase in treatment wait times.  
 In Model 7, the predictor variables used in Models 1-6 remained and an interaction term for 
Medicaid coverage and time was added. Unlike the methadone analysis, the interaction term was not 
associated with treatment wait time, suggesting that Medicaid coverage of buprenorphine did not have 
a differential impact on treatment wait time across study years. The addition of the interaction term did, 
however, increase the association between Medicaid coverage of buprenorphine and treatment wait 
time. When accounting for the interactive effect of Medicaid coverage of buprenorphine over the two 
study time periods, individuals receiving treatment in states with Medicaid coverage of buprenorphine 
experienced a 344% increase in the amount of time they waited to enter treatment, as compared with 
individuals in states without Medicaid coverage of buprenorphine (p=<0.0001). Finally, similar to Models 
5 and 6, detoxification, as compared with rehabilitation, was associated with decreased treatment wait 
time (82% decrease, p=<0.001), and heroin use (72% increase, p=<0.05) and Medicare (83% increase, 
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p=<0.001) were associated with an increase in the mean number of days individuals waited to enter 
substance use treatment. 
 
Discussion 
 This study tested the hypothesis that Medicaid coverage of methadone and buprenorphine would 
be associated with a reduction in the amount of time individuals waited to enter substance use 
treatment. The findings from the final models in this study do not support this hypothesis. For both 
methadone and buprenorphine treatment, state Medicaid coverage was associated with a significant 
increase in treatment wait time. The study hypothesis was driven by the expectation that Medicaid 
coverage of methadone and buprenorphine would increase the availability and accessibility of these 
treatments because more programs would offer these treatments and more individuals would utilize 
them. As described in Tables 2A.4 and 2B.4, in both the methadone and buprenorphine samples, there 
was an increased number of methadone and buprenorphine treatment programs per 10,000 population 
and an increased rate of opioid dependent individuals in substance use treatment in states with 
Medicaid coverage of methadone and buprenorphine. While the rate of opioid dependent individuals in 
each state was accounted for, the wait time variable was calculated for all individuals seeking substance 
use treatment, regardless of the type of substance of abuse. Limiting this control to only those 
individuals that were opioid dependent in each state might account for this unexpected association, 
particularly because in the methadone analysis, the direction of the association shifted from a decreased 
wait time among individuals receiving treatment in states with Medicaid coverage of methadone to an 
increased wait time when these state-level control variables were added to the model. 
 Several of the findings from this study are consistent with the literature, including the associations 
between unemployment96, unstable housing/homelessness96, and lack of health insurance94 and 
increased treatment wait time. Unlike other studies, this study did not find an increase in treatment wait 
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times for blacks, cocaine users or individuals with psychological problems. Additionally, similar to 
previous studies in which findings regarding sex were mixed,100,102,105 males in this study experienced 
increased wait times in the methadone analysis, but decreased wait times in the buprenorphine 
analysis. Similar to other studies, our findings regarding age were also inconsistent across the 
methadone and buprenorphine analyses.106,117 In the methadone analysis, individuals less than 18 years 
of age experienced the longest treatment wait time, whereas individuals aged 25-34 experienced the 
longest wait time in the buprenorphine analysis.  Finally, the strongest association found in this study 
was between time and treatment wait time in the methadone analysis, with individuals enrolled in 
substance treatment in 2008 waiting 410% longer to enter treatment than individuals enrolled in 
substance use treatment in 1998.  
 
Limitations 
Multiyear data regarding Medicaid coverage of methadone and buprenorphine by state were not 
available for consecutive years. This limited my ability to detect the direct impact of this policy, 
particularly when the policy changed in some states. Given this limitation, it is not possible to determine 
whether Medicaid policy regarding coverage of methadone and buprenorphine led to an increase or 
decrease in the number of methadone and buprenorphine programs or individuals seeking treatment 
for opioid dependence. The findings presented in this paper simply indicate that some of the factors 
examined were associated.  
This study utilized data from TEDS-A, which, for the most part, only includes individuals enrolled in 
publicly funded substance use treatment programs. The majority of privately owned treatment facilities, 
which according to SAMHSA accounts for approximately twenty-nine percent of outpatient methadone 
programs, are not included in the TEDS-A data.201 Additionally, individuals treated through private 
physicians that are not contained within a substance use treatment facility, which is the case for the 
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majority of buprenorphine patients, are not included in TEDS-A.202 The amount of time that individuals 
in private treatment programs and those being seen by individual doctors waited to enter a treatment 
program is unknown; therefore, the exclusion of these individuals may result in a skewed representation 
of treatment wait times for methadone and/or buprenorphine patients overall. 
Finally, there was a significant amount of missing data for the outcome of interest in this study. 
Multiple imputation and listwise deletion were performed on each single year sample; however, only 
listwise deletion and bootstrapped listwise deletion could be performed on the combined year samples 
due to the very large sample size. For the 1998 methadone analyses, the association between Medicaid 
coverage of methadone and treatment wait time differed, with the bootstrapped LD (Table 2A.10) and 
LD (Table 2A.11) analyses indicating that Medicaid coverage of methadone was associated with a 
decrease in treatment wait time. The MI analysis (Table 2A.12), however, indicated that Medicaid 
coverage was significantly associated with an increase in treatment wait time, which was consistent with 
the findings of the 1998-2008 bootstrapped LD analysis presented in this paper. The 2008 bootstrapped 
LD (Table 2A.7), LD (Table 2A.8), and MI analyses (Table 2A.9) all indicated that Medicaid coverage of 
methadone was significantly associated with an increase in treatment wait time, which is also consistent 
with the findings presented in this paper, although the effect size in the 2008 MI methadone analysis is 
smaller than the effect size in the LD and bootstrapped LD analyses. For the single year buprenorphine 
analyses, the findings are consistent with the direction of the bootstrapped 2006-2008 LD analysis 
presented in this paper, in that they also indicate that Medicaid coverage of buprenorphine was 
associated with an increase in treatment wait time. Both single year buprenorphine MI analyses (Tables 
2B.9 and 2B.12), however, produced more conservative effect sizes than the single year LD (Tables 2B.8 
and 2B.11), single year bootstrapped LD (Tables 2B.7 and 2B.10) and the combined year bootstrapped 
LD (Table 2B.5) presented in this paper. While these associations were all significant, the variability in 
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the effect sizes across these analyses warrants a cautious interpretation of the extent of the combined 
year associations presented in this paper. 
 
Conclusion 
 Overall, the findings of this study highlight significant delays to substance use treatment entry. 
Individuals in the methadone sample waited an average of five days to enter treatment, and individuals 
in the buprenorphine sample waited an average of 6 days to enter treatment. In addition, several 
variables included in these analyses were associated with an even greater increase in average wait time, 
including Medicaid coverage of methadone and buprenorphine and younger age. Taken together, these 
findings indicate a significant gap in the demand versus availability of substance use treatment in the US. 
Further, given the fact that attrition for treatment entry is most significant within the first twenty-four 
hours after the initial contact is made with a program, these findings may provide insight into the low 









Between 2002 and 2012, substance use treatment admissions for opioid dependence increased 
steadily in the United States, from 18% to 26%, while treatment for alcohol, marijuana, cocaine and 
methamphetamines have either decreased or remained stable.1 Several types of treatment are currently 
available for opioid dependence, but they fall into two main categories of modality: drug-free 
inpatient/outpatient treatment, which includes inpatient rehabilitation programs such as therapeutic 
communities, and outpatient support groups such as Narcotics Anonymous which are largely focused on 
abstinence; and medication-assisted treatment (MAT), which includes methadone, buprenorphine and 
naltrexone. Of these forms of treatment, MAT have been shown to be the most effective at reducing on-
going opioid use by suppressing withdrawal symptoms and blocking the effects for other opioids, such 
as heroin.4,5,35,36 This quality is critical in treating opioid dependence because it can both reduce the 
likelihood of sustained or increased use of other opioids, as well as decrease the likelihood of overdose.  
Despite overwhelming evidence supporting the effectiveness of MAT, these treatments are provided 
by a minority of substance use treatment programs and used by only 10% of opioid dependent 
individuals.3,68,210 Further, a recent longitudinal analysis of substance use treatment data indicates that 
MAT utilization is declining, even in the face of a sustained increase in opioid use and dependence in the 
United States. Between 2002 and 2012, the use of MAT decreased from 35% to 28%.1  
Previous research investigating potential explanations for limited uptake and provision of MAT has 
found individual level factors, such as cocaine injecting or crack smoking60,61, homelessness62, recent or 
previous incarceration61,62, injection drug use60–62, previous negative experiences with MAT63–65, 
perceived stigma associated with medication assisted treatments, particularly methadone,65–69 and the 
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perceived punitive treatment structure of methadone programs,70 to be associated with a decreased 
likelihood of MAT utilization. Factors previously found to be associated with an increased likelihood of 
MAT use include being female,61,62,71 married71, having Medicaid coverage62, use of heroin60,62,64, older 
age61,62 and having previously been in substance use treatment60,71. To date, we are unaware of any 
research investigating the relationship between structural factors such as Medicaid coverage of 
methadone, and the use of MAT by opioid dependent individuals, which is the primary objective of this 
study. In addition to Medicaid coverage of methadone, additional structural factors related to the 
economic environment and the need for substance use treatment within states were included in this 
study. The selection of these additional structural variables was guided by a framework developed by 
Schneider and Jacoby to investigate factors related to state coverage of Medicaid optional services. The 
structural factors utilized in this study include the percent of residents receiving Medicaid in each state, 
the rate of opioid dependent individuals enrolled in substance use treatment and the rate of methadone 
programs in each state.193  
 
Methods 
This study hypothesized that individuals receiving substance use treatment in states with Medicaid 
coverage of methadone will be more likely to utilize MAT than individuals receiving substance use 
treatment in states with no Medicaid coverage of methadone. To test this hypothesis, an individual-level 
analysis was conducted with Medicaid coverage of methadone as the main predictor of interest.  
Additional predictor variables included a combination of individual-level demographic characteristics, 
program-level characteristics and structural variables which served as proxies for the state environment. 





Analytic Sample  
Individual-level substance use treatment admission data were obtained from the Treatment 
Episodes Data Set-Admissions (TEDS-A) for the calendar years of 1998 and 2008. The TEDS-A is a publicly 
available administrative dataset comprised of new admissions to most publicly funded alcohol and 
substance use treatment facilities in the United States. TEDS-A data are available to the public by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) and reflect all encounters in 
publicly funded substance use treatment programs in a given year.127 The TEDS-A does not include an 
identifier to distinguish unique individuals; therefore, if the same person enters a treatment program 
three times in a given year, TEDS-A counts this as three distinct treatment episodes, rather than one.   
Once the TEDS-A data were obtained from SAMHSA, they were matched with state-level variables 
based on an indicator variable representing the state. For instance, if the methadone treatment rate for 
NJ was 40.5, every individual receiving treatment in NJ would have 40.5 for the methadone treatment 
rate variable in the final dataset. This matching was done for each study year and the data were then 
merged into a final dataset that contained both study years. In the final combined dataset, the unit of 
analysis was person-year. 
The analytic sample is described in Figure 3.1. Only opioid users were retained in the final dataset 
given that the outcome of this analysis is use of medication assisted treatment, and those treatments 
are only indicated for opioid users. The final sample was restricted to thirty eight states that had 
sufficient data for both study years on the main predictor variables of interest and the outcome variable. 
Individuals enrolled in substance use treatment in the following states were included in the final sample:  
Alaska, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, 
Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, 
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Individual and Program-Level Variables 
Individual and program-level variables such as sex, age, race, ethnicity, gender, education, marital 
status, employment, income, housing, drug use, program type and insurance coverage were obtained 
from TEDS-A.  
 
Structural Variables 
Structural variables used in this study included the percent of residents in each state receiving 
Medicaid, the rate of methadone programs in each state, the rate of opioid dependent individuals 
enrolled in substance use treatment in each state and state Medicaid coverage of methadone. Each 
continuous variable (percent of residents in receiving Medicaid, rate of opioid dependent individuals 
enrolled in treatment and the rate of methadone programs) was standardized by dividing the mean 
score of that variable by the standard deviation in order to create a common scale. A description of each 
structural variable follows. 
 
Percent of Residents Receiving Medicaid 
 Data regarding Medicaid beneficiaries were obtained from the Centers for Medicaid and Medicare 
(CMS), Medicaid Statistical Information System.  The total number of beneficiaries was obtained for 
each state and then the proportion of residents receiving Medicaid was calculated using population 
totals obtained from the United States Census. Data were obtained for 1999 (1998 Medicaid beneficiary 
data were not available) and 2008. 
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Rate of Opioid Dependent Individuals Enrolled in Substance Use Treatment 
 The number of opioid dependent individuals receiving substance use treatment was gathered from 
the TEDS-A data set for the years 1998 and 2008. In order to standardize the number of individuals per 
state, a treatment rate of individuals per 1 million population was calculated based on the number of 
opioid dependent individuals in any type of substance use treatment each year and the population of 
each state.  
 
Rate of Methadone Programs 
 The number of methadone programs was obtained from the Uniform Facility Data Set (UFDS) for 
1998, and the National Survey of Substance Abuse Treatment Services (N-SSATS), formerly known as the 
UFDS, for 2008. The UFDS and N-SSATS include all private and publicly funded substance use treatment 
programs in the United States. The UFDS and N-SSATS data used for this study were limited to the total 
number of programs providing methadone in 1998 or 2008. In order to standardize the number of 
programs per state, a program rate of programs per 10,000 population was calculated based on the 
number of methadone programs and the population of each state.  
 
Medicaid Coverage of Methadone 
State Medicaid coverage of methadone for 1998 and 2008 was obtained from two sources. For 
1998, data were obtained from McCarty et al’s study, “Methadone Maintenance and State Medicaid 
Managed Care Programs”.142 For 2008, Medicaid coverage of methadone by state was obtained from 
the State Financing for Medication Assisted Treatment study.9 For both study years, Medicaid coverage 






 Data regarding MAT utilization was gathered from TEDS-A for 1998 and 2008. In the TEDS-A, MAT is 
a category of treatment that includes two types of treatment: methadone and buprenorphine. The 
TEDS-A question regarding MAT does not, however, distinguish between these two treatment types. In 
1998, the only medication assisted treatment available in the United States was methadone; however, 
in 2008, buprenorphine was also available as a MAT option. This study utilizes both study years, but only 
examines the influence of Medicaid coverage of methadone on MAT use. 
 
Analytic Approach  
 Bivariate logistic regression was used to examine the unadjusted association between Medicaid 
coverage of methadone and the utilization of MAT. Multivariable logistic regression was then used to 
model the relationship between all predictor variables and MAT utilization in a stepwise manner. 
Models were tested for 1998, 2008 and the combined 1998-2008 years. The final combined year model 
included an interaction term to test for the combined effects of time and Medicaid coverage of 
methadone on the utilization of MAT.  
 All associations were considered statistically significant at the p<.05 level. Statistical analyses were 
performed using SAS 9.3 (SAS Institute, Cary, NC). The City University of New York’s Human Research 
Protections Program Office approved this study. 
 
Missing Data 
There was a significant amount of missing data in the 1998 and 2008 samples. Missing data can be 
missing completely at random (MCAR), missing at random (MAR) and missing not at random (MNAR). To 
explore the patterns of missing data in this study, comparisons were made between observations 
containing missing data and those with no missing data on all study variables for 1998 and 2008 (see 
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Tables 3.1 and 3.2). These comparisons indicated that cases with missing data were significantly 
different from cases with no missing data on nearly every study variable in 1998 and the majority in 
2008, indicating that the data were not likely MCAR. Data in this study were treated as MAR and both 
Listwise Deletion (LD) and Multiple Imputation (MI) were used to handle these missing data. For LD, 
cases that contained at least one missing value for any study variable were eliminated from analyses. 
For MI, all study variables, including the outcome variable, were included in the imputation procedure. A 
series of five imputations was performed using the Markov Chain Monte Carlo method in SAS 9.3 (SAS 
Institute, Cary, NC). While LD and MI were performed for each single study year; only LD could be 
performed in the combined year analyses due to the very large sample size.  
 
Resampling 
 Even after restricting the final dataset based on study criteria, the remaining sample sizes were 
quite large, raising concern regarding misleading inferences about relatively small effects.184 
Bootstrapping is a resampling technique used to validate non-normally distributed data and produce 
unbiased estimates that demonstrate good internal validity, which is crucial in large sample sizes.143 
Bootstrapping was performed on the single year and combined year LD samples to ensure that study 
findings were consistent across smaller and different samples. Bootstrapping was carried out using an 
unrestricted random sample of individuals selected from the 1998, 2008 and combined 1998-2008 LD 
datasets. Each of these samples was replicated in 100 separate datasets and then combined to form a 
final sample for analysis of the single and combined study years. 
The final stepwise models presented in this paper are from the combined year (1998-2008) 
bootstrapped LD analyses (see Table 3.5). The results of the 2008 bootstrapped LD analyses are 
contained in Table 3.7 and the 1998 bootstrapped LD analyses are presented in Table 3.10. For the 
results of the combined 1998-2008 LD analyses, the reader is referred to Table 3.6. The single year LD 
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results can be found in Tables 3.8 (2008) and 3.11 (1998). The results of the 2008 and 1998 MI analyses 
can be found in Tables 3.9 and 3.12, respectively.  
 
Results 
 Figure 3.1 depicts the various analytic sample sizes for each step of the analyses conducted, as well 
as for the overall sample and sample sub-sets. The demographic characteristics of the final combined 
1998-2008 bootstrapped LD sample are described in Table 3.3. The sample was predominately male 
(60%), white (66%) and non-Hispanic (93%). The majority of the sample was high school educated (67%), 
one-fifth were employed (20%) and over one-third were unstably housed (41%). The age of the sample 
was evenly distributed across all categories. The overwhelming majority of the sample (81%) was 
enrolled in non-rehabilitation treatment programs, such as detoxification or outpatient programs. Less 
than one-fifth (19%) of the sample was receiving MAT, and just over one-quarter reported having a 
psychological problem. Heroin was the most commonly used drug (71%), followed by cocaine/crack 
(35%) and synthetic opioids (33%). Close to half of the sample (43%) reported current IDU at the time of 
admission. The majority of the sample (53%) was uninsured and had no reported income (43%). The 
overwhelming majority of the sample (85%) were enrolled in substance use treatment programs in 
states that provided Medicaid coverage of methadone. As detailed in Table 3.4, individuals receiving 
treatment in states with Medicaid coverage of methadone were more likely to be male, black, other 
race, high school educated, unstably housed, older, enrolled in outpatient or detoxifications programs, 
receiving MAT, reporting heroin and cocaine/crack use, using 1 or 2 substances, an IDU, have Medicaid 
coverage or private insurance, report public assistance, retirement/pension or other income as their 
primary source of income and receive substance use treatment in states with a higher rate of 
methadone programs and opioid dependent individuals in treatment. 
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 Findings from the unadjusted bivariate and adjusted multivariate logistic regression analyses are 
displayed in Table 3.5. Given the large number of significant associations, only significant predictors with 
OR<0.5 or OR>2.0 will be explored in detail.   
 Model 1 tested the unadjusted association between the main predictor of interest, Medicaid 
coverage of methadone, and MAT utilization. This association was significant and indicated that being 
enrolled in substance use treatment programs in states with Medicaid coverage of methadone was 
associated with an increased odds of MAT utilization (OR=4.79; 95% CI 4.14-5.54). 
 In Model 2, Medicaid coverage of methadone was examined along with the addition of demographic 
characteristics including sex, race, ethnicity, education, marital status, employment, unstable housing 
and age. Medicaid coverage of methadone remained a significant predictor of MAT use in this model 
(OR=4.48; 95% CI 3.87-5.54). In addition, age was also significant, with individuals younger than 24 years 
old less likely to use MAT than individuals that were 45 years of age and older (OR=0.32; 95% CI 0.28-
0.36).  
 Model 3 examined Medicaid coverage of methadone along with the demographic variables in Model 
2 and the addition of predictor variables related to substance use and treatment, including treatment 
program type, MAT use, psychological problems, the total number and type of substances used at the 
time of treatment admission and whether the person was injecting drugs at the time of admission. 
Medicaid coverage of methadone continued to be associated with an increased odds of MAT utilization 
(OR=3.03; 95% CI 2.58-3.56). Individuals using heroin (OR=5.64; 95% CI 4.77-6.62), non-prescription 
methadone (OR=8.94; 95% CI 7.17-11.08), synthetic opioids (OR=3.94; 95% CI 3.39-4.58) and reporting 
one drug of abuse at treatment entry, as compared to individuals reporting three drugs (OR=4.18; 95% 
CI 3.65-4.77) also had an increased odds of using MAT. Attending a rehabilitation program, as compared 
with non-rehabilitation programs such as detoxification or outpatient (OR=0.17; 95% CI 0.14-0.20), and 
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younger age, particularly individuals less than 24 years age, as compared to 45 and over (OR=0.33; 95% 
CI 0.29-0.38), were associated with a decrease in the odds of using MAT.  
 Model 4 included all of the predictor variables contained in the previous models, as well as the 
addition of health insurance coverage and primary source of income. In this model, Medicaid coverage 
of methadone (OR=3.16; 95% CI 2.69-3.73), heroin use (OR=5.75; 95% CI 4.88-6.8), non-prescription 
methadone use (OR=8.25; 95% CI 6.63-10.31), synthetic opioid use (OR=3.90; 95% CI 3.36-4.55) and 
reporting one (OR=4.44; 95% CI 3.88-5.09)  or two (OR=2.03; 95% CI 1.83-2.24) drugs of abuse at 
treatment entry, as compared to reporting three drugs, were all associated with an increased likelihood 
of MAT use. Attending a rehabilitation program, as compared to detoxification or outpatient programs 
(p=0.16; 95% CI 0.14-0.19), and younger age, particularly being less than 24, as compared to individuals 
45 and over (OR=0.33; 95% CI 0.29-0.38), continued to be associated with a decreased likelihood of MAT 
use in Model 4. 
 Model 5 contained all variables utilized in the previous four models as well as the addition of 
structural variables related to the state environment, including the rate of methadone treatment 
programs, rate of opioid dependent individuals in treatment and the percent of residents receiving 
Medicaid. The addition of these structural variables strengthened the association between Medicaid 
coverage of methadone and MAT use (OR=6.11; 95% CI 5.03-7.4). In addition, use of heroin (OR=6.44; 
95% CI 5.41,7.66), non-prescription methadone (OR=7.17; 95% CI 5.70,8.98), synthetic opioids (OR=3.90; 
95% CI 3.32-4.57) and benzodiazepines (OR=2.03; 95% CI 1.69-2.44), as well as reporting one drug of 
abuse at treatment entry (OR=4.35; 95% CI 3.77-4.96), as compared to three drugs, were all associated 
with increased odds of MAT use. Similar to Model 4, attending a rehabilitation program, as compared to 
detoxification or outpatient programs (OR=0.16; 95% CI 0.14-0.19), and younger age, specifically being 
less than 24 years age, as compared to individuals 45 and over (OR=0.37; 95% CI 0.32-0.42), continued 
to be associated with decreased odds of MAT use. 
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 Model 6 included the variables used as predictors in Model 5, as well as the addition of the variable 
time to account for any differences in the two time periods. In this model, Medicaid coverage of 
methadone continued to be associated with an increased likelihood of MAT use (OR=6.42; 95% CI 5.26-
7.78), as did heroin use (OR=6.42; 95% CI 5.37-7.61), non-prescription methadone use (OR=7.17; 95% CI 
5.74-9.05), synthetic opioid use (OR=3.94; 95% CI 3.36-4.63), benzodiazepine use (OR=2.01; 95% CI 1.68-
2.43) and reporting one drug of abuse at treatment entry (OR=4.35; 95% CI 3.81-5.01), as compared 
reporting three drugs. Enrollment in a rehabilitation program, as compared to detoxification or 
outpatient programs (p=0.16; 95% CI 0.14-0.19), and being less than 24 years age, as compared to 45 
and over (OR=0.37; 95% CI 0.32-0.42), continued to be associated with a decreased likelihood of MAT 
use. 
 Model 7 included all of the predictor variables from Models 1-6 as well as the addition of an 
interaction term for Medicaid coverage and time. The interaction term was not significant in this model; 
however, Medicaid coverage (OR=5.37; 95% CI 3.72-7.76), use of heroin (OR=6.36; 95% CI 5.39-7.63), 
non-prescription methadone (OR=7.24; 95% CI 5.69-8.98), synthetic opioids (OR=3.97; 95% CI 3.34-4.6) 
and benzodiazepines (OR=2.03; 95% CI 1.67-2.42), as well as reporting one drug of abuse at treatment 
entry (OR=4.39; 95% CI 3.79-4.99), as compared to three drugs, all continued to be associated with an 
increased odds of MAT use. Finally, utilizing a rehabilitation program, as compared to detoxification or 
outpatient programs (p=0.16; 95% CI 0.14-0.19), and being less than 24 years age, as compared to 45 
and over (OR=0.37; 95% CI 0.32-0.42), continued to be associated with a decreased odds of MAT use. 
 
Discussion 
 This study tested the hypothesis that receiving substance use treatment in a state with Medicaid 
coverage of methadone would increase the likelihood of MAT use among opioid dependent individuals. 
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The findings from this study support this hypothesis. Across all seven models, Medicaid coverage of 
methadone was significantly associated with higher odds of using MAT for treatment. 
 In addition to Medicaid coverage of MAT, several variables remained significantly associated with 
higher odds of MAT utilization across models, but did not have an OR>2.0. These variables included 
being Hispanic, married, employed, cocaine use, benzodiazepine use, reporting two substances of abuse 
at admission, as compared to three, having no health insurance, receiving substance use treatment in 
states with an increased number of methadone programs and receiving treatment in a state with an 
increased percentage of Medicaid beneficiaries. Significant variables that were associated with reduced 
odds of MAT use across all study models, but did not have an OR<0.5, included being male, identifying 
as other race, as compared to white, being between 25-34 years old and 35-44 years old, as compared 
to being over 44 years old, reporting psychological problems, having a retirement/pension or no income 
as the primary source of income, receiving substance use treatment in a state with fewer opioid 
dependent individuals and receiving substance use treatment in 1998 as compared to 2008. 
 The significant factors associated with increased odds of MAT use in the final model of this study 
that are consistent with the literature include older age61,62, being married71, using heroin60,64, 
crack/cocaine use61, and having Medicaid coverage62. Factors in this study that were associated with 
reduced odds of MAT use that are consistent with the literature include being male61,62,71 and black62. 
Contrary to previous findings, this study found increased odds of MAT utilization among IDUs62 and no 
association between unstable housing and MAT use62,64.  
 The positive association between age and increased odds of MAT use that was found in this study, 
and has been observed in other studies, is particularly noteworthy given the current opioid epidemic. 
While the average age of individuals attending substance use treatment in the United States is 35 years 
old, recent trend data from TEDS-A indicate that between 2002 and 2012, the largest increase in 
treatment admissions due to heroin use was among 20-34 year old non-Hispanic whites.1 Given the 
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steady increase in the number of young opioid users over the last decade, and the importance of 
providing the most effective treatments to opioid dependent individuals as early on in their drug using 
careers as possible, it is critical that medication assisted treatments are available and accessible to 
young opioid users. Given this finding, and the precipitous increase in the use of opioids by young 
people in the United States, future research investigating the reasons for low MAT utilization among this 
population is critical.  
  
Limitations 
This study is subject to several limitations. The primary purpose of this study was to test the 
association between state Medicaid coverage of methadone and the use of methadone treatment by 
opioid dependent individuals. However, the TEDS-A does not distinguish between methadone and 
buprenorphine use; rather, these treatments are lumped together in one question about MAT use. In 
1998, methadone was the only approved MAT available for the treatment of opioid dependence in the 
United States; however, in 2008 buprenorphine was also available. An affirmative response to MAT use 
in the 2008 TEDS-A could indicate either methadone or buprenorphine treatment. In the 1998 analysis 
(Table 2A.10), Medicaid coverage of methadone was associated with an increased likelihood of MAT 
utilization (OR=2.33; 95% CI 2.06-2.62). In the 2008 analysis (Table 2A.8), this association was also 
significant, but stronger (OR=8.16; 95% CI 6.51-10.22). The strengthening of this association could be the 
result of several factors; however, it is possible that the increased association between study years is 
due to the inclusion of buprenorphine in the MAT question. Given this, this study may be subject to 
response bias due to the double-barreled question regarding MAT use in the 2008 TEDS-A. 
Another limitation of the TEDS-A data is that they do not represent the universe of treatment 
admissions in the United States. Rather, the majority of TEDS-A data come from publicly funded 
substance use treatment programs. Most privately owned treatment facilities, which account for 
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approximately twenty-nine percent of outpatient methadone programs in the United States, are not 
included in TEDS-A.201 The exclusion of privately funded substance use treatment programs may reduce 
the external validity of the findings in this study. 
Finally, missing data was a significant issue in this study. In order to address this limitation, MI and 
LD were performed on each single year sample. Additionally, bootstrapping was conducted on the LD 
samples to validate these findings. Due to the large sample size in the combined year analyses, MI could 
not be performed. In comparing the results across the three 1998 analyses, the associations between 
Medicaid coverage of methadone and MAT utilization were consistent, with the bootstrapped LD (Table 
3.10), LD (Table 3.11) and MI analyses (Table 3.12) indicating that individuals receiving treatment in 
states with Medicaid coverage of methadone had approximately twice the odds of using MAT, as 
compared with individuals in states with no Medicaid coverage of methadone. The findings across the 
2008 analyses were also consistent regarding the significant association between Medicaid coverage of 
methadone and MAT utilization; however, in the 2008 MI analysis (Table 3.9), the odds ratio was 2.59 
(95% CI 2.54-2.65), compared to 8.00 (95% CI 7.08-8.99) in the LD analysis (Table 3.8) and 8.16 (95% CI 
6.51-10.22) in the bootstrapped LD analysis (Table 3.7). In light of the variability in effect sizes across the 
2008 analyses, combined year analyses presented in this paper should be interpreted with caution. 
Despite the limitations of the TEDS-A, it is the only national data set containing substance use 
treatment admissions. These data are widely used by researchers and federal agencies to gain a better 
understanding of the characteristics of individuals enrolled in substance use treatment in the United 
States. The findings presented here, while subject to limitations, utilized TEDS-A data to provide a novel 







 Despite strong evidence supporting the effectiveness of MAT for treating opioid dependence, MAT 
utilization has decreased over the last decade. During the same time period, opioid use and dependence 
have increased significantly, particularly among non-Hispanic whites between the ages of 20-34. In this 
study, MAT use was negatively associated with age, such that individuals younger than 44 years old 
were less likely to utilize MAT as compared with individuals 45 and older. Understanding the factors 
associated with decreased utilization of MAT may help increase the availability and accessibility of these 
treatments, which may help to reduce the public health consequences of opioid dependence.   
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Chapter 8: Discussion and Conclusion 
 
The purpose of this dissertation was twofold: (1) to provide a state-level examination of the 
influence of factors related to the need for substance use treatment, and the extent to which the 
economic environment of states are correlated with Medicaid coverage of methadone and 
buprenorphine; and, (2) to investigate the impact that Medicaid coverage of these treatments has on 
individuals seeking substance use treatment in the United States, in terms of the amount of time a 
person waits to enter substance use treatment and the extent to which opioid dependent individuals 
utilize MAT.  
This chapter provides an overview of the study findings presented in Chapter 5, 6 and 7, policy 
recommendations related to these findings, limitations to this dissertation and a discussion of future 
research directions based on this work. 
 
Discussion of Results 
Is the economic situation of a state correlated with Medicaid coverage of methadone or 
buprenorphine? The findings of these analyses were mixed. Two measures, FMAP and per capita 
income, were significant across all study years for both methadone and buprenorphine, indicating that 
states with greater wealth were more likely to cover methadone or buprenorphine for Medicaid 
beneficiaries. The correlation between substance use treatment block grant funding, annual state 
expenditures and Medicaid coverage of methadone or buprenorphine were not consistent, varying in 
the year-to-year analyses, as well as across measures. The final measure of state wealth, the percent of 
residents receiving Medicaid, was not correlated with Medicaid coverage of methadone or 
buprenorphine in any study year. The lack of consistent findings across the remaining three economic 
variables and respective treatment types may provide evidence for a weak relationship between these 
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variables, or they may indicate that they are poor proxy variables for state wealth. The percent of 
residents receiving Medicaid and amount of substance abuse block grant funding states receive only 
capture the wealth, or lack thereof, of a portion of a state’s population; whereas, per capita income and 
FMAP rate serve as more general indicators of population wealth. Further research using these and 
other novel proxy measures for state wealth can provide additional evidence as to the extent of the 
relationship between state wealth and Medicaid coverage of methadone or buprenorphine.   
Is the need for opioid treatment correlated with Medicaid coverage of methadone and 
buprenorphine? The results regarding need for treatment, particularly for methadone, were also 
inconsistent. For methadone, the rate of opioid dependent individuals was correlated with an increased 
likelihood of Medicaid coverage in 1998 and the combined year analysis; however, the confidence 
intervals in these analyses were quite large and as such indicate a weak relationship. Similarly, while 
there was a consistent correlation between the rate of methadone programs and Medicaid coverage of 
methadone across all study years, the confidence intervals associated with each of these analyses were 
also very large. Finally, there was no relationship between either need factor and Medicaid coverage of 
buprenorphine. 
Is Medicaid coverage of methadone or buprenorphine associated with shorter wait times for 
substance use treatment entry? For both methadone and buprenorphine, Medicaid coverage was 
associated with a significantly longer wait time. Individuals enrolled in substance use treatment in states 
with Medicaid coverage of methadone waited 219% longer than individuals in states without Medicaid 
coverage. For buprenorphine, the wait time was 344% longer for individuals enrolled in substance use 
treatment programs in states with Medicaid coverage, as compared to individuals in states without 
Medicaid coverage. While these findings do not confirm the study hypothesis, additional research is 
warranted and should include the proportion of all individuals in substance use treatment in each state, 
rather than a subset of in-treatment individuals.   
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Other factors associated with increased wait times for the methadone analysis include being male, 
other race, as compared to white, employed, unstably housed, less than 18 years old or between 25-44 
years old, as compared to individuals over 44, reporting one substance of abuse, as compared to three, 
having Medicaid, Medicare or no insurance, as compared to private insurance, having 
retirement/pension or other income as the primary income source, as compared with a salary and 
receiving treatment in 2008, as compared to 1998. Factors that were associated with a decrease in the 
mean number of days individuals waited to enter treatment in the methadone analysis included being 
Hispanic, attending outpatient or detoxification programs, as compared to rehabilitation, utilizing MAT, 
reporting no substances of abuse at the time of treatment, as compared to three and having no income, 
as compared to having a salary as the primary source of income. 
Variables that were associated with increased treatment wait time in the buprenorphine analysis, 
include younger age, reported psychological problems, heroin use, synthetic opioid use and Medicare 
and no health insurance (as compared with private insurance). Factors that were associated with a 
decrease in the mean number of days individuals waited to enter treatment included being male, black 
(as compared to white), Hispanic, being employed, use of MAT, detoxification and outpatient program 
enrollment, as compared to enrollment in a rehabilitation program, opioid use, reporting one substance 
of abuse, as compared to three and reporting public assistance, retirement/pension, other income 
source or no income, as compared to salary as the primary source of income.  
Is Medicaid coverage of methadone associated with an increase in the utilization of MAT? The 
results of this analysis indicate that Medicaid coverage of methadone is associated with increased odds 
of MAT utilization. Other factors that were associated with increased odds of MAT utilization include 
being Hispanic, married, employed, using heroin, non-prescription methadone, cocaine, synthetic 
opioids, benzodiazepines, reporting one or two drugs of abuse, as compared with three, and having 
Medicaid or no insurance, as compared with private insurance. Factors associated with decreased odds 
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of MAT use include being male, black or other race, as compared to white, less than 44 years of age, 
attending a rehabilitation program versus a non-rehabilitation program (detoxification and outpatient), 
reporting psychological problems, having retirement/pension or no income as the primary source of 
income, as compared to salary and receiving treatment in 2008, as compared to 1998.  
 
Policy Recommendations 
Based on the main findings of this dissertation, the following policy recommendations are proposed: 
Finding:  State wealth is correlated with Medicaid coverage of MAT 
The results from Aim 1 (Chapter 5) indicate a significant relationship between increased state wealth 
and Medicaid coverage of MAT. This finding was consistent across both the methadone and 
buprenorphine analyses and all study years. In addition to these findings, recent data regarding 
prescribing patterns for opioids demonstrate that states with the highest levels of opioid prescribing, 
which serves as a proxy for prescription opioid use, also have some of the lowest per capita incomes and 
highest FMAP rates in the country.211 Further, two of the five states with the highest rates of opioid 
prescribing did not cover either methadone or buprenorphine and three of the five states only provided 
Medicaid coverage of methadone or buprenorphine, but did not cover both.9  
Recommendation:  
1. Increase reimbursement incentives for Medicaid coverage of MAT in states with less overall 
wealth in order to increase access to evidence based treatments for opioid dependence. 
 
Finding:  Substance use treatment entry wait time averaged between 5-6 days 
One of the most important findings from the Aim 2 analysis (Chapter 6) was the fact that individuals 
waited, on average, 5-6 days to enter substance use treatment. Prior research has found that the first 24 
hours following a person’s initial contact with a treatment program is the most critical in order to 
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engage and maintain an individual in substance use treatment.92 Given the increase in opioid use and 
dependence, novel approaches are needed to increase treatment capacity and continuity in order to 
reduce the amount of time that individuals wait to enter substance use treatment. The following two 
regulatory issues serve as impediments to expeditious entry into MAT programs.  
 
MAT pre-authorization: The majority of state Medicaid programs require that pre-authorization of 
buprenorphine treatment must be obtained prior to a person initiating treatment as well as when they 
renew their prescription. Physicians and treatment programs have argued that this policy is 
unnecessarily onerous and contributes significantly to both delays to treatment entry, as well as 
interruptions in the continuity of MAT.212,213 These pre-authorization requirements may prevent 
individuals from initiating treatment altogether, and may also expose individuals that are already 
maintained on buprenorphine treatment to interruptions in their treatment regimen, which in turn 
could increase their risk of relapse. 
Recommendation:  
1. Streamline or remove pre-authorization requirements for preferred providers or Medicaid 
beneficiaries with existing prescriptions in order to reduce delays to initiating or continuing 
buprenorphine treatment. 
 
Lack of integration of opioid treatment into the primary medical care system: Prior to the passage of the 
DATA 2000 and approval of buprenorphine in 2002, MAT in the United States was limited only to 
methadone, which was administered at opioid treatment programs (OTPs) that were typically 
segregated from other types of medical care. Many experts believe that this segregation increased the 
stigmatization of opioid users and created additional barriers to treatment accessibility.51–53,214 While 
DATA 2000 and the approval of buprenorphine have helped to integrate substance use treatment into 
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more mainstream medical settings, the restrictions on the administration of methadone remain in place. 
Additionally, the waiver requirements that doctors must complete in order to become buprenorphine 
prescribers have been identified as a barrier to becoming a buprenorphine provider.79–81,84–86 Both the 
restrictions on methadone provision and requirements for buprenorphine provision likely contribute to 
the lack of available programs and providers, as well as the low utilization of MAT, which in turn 
contributes to longer waiting times across substance use treatment services. 
Recommendations:  
1. Allow for the administration of all forms of MAT in primary care settings.  
2. Provide incentives and/or subsidies to physicians in areas with limited MAT availability to 
prescribe buprenorphine. 
  
Finding: Younger age is associated with both an increase in treatment wait time and decreased odds 
of MAT use  
The Aim 2 analysis (Chapter 6) indicated that individuals under the age of 18 experienced a 92% 
increase in treatment wait time, as compared to individuals over 44 years of age. In the Aim 3 analysis, 
as age decreased, so did the odds that an opioid dependent individual would use MAT. These findings, 
coupled with the fact that TEDS-A data from 2002-2012 show the largest increase in treatment 
admissions due to heroin use among 20-34 year olds1, suggest that increased efforts are required in 
order to reach and engage younger opioid users in substance use treatment. Such efforts could include 
an increased use of outreach services that specifically target younger opioid users, with an emphasis on 
educating young opioid users about their options for substance use treatment services, including 






1. Amend state and federal budget policies so that substance use treatment programs can be 
reimbursed for outreach services that target hard-to-reach groups who are disproportionately 
impacted by substance use. 
2. Provide incentives for substance use treatment programs to expand their programming 
capacity to provide specialized services to younger substance users. 
 
Finding:  Enrollment in a substance use treatment program in a state with Medicaid coverage of 
methadone is associated with an increased odds of MAT use 
Findings from the Aim 3 analysis (Chapter 7) demonstrated that for an individual enrolled in a 
substance use treatment program in a state with Medicaid coverage of methadone, the odds of them 
enrolling in MAT was 5 times greater than for an individual receiving treatment in a state without 
Medicaid coverage of methadone (OR=5.37). This finding suggests that the coverage options offered by 
insurance companies influence the types of treatments that opioid users utilize.  
As of 2013, buprenorphine was covered in all 50 states for Medicaid beneficiaries; however, 
methadone was only covered in 30 states. Such policies that limit coverage options employ a “one size 
fits all” model, despite the fact that the appropriateness and satisfaction of each treatment varies across 
individuals. Limitations to the types of substance use treatment may lead to an increased likelihood of 
relapse if the treatments that are covered by Medicaid do not work for particular individuals.  
Recommendation:   







 This dissertation project served as an initial exploration of state-level influences on Medicaid 
coverage of methadone and buprenorphine treatment, and the impact of this coverage on the 
utilization of substance use treatment. While novel, this study is subject to several limitations.  
 The design of this study was constructed based on the availability of the primary variable of interest, 
Medicaid coverage of methadone and buprenorphine. Longitudinal Medicaid coverage data across 
multiple years were not publicly available. Because of this, the analyses for all three aims of this 
dissertation were limited to the two time periods that state Medicaid coverage data were publicly 
available for each treatment type (1998 and 2008 for methadone, and 2006 and 2008 for 
buprenorphine).9,54,142 This limitation reduced my ability to detect causality and the immediate and 
direct effects of changes in Medicaid coverage of each treatment, given that I was unable to determine 
the exact timing of any changes in Medicaid coverage.  
The Treatment Episodes Data Set-Admissions served as my primary data source for this study, and 
there are noteworthy limitations to the TEDS-A. First, the TEDS-A is consists of data reported primarily 
by publicly funded substance use treatment facilities to the SAMHSA, as per state requirement.122 Most 
privately owned treatment facilities, of which approximately 29% of outpatient methadone programs 
are in the United States, are not required to report their treatment data as per state regulations, and are 
therefore not likely to be included in the TEDS-A.201 This limitation may have introduced selection bias 
into both the methadone and buprenorphine analyses given that only a portion of private programs are 
required to report their admission data.122 Further, the TEDS-A does not contain treatment episodes 
from private practice physicians or those physicians operating outside of licensed substance use 
treatment programs. In 2012, only 19% of buprenorphine clients received their treatment from an 
opioid treatment program (OTP); therefore, the overwhelming majority of buprenorphine clients are not 
included in the TEDS-A.215 Given this, it is conceivable that the individuals contained within the TEDS-A 
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that received buprenorphine treatment are different from the overall population of buprenorphine 
patients in the US. This may limits the generalizability of the analyses presented in Chapter 6 and 7. 
When data collection began for the TEDS-A, methadone was the primary MAT provided in the 
United States. When buprenorphine was introduced in 2002, the TEDS included buprenorphine within 
an existing question regarding MAT, rather than differentiating between methadone and 
buprenorphine. Including a double-barreled question is likely to result in response bias, particularly for 
analyses such as these that seek to differentiate between the two treatment types.216 The TEDS-A 
response structure for MAT limited my ability to explore the utilization of each treatment separately in 
the Chapter 7 analyses. Because of this, the findings regarding methadone utilization in 2008 and the 
combined 1998-2008 analyses may be overestimated given that the outcome variable, MAT use, likely 
included some individuals utilizing buprenorphine treatment.  
 The TEDS-A contains a combination of patient self-reported responses as well as program-reported 
responses. (Justin Gaertner, SAMHDA User Support, personal communication, April 7, 2015). Variables 
that are self-reported may be subject to social desirability bias, given the sensitive nature of many of the 
items, including self-reported psychological problems. Additionally, some variables in the TEDS-A may 
also be subject to recall bias given that some questions refer to past behavior. Variables that may be 
impacted by recall bias include self-report of substance use at admission and number of prior treatment 
episodes.  
 A final limitation of the TEDS-A is that a significant amount of data were missing, particularly for the 
treatment wait time and health insurance coverage variables. These missing data may introduce bias, 
particularly when performing analyses using listwise deletion. Both listwise deletion and multiple 
imputation were employed prior to analyses to handle missing data in the analyses presented in Chapter 
6 and 7; however, the sample was first limited to individuals receiving substance use treatment in states 
with ~50% missing data on any one variable included in the analyses. Sub-setting the sample to 
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individuals in a select number of states may have introduced a threat to external validity given that 
individuals residing in states that were excluded based on significant missing data may be different from 
the individuals residing in states with ~50% or less missing data for any one variable. 
Despite the limitations associated with the TEDS-A, it serves as the most comprehensive source of 
individual-level data regarding substance use treatment admissions in the United States. Additionally, 
the TEDS-A is the only dataset that provides individual-level data on treatment wait times across the 
United States.  
A final limitation associated with the datasets utilized in this study comes from the UFDS and N-
SSATS. Similar to the TEDS-A, there is a known bias associated with the substance use treatment 
programs included in the UFDS and N-SSATS datasets. The UFDS and N-SSATS datasets were used to 
calculate the rate of methadone and buprenorphine programs per state. The response rate for these 
surveys was significant (88% in 1998; 97% in 2006; and, 94% in 2008); however, similar to the TEDS-A, 
the UFDS and N-SSATS do not include private physicians that are not contained within or affiliated with a 
substance use treatment program. Given this, the association between the rate of buprenorphine 
programs and Medicaid coverage is likely to be underestimated. 
While this dissertation is subject to several limitations, it provides an important contribution to the 
literature regarding the impact of Medicaid coverage on opioid dependent individuals. While prior 
research has documented the ways in which Medicaid coverage restrictions of methadone and 
buprenorphine impact substance use treatment facilities, to date we are not aware of any study 








Previous research has investigated individual and program-level factors that are associated with 
wait time to enter substance use treatment and MAT utilization. This dissertation adds to that literature 
by both confirming and refuting some of the previous findings. This dissertation also provides a novel 
contribution to the literature through the investigation of Medicaid coverage of methadone and 
buprenorphine, the wait time associated with substance use treatment entry and MAT utilization. While 
the analyses conducted for this dissertation are historical, they reflect a time when opioid use and 
substance use treatment admissions were increasing, but MAT utilization was decreasing. This is 
particularly important given the public health significance of opioid use in the United States and the 
relatively low utilization of the most evidence-based approaches to treating opioid dependence.  
The analyses in this dissertation were preliminary and were subject to several limitations. The lack of 
publicly available secondary data regarding Medicaid coverage of methadone and buprenorphine 
treatment was a significant limiting factor in the design of this study. Future research might include 
primary data collection with State Medicaid administrators regarding Medicaid coverage patterns over 
repeated years in order to conduct a more rigorous analysis of the impact of Medicaid coverage of 
methadone and buprenorphine on individuals seeking substance use treatment. 
This dissertation did not include any analyses since the passage of the PPACA, most specifically since 
2014 when substance use treatment became an Essential Health Benefit. Future analyses should explore 
the availability of methadone and buprenorphine post-PPACA implementation for Medicaid 
beneficiaries as well as privately insured individuals. There is significant hope that the passage of the 
PPACA will improve access to and utilization of substance use treatment; however, the variability in the 
availability of treatment modalities will undoubtedly persist. Future research should investigate changes 
to the availability of methadone and buprenorphine treatments, potentially comparing the utilization of 
these evidence based treatments before and after PPACA implementation.  
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Finally, while this dissertation investigated Medicaid coverage of methadone and buprenorphine as 
a dichotomous variable, future research might include a more nuanced definition of this variable. In 
some states Medicaid programs cover methadone and/or buprenorphine treatments, but the use of 
them is limited by pre-authorization requirements for treatment initiation or restrictions to the length of 
time that individuals can use them.213 These restrictions could have a significant impact on treatment 
engagement, utilization of MAT and treatment outcomes. Future studies might define Medicaid 
coverage as a polytomous variable, including categories such as full coverage, no coverage, restricted 
coverage, or even more specifically, restricted coverage based on lifetime limits and restricted coverage 
based on pre-authorization. Creating a more specific definition of the ways in which Medicaid coverage 
is restricted might result in an increased ability to detect the specific impact of these restrictions.    
 
Conclusion 
This dissertation provided an historical analysis of the availability of the two most effective 
treatments for opioid dependence during a time when both nonmedical use of prescription opioids and 
heroin use increased significantly in the United States. The impetus for this study was to better 
understand why some states provided coverage of methadone and buprenorphine for Medicaid 
beneficiaries while others did not, and how Medicaid coverage of these treatment impacted opioid 
dependent individuals’ access to treatment. While this study had limitations, particularly based on the 
availability of complete and multi-year data, it addressed a significant gap in the literature by examining 
factors related to Medicaid coverage at the state-level and the impact of this coverage on individuals 
enrolled in substance use treatment.   
Since 2008, significant progress has been made with respect to substance use treatment and 
Medicaid coverage. In 2008, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction 
Equity Act of 2008 (MHPAEA) was passed, paving the way for elimination of differential benefits for 
107 
 
substance use treatment as compared to those placed on medical/surgical benefits. Additionally, in 
2010, the PPACA was passed, paving the way for the expansion of Medicaid coverage to an increased 
number of individuals in thirty one states and the prioritization of substance use treatment as an 
essential health benefit. These policy changes have been considered unprecedented by substance use 
treatment experts217 because of their potential to significantly increase access to substance treatment 
services. However, while these policies provide incredible opportunities for reducing barriers to 
treatment, it is critical that we remain cautiously optimistic because an expansion of coverage does not 
necessarily equal an increase in accessibility or utilization. In Massachusetts, for example, where 
universal health insurance was provided to nearly all state residents prior to the passage of the PPACA, 
admissions to substance use treatment programs, which had been expected to increase significantly, 
remained flat.218 Since the early 2000s, substance use treatment admissions for opioids have increased 
steadily, yet since the passage of PPACA, the total number of substance use treatment facilities has 
decreased, from 17,204 in 2010 to 14,630 in 2013, as has the utilization of MAT.219,220 In order to keep 
pace with an expansion in the population of individuals with health insurance that are in need of 
substance use treatment, there must be a concurrent expansion in services in order to ensure that 
substance use treatment is accessible. Future research should monitor the impact of the expansion in 
Medicaid coverage, the prioritization of substance use treatment as an EHB and the extent to which the 
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Figure 1.2: Factors Influencing State Medicaid Coverage of Methadone and Buprenorphine, Utilizing an Adapted Version of 
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Figure 1.3:  Analytic Sample for Aim 1, State-Level Analysis of Economic and Need Factors and Medicaid Coverage of Methadone and Buprenorphine
Methadone, 1998 & 2008 Buprenorphine, 2006 & 2008 
2006-2008 combined, N=93
States excluded due to missing data: 
AK, DC, GA, MS, NC, RI, SC
2006, N=48










Change in Methadone Coverage
State 1998 2008 Began Covering 2006 2008 Began Covering Stopped Covering 
AL 1 1 0 0
AK 0 1 x 1 1
AZ 1 1 1 1
AR 0 0 0 0
CA 1 1 1 1
CO 0 1 x 0 1 x
CT 1 1 0 1 x
DE 1 1 1 1
DC 1 — 0 —
FL 1 1 1 1
GA 1 1 0 1 x
HI 1 1 1 1
ID 0 0 0 0
IL 0 1 x 1 1
IN 0 0 0 1 x
IA 0 1 x 0 1 x
KS 0 0 0 1 x
KY 0 0 0 0
LA 0 0 0 0
ME 1 1 0 1 x
MD 1 1 1 1
MA 1 1 1 1
MI 1 1 1 1
MN 1 1 1 0 x
MS 0 — 0 —
MO 0 1 x 0 1 x
MT 0 0 0 1 x
NE 0 1 x 1 1
NV 1 1 0 1 x
NH 0 1 x 0 1 x
NJ 1 1 1 1
NM 0 0 1 1
NY 1 1 1 1
NC 1 — 1 —
ND 0 — 1 1
OH 1 1 1 1
OK 0 1 x 0 1 x
OR 1 1 0 1 x
PA 1 1 1 1
RI 1 — 1 —
SC 0 0 0 —
SD 0 1 x 1 1
TN 0 1 x 1 1
TX 0 — 0 1 x
UT 1 1 0 0
VT 0 1 x 1 1
VA 0 1 x 1 1
WA 1 1 1 1
WV 0 0 1 0 x
WI 1 1 1 1
WY 0 0 1 1
Total 25 34 12 28 38 14 2
Medicaid Coverage of Methadone Medicaid Coverage of Buprenorphine Change in Buprenorphine Coverage
Table 1.1: Medicaid Coverage of Methadone (1998, 2008) and Buprenorphine (2006, 2008) 
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Table 1.2: Results of Bivariate Logistic Regression Analyses for Medicaid Coverage and Economic and Need Factors
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Economic Factors
  FMAP 0.36 (0.18-0.72) 0.004 0.17 (0.06-0.51) 0.002 0.3 (0.17-0.51) <0.0001 0.38 (0.18-0.75) 0.006 0.12 (0.03-0.50) 0.004 0.30 (0.17-0.52) <0.0001
  % of Res Rec'v Medicaid 1.09 (0.61-1.93) 0.777 0.82 (0.42-1.59) 0.553 1.25 (0.81-1.94 0.309 1.24 (0.69-2.24) 0.471 0.79 (0.37-1.69) 0.536 1.10 (0.70-1.72) 0.678
  Per Capita Income 2.00 (1.42-7.57) 0.005 5.16 (1.45-18.30) 0.011 3.45 (1.87-6.35) <0.0001 2.11 (1.03-4.31) 0.04 13.12 (1.92-89.79) 0.009 3.97 (1.92-8.21) 0.0002
  SABG 11.73 (0.99-137.66) 0.05 1.92 (0.74-4.96 0.177 5.42 (0.52-56.41) 0.157 2.24 (0.94-5.36) 0.071
  State expenditures 4.74 (1.34-16.71) 0.016 6.03 (0.88-41.57) 0.068 7.9 (2.39-26.14) 0.001 2.79 (0.91-8.53) 0.073 1.75 (0.46-6.59) 0.411 2.38 (1.01-5.61) 0.048
Need factors
  Rate indiv in opioid tx/10,000 pop 114.2 (2.32->999.99) 0.017 2.57 (0.73-9.00) 0.14 9.68 (2.52-37.18) 0.001 1.44 (0.76-2.70) 0.215 1.42 (0.55-3.69) 0.472 1.55 (0.90-2.67) 0.118
  Rate of meth progs/1M pop 6.11 (1.58-23.58) 0.009 5.89 (1.22-28.38) 0.027 6.5 (2.42-17.44) 0.0002
  Rate of bupe progs/1M pop 1.52 (0.78-2.95) 0.264 1.57 (0.53-4.70) 0.417 1.69 (0.92-3.11) 0.094
Medicaid Coverage of Buprenorphine
2008, n=452006, n=48











1998 , N=1,704,606 2008 , N=2,016,672
1998 , individuals in 14 
states N=357,031
2008 , individuals in 14 
states N=432,993
2008, individuals in 38 
states, N=162,242
1998, individuals in 14 states, 
BS sample, N=29,500
2008, individuals in 14 states, BS 
sample, N=24,400
1998, individuals in 14 states, 
MI sample, N=1,364,735
2008, individuals in 14 states, 
MI sample, N=2,034,778
1998-2008 combined, no 
missing, N=260,425
1998-2008 combined, BS sample, 
N=26,100
Figure 2A.1:  Analytic Sample, Treatment Wait Time and Medicaid Coverage of Methadone




Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=270,751 N=162,242
n ( %) n ( %)
Medicaid Coverage of Methadone*** 260197 (96%) 72749 (45%)
   missing n=0 n=0
Male*** 175226 (65%) 113360 (70%)
   missing n=71 n=0
Race
  White*** 182659 (77%) 122257 (75%)
  Black*** 42224 (18%) 26327 (16%)
  Other Race*** 13853 (6%) 13658 (8%)
   missing n=32015 n=0
Hispanic*** 30456 (13%) 21725 (13%)
   missing n=30074 n=0
HS Education*** 164153 (62%) 105755 (65%)
   missing n=7505 n=0
Married*** 42376 (19%) 37988 (23%)
   missing n=46685 n=0
Employed*** 76133 (29%) 62813 (29%)
   missing n=5325 n=0
Unstably housed*** 81587 (31%) 66890 (41%)
   missing n=9355 n=0
Age
   <18* 30396 (11%) 14646 (9%)
  18-24*** 54197 (20%) 31165 (19%)
  25-34 71340 (26%) 42935 (26%)
  35-44*** 57560 (21%) 35959 (22%)
  >45*** 57258 (21%) 37537 (23%)
   missing n=0 n=0
Program Type
  Outpatient*** 196290 (73%) 99686 (61%)
  Detox*** 42731 (16%) 42280 (26%)
  Rehab*** 31706 (12%) 20276 (13%)
   missing n=24 n=0
Patient receiving MAT*** 5901 (2%) 2232 (1%)
   missing n=24875 n=0
Psych Problems*** 98042 (45%) 40914 (25%)
   missing n=52097 n=0
Drug use reported at admit
  Heroin*** 20136 (7%) 4219 (3%)
      missing n=0 n=0
  Non prescription Methadone*** 1857 (1%) 952 (1%)
      missing n=0 n=0
  Synthetic opioids*** 42859 (16%) 17263 (11%)
      missing n=0 n=0
Table 2A.1 Comparison of Characteristics of Cases with Missing Data on Any Variables 
Compared to Cases with No Missing Data, Treatment Wait Time and Medicaid 
Coverage of Methadone Analysis, 2008
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Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Any opiates*** 16673 (6%) 5694 (6%)
      missing n=0 n=0
  Cocaine/Crack*** 65011 (24%) 33899 (21%)
      missing n=0 n=0
  Benzodiazepine*** 8713 (3%) 4045 (2%)
      missing n=0 n=0
# of subs reported at admit
0*** 22340 (8%) 439 (<1%)
1*** 127338 (47%) 78996 (49%)
                                  2*** 74163 (27%) 47490 (29%)
3*** 46910 (17%) 35317 (22%)
      missing n=0 n=0
IDU*** 20205 (7%) 10765 (7%)
      missing n=22771 n=0
Client Insurance Type
  Medicaid 12495 (18%) 16997 (10%)
  Medicare*** 3958 (6%) 11115 (7%)
  No insurance*** 42205 (61%) 110369 (68%)
  Private Insurance*** 11008 (16%) 23761 (15%)
      missing n=201085 n=0
Primary Source of Income
  Public Assistance*** 7783 (3%) 7231 (4%)
  Retirement/Pension*** 20073 (9%) 11092 (7%)
  Other Income*** 38016 (16%) 17640 (11%)
  No income*** 95252 (41%) 52664 (32%)
  Salary*** 72101 (31%) 73615 (45%)
      missing n=113201 n=0
Continuous variables
Days Waiting to Enter Treatment*** 15.71 (105.5) 5.18 (18.07)
Per capita Income*** $38,753 ($3,057) $39,302 ($4,464)
Rate of methadone programs/10K pop*** 2.51 (1.49) 1.94 (1.01)
Rate of individuals in tx/1M pop*** 12.89 (4.71) 9.45 (3.47)






Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=258,848 N=98,183
n ( %) n ( %)
Medicaid Coverage of Methadone*** 134191 (52%) 40577 (41%)
   missing n=0 n=0
Male*** 183654 (72%) 69830 (71%)
   missing n=4646 n=0
Race
  White*** 157958 (64%) 68747 (70%)
  Black*** 55657 (22%) 20832 (21%)
  Other Race*** 35064 (14%) 8604 (9%)
   missing n=10169 n=0
Hispanic*** 27462 (11%) 9054 (9%)
   missing n=12213 n=0
HS Education** 136410 (59%) 58507 (60%)
   missing n=27435 n=0
Married*** 59240 (25%) 26383 (27%)
   missing n=19467 n=0
Employed*** 92304 (39%) 41054 (42%)
   missing n=22935 n=0
Unstably housed*** 60828 (28%) 36317 (37%)
   missing n=38811 n=0
Age
   <18* 30417 (12%) 11897 (12%)
  18-24*** 40139 (16%) 17034 (17%)
  25-34*** 71268 (28%) 28282 (29%)
  35-44*** 78759 (30%) 28737 (29%)
  >45*** 38265 (15%) 12233 (12%)
   missing n=0 n=0
Program Type
  Outpatient*** 159847 (62%) 65471 (67%)
  Detox*** 75266 (29%) 15227 (16%)
  Rehab*** 23702 (9%) 17485 (18%)
   missing n=33 n=0
Patient receiving MAT 3348 (1%) 1325 (1%)
   missing n=17473 n=0
Psych Problems*** 33719 (20%) 16671 (17%)
   missing n=92145 n=0
Drug use reported at admit
  Heroin*** 12029 (5%) 3812 (4%)
      missing n=0 n=0
  Non prescription Methadone 357 (<1%) 155 (<1%)
      missing n=0 n=0
  Synthetic opioids*** 5116 (2%) 2211 (2%)
      missing n=0 n=0
Table 2A.2 Comparison of Characteristics of Cases with Missing Data on Any Variables 
Compared to Cases with No Missing Data, Treatment Wait Time and Medicaid 
Coverage of Methadone Analysis, 1998
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Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Any opiates*** 16673 (6%) 5694 (6%)
      missing n=0 n=0
  Cocaine/Crack*** 63023 (24%) 31240 (32%)
      missing n=0 n=0
  Benzodiazepine*** 2109 (1%) 1000 (1%)
      missing n=0 n=0
# of subs reported at admit
0*** 17460 (7%) 1710 (2%)
1*** 127932 (49%) 43679 (44%)
                                  2*** 73909 (29%) 31115 (32%)
3*** 39547 (15%) 21679 (22%)
      missing n=0 n=0
IDU*** 14765 (6%) 6956 (7%)
      missing n=19081 n=0
Client Insurance Type
  Medicaid 9091 (9%) 8522 (9%)
  Medicare*** 6494 (6%) 16368 (17%)
  No insurance*** 78817 (74%) 64433 (66%)
  Private Insurance*** 12169 (11%) 8860 (9%)
      missing n=152277 n=0
Primary Source of Income
  Public Assistance*** 9588 (7%) 5244 (5%)
  Retirement/Pension*** 6220 (4%) 6803 (7%)
  Other Income*** 25521 (18%) 10001 (10%)
  No income*** 42658 (29%) 31226 (32%)
  Salary*** 61633 (42%) 44909 (46%)
      missing n=113201 n=0
Continuous variables
Days Waiting to Enter Treatment*** 3.38 (28.3) 6.03 (45.0)
Per capita Income*** $26,246 ($2,400) $24,952 ($1,797)
Rate of methadone programs/10K pop*** 1.82 (1.02) 1.43 (0.87)
Rate of individuals in tx/1M pop*** 5.61 (2.34) 2.71 (0.98)








Individuals in States with Medicaid Coverage of Methadone 11235 (43%)
Male 18429 (71%)
Race
  White 19177 (73%)
  Black 4680 (18%)
  Other Race 2243 (9%)
Hispanic 3118 (12%)
HS Education 16455 (63%)
Married 6423 (25%)
Employed 10462 (40%)
Unstably housed 10435 (40%)
Age
  <18 2722 (10%)
  18-24 4800 (19%)
  25-34 7033 (27%)
  35-44 6708 (26%)
  >45 4837 (19%)
Program Type
  Outpatient 16649 (64%)
  Detox 5706 (22%)
  Rehab 3745 (14%)
Patient receiving MAT 324 (1%)
Psych Problems 5738 (22%)
Drug use reported at admit
  Heroin 789 (3%)
  Non prescription Methadone 120 (<1%)
  Synthetic opioids 1534 (6%)
  Any opioids 2270 (9%)
  Cocaine/Crack 6628 (25%)
  Benzodiazepine 511 (2%)







  Medicaid 2515 (10%)
  Medicare 2789 (11%)
  No insurance 17568 (67%)
  Private Insurance 3228 (12%)
Primary Source of Income
  Public Assistance 1223 (5%)
  Retirement/Pension 1762 (7%)
  Other Income 2749 (11%)
  No income 8464 (32%)
  Salary 11902 (46%)
Continuous variables Mean (SD)
Days Waiting to Enter Treatment 5.14 (24.66)
Per Capita Income $33,740 ($7,838)
Rate of methadone programs/10K pop 1.74 (1.00)
Rate of individuals in tx/1M pop 6.82 (4.30)
Percent of residents rec'v Medicaid 15.81 (5.05)
Table 2A.3: Descriptive Characteristics of Bootstrapped Listwise Deletion Sample 




Medicaid Coverage No Medicaid Coverage
N=11,265 N=14,835
n ( %) n ( %)
Male *** 8117 (72%) 10312 (70%)
Race
  White*** 8674 (77%) 10503 (71%)
  Black*** 1522 (14%) 3158 (21%)
  Other Race*** 1069 (9%) 1174 (8%)
Hispanic*** 1976 (18%) 1142 (8%)
HS Education*** 7466 (66%) 8989 (61%)
Married*** 2502 (22%) 3921 (26%)
Employed 4566 (41%) 5896 (40%)
Unstably housed*** 5182 (46%) 5253 (35%)
Age
  <24*** 3005 (27%) 4517 (30%)
  25-34* 2933 (26%) 4100 (28%)
  35-44* 2965 (26%) 3743 (25%)
  >45*** 2362 (21%) 2475 (17%)
Program Type
  Outpatient*** 6149 (55%) 10500 (71%)
  Detox*** 3448 (31%) 2258 (15%)
  Rehab 1668 (15%) 2077 (14%)
Patient receiving MAT*** 212 (2%) 112 (1%)
Psych Problems 2522 (22%) 3216 (22%)
Drug use reported at admit
  Heroin*** 425 (4%) 364 (2%)
  Non prescription Methadone*** 15 (<1%) 105 (1%)
  Any opiates*** 811 (7%) 1459 (10%)
  Cocaine/Crack 2797 (25%) 3831 (26%)
  Synthetic opioids*** 439 (4%) 1095 (7%)
  Benzodiazepine*** 135 (1%) 376 (3%)
# of subs reported at admit
0*** 168 (1%) 77 (1%)
1*** 5894 (52%) 6412 (43%)
                                       2* 3307 (29%) 4551 (31%)
3*** 1896 (17%) 3795 (26%)
IDU*** 591 (5%) 1201 (8%)
Client Insurance Type
  Medicaid*** 952 (8%) 1563 (11%)
  Medicare*** 746 (7%) 2043 (14%)
  No insurance*** 7421 (66%) 10147 (68%)
  Private Insurance*** 2146 (19%) 1082 (7%)
Primary Source of Income
  Public Assistance 539 (5%) 684 (5%)
  Retirement/Pension*** 849 (8%) 913 (6%)
  Other Income*** 1384 (12%) 1365 (9%)
  No income 3588 (32%) 4876 (33%)
  Salary*** 4905 (44%) 6997 (47%)
Continuous variables
Days Waiting to Enter Treatment 4.8 (31.7) 5.4 (17.5)
Per capita Income*** $36,453 ($7,967) $31,681 ($7,075)
Rate of methadone programs/10K pop*** 1.95 (0.37) 1.58 (1.27)
Rate of individuals in tx/1M pop*** 7.3 (3.8) 6.5 (4.6)




Table 2A.4: Comparison of Characteristics of Bootstrapped Listwise Deletion Sample by 





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone covered -0.12 (-0.19,-0.04)** -11.31 -0.06 (-0.14,0.02) -5.82 -0.16 (-0.24,-0.08)*** -14.79 -0.18 (-0.26,-0.1)*** -16.47 0.64 (0.55,0.73)*** 89.65 0.8 (0.7,0.89)*** 122.55 1.16 (1.03,1.29)*** 218.99
Male 0.06 (-0.02,0.14) 6.18 0.16 (0.07,0.24)** 17.35 0.15 (0.07,0.23)** 16.18 0.11 (0.02,0.19)* 11.63 0.14 (0.06,0.22)** 15.03 0.14 (0.06,0.22)** 15.03
Race
  Black 0.34 (0.24,0.44)*** 40.49 0.21 (0.11,0.31)*** 23.37 0.2 (0.1,0.3)*** 22.14 -0.03 (-0.13,0.07) -2.96 -0.03 (-0.13,0.07) -2.96 -0.04 (-0.14,0.06) -3.92
  Other Race 0.15 (0.02,0.29)* 16.18 0.26 (0.13,0.4)** 29.69 0.29 (0.15,0.42)*** 33.64 0.16 (0.03,0.29)* 17.35 0.18 (0.05,0.31)* 19.72 0.13 (0,0.26)* 13.88
  White (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Hispanic -0.75 (-0.87,-0.63)*** -52.76 -0.85 (-0.97,-0.72)*** -57.26 -0.83 (-0.95,-0.71)*** -56.40 -0.43 (-0.55,-0.31)*** -34.95 -0.34 (-0.46,-0.22)*** -28.82 -0.31 (-0.43,-0.19)*** -26.66
HS Education -0.14 (-0.23,-0.06)** -13.06 -0.09 (-0.18,-0.01)* -8.61 -0.08 (-0.16,0.01) -7.69 -0.01 (-0.09,0.07) -1.00 0 (-0.08,0.08) 0.00 0 (-0.08,0.08) 0.00
Married 0.08 (-0.01,0.17) 8.33 -0.03 (-0.12,0.06) -2.96 -0.01 (-0.09,0.08) -1.00 -0.02 (-0.11,0.07) -1.98 -0.06 (-0.14,0.03) -5.82 -0.03 (-0.11,0.06) -2.96
Employed 0.27 (0.19,0.35)*** 31.00 0.24 (0.16,0.32)*** 27.12 0.43 (0.31,0.54)*** 53.73 0.28 (0.17,0.39)*** 32.31 0.23 (0.12,0.35)*** 25.86 0.22 (0.1,0.33)** 24.61
Unstably Housed 0.07 (-0.01,0.16) 7.25 0.13 (0.04,0.21)* 13.88 0.15 (0.07,0.24)** 16.18 0.25 (0.16,0.33)*** 28.40 0.24 (0.15,0.32)*** 27.12 0.26 (0.17,0.34)*** 29.69
Age
  <18 0.58 (0.42,0.75)*** 78.60 0.46 (0.3,0.63)*** 58.41 0.48 (0.31,0.65)*** 61.61 0.61 (0.45,0.78)*** 84.04 0.69 (0.52,0.85)*** 99.37 0.65 (0.49,0.82)*** 91.55
  18-24 0.36 (0.24,0.49)*** 43.33 0.2 (0.07,0.32)* 22.14 0.22 (0.09,0.35)** 24.61 0.18 (0.06,0.31)* 19.72 0.21 (0.08,0.33)* 23.37 0.2 (0.08,0.33)* 22.14
  25-34 0.32 (0.21,0.43)*** 37.71 0.23 (0.12,0.34)*** 25.86 0.24 (0.13,0.35)*** 27.12 0.2 (0.09,0.31)** 22.14 0.24 (0.13,0.35)*** 27.12 0.23 (0.12,0.34)*** 25.86
  35-44 0.24 (0.13,0.35)*** 27.12 0.34 (0.23,0.45)*** 40.49 0.33 (0.21,0.44)*** 39.10 0.28 (0.17,0.39)*** 32.31 0.35 (0.24,0.46)*** 41.91 0.34 (0.23,0.45)*** 40.49
  >44 (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.26 (-0.37,-0.15)*** -22.89 -0.28 (-0.4,-0.17)*** -24.42 -0.55 (-0.66,-0.44)*** -42.31 -0.65 (-0.77,-0.54)*** -47.80 -0.66 (-0.78,-0.55)*** -48.31
  Detox -2.15 (-2.28,-2.02)*** -88.35 -2.19 (-2.32,-2.06)*** -88.81 -2.47 (-2.6,-2.34)*** -91.54 -2.56 (-2.69,-2.42)*** -92.27 -2.63 (-2.77,-2.5)*** -92.79
  Rehab (ref) ref ref ref ref ref ref ref ref ref ref
Enrolled in MAT -1.13 (-1.49,-0.78)*** -67.70 -1.08 (-1.44,-0.73)*** -66.04 -1.12 (-1.47,-0.77)*** -67.37 -1.11 (-1.46,-0.76)*** -67.04 -1.11 (-1.46,-0.76)*** -67.04
Psych Problems 0.24 (0.14,0.33)*** 27.12 0.17 (0.07,0.26)** 18.53 0.13 (0.04,0.23)* 13.88 0.09 (0,0.19) 9.42 0.09 (-0.01,0.18) 9.42
Drug Use
  Heroin -0.04 (-0.64,0.56) -3.92 0.05 (-0.55,0.65) 5.13 -0.14 (-0.73,0.44) -13.06 -0.05 (-0.64,0.54) -4.88 -0.09 (-0.68,0.5) -8.61
  Non-rx Methadone -0.19 (-0.78,0.39) -17.30 -0.1 (-0.68,0.49) -9.52 -0.33 (-0.9,0.24) -28.11 -0.41 (-0.97,0.15) -33.63 -0.47 (-1.03,0.09) -37.50
  Cocaine 0.09 (0,0.19) 9.42 0.06 (-0.04,0.16) 6.18 -0.07 (-0.17,0.02) -6.76 -0.02 (-0.11,0.08) -1.98 -0.06 (-0.16,0.04) -5.82
  Synthetic Opioids 0.14 (-0.46,0.74) 15.03 0.05 (-0.56,0.65) 5.13 -0.18 (-0.76,0.41) -16.47 -0.19 (-0.79,0.4) -17.30 -0.29 (-0.88,0.31) -25.17
  Benzodiazepines 0.47 (0.21,0.74)** 60.00 0.42 (0.16,0.68)* 52.20 -0.08 (-0.34,0.18) -7.69 0.05 (-0.21,0.31) 5.13 0.07 (-0.19,0.33) 7.25
  Any Opioids 0.45 (-0.17,1.07) 56.83 0.41 (-0.22,1.03) 50.68 0.44 (-0.17,1.05) 55.27 0.48 (-0.13,1.09) 61.61 0.53 (-0.08,1.15) 69.89
Ttl # of Drugs Used
0 -0.18 (-0.56,0.2) -16.47 -0.23 (-0.61,0.15) -20.55 -0.8 (-1.18,-0.43)*** -55.07 -0.57 (-0.95,-0.2)* -43.45 -0.71 (-1.08,-0.33)** -50.84
1 0.19 (0.08,0.3)** 20.92 0.13 (0.02,0.24)* 13.88 0.08 (-0.03,0.19) 8.33 0.13 (0.02,0.24)* 13.88 0.12 (0.01,0.23)* 12.75
2 0.07 (-0.04,0.18) 7.25 0.05 (-0.06,0.15) 5.13 0.05 (-0.05,0.16) 5.13 0.07 (-0.04,0.17) 7.25 0.07 (-0.03,0.17) 7.25
3 (ref) ref ref ref ref ref ref ref ref ref ref
IDU -0.1 (-0.28,0.07) -9.52 -0.1 (-0.27,0.07) -9.52 0.03 (-0.14,0.19) 3.05 0.01 (-0.15,0.17) 1.01 0.02 (-0.14,0.18) 2.02
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Health Insurance Type
  Medicaid 0.49 (0.32,0.66)*** 63.23 0.35 (0.19,0.52)*** 41.91 0.38 (0.21,0.55)*** 46.23 0.31 (0.14,0.48)** 36.34
  Medicare 0.05 (-0.1,0.21) 5.13 0.36 (0.21,0.52)*** 43.33 0.39 (0.23,0.54)*** 47.70 0.39 (0.24,0.55)*** 47.70
  No Insurance 0.39 (0.28,0.51)*** 47.70 0.4 (0.29,0.51)*** 49.18 0.47 (0.35,0.58)*** 60.00 0.45 (0.34,0.56)*** 56.83
  Private Insurance (ref) ref ref ref ref ref ref ref ref
Primary Income
  Public Assistance 0.11 (-0.09,0.3) 11.63 -0.02 (-0.21,0.17) -1.98 -0.01 (-0.2,0.17) -1.00 0.002 (-0.19,0.19) 0.40
  Retirement/Pension 0.54 (0.34,0.73)*** 71.60 0.45 (0.26,0.64)*** 56.83 0.45 (0.26,0.64)*** 56.83 0.44 (0.25,0.63)*** 55.27
  Other Income Source 0.33 (0.18,0.47)*** 39.10 0.25 (0.1,0.39)** 28.40 0.14 (-0.01,0.28) 15.03 0.16 (0.01,0.3)* 17.35
  No Income 0.06 (-0.06,0.17) 6.18 -0.19 (-0.31,-0.07)* -17.30 -0.24 (-0.36,-0.12)*** -21.34 -0.22 (-0.34,-0.1)** -19.75
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)*** -0.01 -0.0001 (-0.0001,-0.0001)*** -0.01 -0.0001 (-0.0001,-0.0001)*** -0.01
  Methadone Prog Rate -0.49 (-0.54,-0.44)*** -38.74 -0.53 (-0.57,-0.48)*** -41.14 -0.49 (-0.54,-0.45)*** -38.74
  Rate of Indiv in Tx 0.1 (0.08,0.11)*** 10.52 0.06 (0.04,0.07)*** 6.18 0.04 (0.03,0.06)*** 4.08
  % of res w/Medicaid 0.18 (0.17,0.2)*** 19.72 0.15 (0.14,0.17)*** 16.18 0.13 (0.12,0.14)*** 13.88
Time 1.22 (1.02,1.41)*** 238.72 1.63 (1.41,1.85)*** 410.39
Medicaid Cov * Time -0.7 (-0.88,-0.53)*** -50.34
*=p<0.05
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 7: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables, time and interaction term
***=p<0.0001
**=p<0.001
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Table 2A.5: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Methadone, Combined 1998-2008, N=26,100
Model 6: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables and time
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone covered -0.03 (-0.06,-0.10)* -2.96 0.02 (-0.01,0.04) 2.02 -0.14 (-0.16,-0.11)*** -13.06 -0.13 (-0.15,-0.1)*** -12.19 0.72 (0.69,0.75)*** 105.44 0.9 (0.87,0.93)*** 145.96 1.42 (1.38,1.46)*** 313.71
Male -0.01 (-0.04,0.01) -1.00 0.07 (0.04,0.1)*** 7.25 0.08 (0.06,0.11)*** 8.33 0.04 (0.02,0.07)** 4.08 0.05 (0.02,0.07)** 5.13 0.06 (0.03,0.08)*** 6.18
Race
   Black 0.22 (0.19,0.26)*** 24.61 0.17 (0.14,0.2)*** 18.53 0.16 (0.13,0.19)*** 17.35 -0.05 (-0.08,-0.02)** -4.88 -0.05 (-0.08,-0.02)* -4.88 -0.04 (-0.07,-0.01)* -3.92
  Other Race 0.01 (-0.03,0.06) 1.01 0.2 (0.15,0.24)*** 22.14 0.23 (0.18,0.27)*** 25.86 0.09 (0.05,0.13)*** 9.42 0.09 (0.04,0.13)*** 9.42 0.02 (-0.02,0.06) 2.02
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.61 (-0.65,-0.57)*** -45.66 -0.7 (-0.74,-0.66)*** -50.34 -0.7 (-0.74,-0.66)*** -50.34 -0.25 (-0.29,-0.21)*** -22.12 -0.15 (-0.19,-0.11)*** -13.93 -0.11 (-0.15,-0.07)*** -10.42
HS Education -0.14 (-0.17,-0.11)*** -13.06 -0.14 (-0.16,-0.11)*** -13.06 -0.12 (-0.15,-0.1)*** -11.31 -0.07 (-0.1,-0.04)*** -6.76 -0.06 (-0.09,-0.03)*** -5.82 -0.05 (-0.08,-0.03)*** -4.88
Married 0.02 (-0.01,0.05) 2.02 -0.07 (-0.1,-0.04)*** -6.76 -0.05 (-0.08,-0.02)** -4.88 -0.04 (-0.07,-0.01)* -3.92 -0.06 (-0.08,-0.03)*** -5.82 -0.01 (-0.04,0.02) -1.00
Employed 0.19 (0.17,0.22)*** 20.92 0.15 (0.12,0.18)*** 16.18 0.17 (0.14,0.21)*** 18.53 0.05 (0.02,0.09)* 5.13 0.01 (-0.03,0.04) 1.01 0.01 (-0.03,0.05) 1.01
Unstably Housed 0 (-0.03,0.03) 0.00 -0.02 (-0.05,0) -1.98 -0.01 (-0.04,0.02) -1.00 0.11 (0.08,0.13)*** 11.63 0.08 (0.05,0.1)*** 8.33 0.12 (0.1,0.15)*** 12.75
Age
  <18 0.47 (0.42,0.52)*** 60.00 0.27 (0.22,0.32)*** 31.00 0.33 (0.28,0.39)*** 39.10 0.39 (0.33,0.44)*** 47.70 0.47 (0.42,0.52)*** 60.00 0.44 (0.39,0.49)*** 55.27
  18-24 0.3 (0.26,0.34)*** 34.99 0.15 (0.11,0.18)*** 16.18 0.16 (0.12,0.2)*** 17.35 0.1 (0.06,0.13)*** 10.52 0.11 (0.07,0.15)*** 11.63 0.1 (0.06,0.13)*** 10.52
  25-34 0.25 (0.22,0.29)*** 28.40 0.21 (0.17,0.24)*** 23.37 0.2 (0.17,0.24)*** 22.14 0.14 (0.11,0.18)*** 15.03 0.17 (0.13,0.2)*** 18.53 0.16 (0.12,0.19)*** 17.35
  35-44 0.19 (0.15,0.22)*** 20.92 0.17 (0.13,0.2)*** 18.53 0.16 (0.12,0.19)*** 17.35 0.09 (0.05,0.12)*** 9.42 0.13 (0.09,0.16)*** 13.88 0.12 (0.09,0.16)*** 12.75
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.3 (-0.33,-0.26)*** -25.92 -0.3 (-0.34,-0.26)*** -25.92 -0.62 (-0.65,-0.58)*** -46.21 -0.74 (-0.78,-0.7)*** -52.29 -0.76 (-0.8,-0.73)*** -53.23
  Detox -2.26 (-2.3,-2.22)*** -89.56 -2.26 (-2.3,-2.21)*** -89.56 -2.52 (-2.56,-2.47)*** -91.95 -2.62 (-2.66,-2.58)*** -92.72 -2.68 (-2.72,-2.64)*** -93.14
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.82 (-0.93,-0.71)*** -55.96 -0.85 (-0.96,-0.75)*** -57.26 -0.85 (-0.96,-0.74)*** -57.26 -0.78 (-0.88,-0.67)*** -54.16 -0.72 (-0.83,-0.62)*** -51.32
Psych problems 0.25 (0.22,0.28)*** 28.40 0.24 (0.21,0.27)*** 27.12 0.19 (0.16,0.22)*** 20.92 0.15 (0.13,0.18)*** 16.18 0.14 (0.11,0.17)*** 15.03
Drug Use
  Heroin -0.12 (-0.29,0.04) -11.31 -0.14 (-0.31,0.03) -13.06 -0.28 (-0.44,-0.12)** -24.42 -0.18 (-0.34,-0.02)* -16.47 -0.18 (-0.34,-0.01)* -16.47
  Non-rx Methadone -0.19 (-0.39,0.01) -17.30 -0.17 (-0.37,0.03) -15.63 -0.5 (-0.7,-0.3)*** -39.35 -0.49 (-0.68,-0.29)*** -38.74 -0.48 (-0.67,-0.29)*** -38.12
  Cocaine 0.16 (0.13,0.19)*** 17.35 0.15 (0.12,0.18)*** 16.18 -0.05 (-0.08,-0.03)** -4.88 -0.02 (-0.05,0.01) -1.98 -0.06 (-0.09,-0.03)** -5.82
  Synthetic Opioids -0.06 (-0.22,0.11) -5.82 -0.08 (-0.25,0.09) -7.69 -0.29 (-0.45,-0.13)** -25.17 -0.25 (-0.41,-0.09)* -22.12 -0.29 (-0.45,-0.13)** -25.17
  Benzodiazepines 0.13 (0.04,0.21)* 13.88 0.13 (0.04,0.21)* 13.88 -0.31 (-0.4,-0.23)*** -26.66 -0.26 (-0.35,-0.18)*** -22.89 -0.25 (-0.33,-0.17)*** -22.12
  Any Opioids 0.39 (0.21,0.56)*** 47.70 0.4 (0.22,0.57)*** 49.18 0.34 (0.17,0.51)*** 40.49 0.28 (0.12,0.45)** 32.31 0.27 (0.1,0.44)* 31.00
Ttl # of Drugs Used
0 0.56 (0.43,0.69)*** 75.07 0.58 (0.45,0.7)*** 78.60 -0.18 (-0.3,-0.06)* -16.47 -0.02 (-0.14,0.11) -1.98 -0.26 (-0.39,-0.14)*** -22.89
1 0.29 (0.25,0.32)*** 33.64 0.28 (0.24,0.32)*** 32.31 0.13 (0.1,0.16)*** 13.88 0.16 (0.13,0.2)*** 17.35 0.13 (0.1,0.17)*** 13.88
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
2 0.13 (0.09,0.16)*** 13.88 0.12 (0.08,0.15)*** 12.75 0.09 (0.06,0.12)*** 9.42 0.08 (0.05,0.12)*** 8.33 0.08 (0.05,0.11)*** 8.33
3 (ref) ref ref ref ref ref ref 0 (0,0) 0.00 0 (0,0) 0.00
IDU 0.01 (-0.05,0.06) 1.01 0.02 (-0.04,0.07) 2.02 0.23 (0.18,0.28)*** 25.86 0.22 (0.17,0.27)*** 24.61 0.23 (0.18,0.28)*** 25.86
Health Insurance Type
  Medicaid 0.33 (0.28,0.38)*** 39.10 0.19 (0.14,0.24)*** 20.92 0.19 (0.14,0.24)*** 20.92 0.08 (0.02,0.13)* 8.33
  Medicare 0.09 (0.04,0.14)** 9.42 0.35 (0.3,0.4)*** 41.91 0.36 (0.31,0.41)*** 43.33 0.34 (0.29,0.39)*** 40.49
  No insurance 0.32 (0.29,0.36)*** 37.71 0.29 (0.25,0.32)*** 33.64 0.32 (0.29,0.36)*** 37.71 0.29 (0.26,0.33)*** 33.64
  Private Insurance (ref) ref ref ref ref ref ref ref ref
Primary Income
  Public Asstistance 0.04 (-0.02,0.11) 4.08 -0.07 (-0.13,-0.01)* -6.76 -0.06 (-0.12,0)* -5.82 0.01 (-0.05,0.07) 1.01
  Retirement/Pension 0.13 (0.07,0.19)*** 13.88 0.03 (-0.02,0.09) 3.05 0 (-0.05,0.06) 0.00 0.02 (-0.04,0.07) 2.02
  Other Income Source 0.11 (0.06,0.15)*** 11.63 0.01 (-0.04,0.05) 1.01 -0.12 (-0.17,-0.08)*** -11.31 -0.09 (-0.14,-0.05)*** -8.61
  No Income -0.09 (-0.12,-0.05)*** -8.61 -0.3 (-0.34,-0.27)*** -25.92 -0.36 (-0.39,-0.32)*** -30.23 -0.32 (-0.35,-0.28)*** -27.39
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Per Capita Income '-0.0001 (-0.0001,-0.0001)*** -0.01 -0.0001 (-0.0001,-0.0001)*** -0.01 '-0.0001 (-0.0001,-0.0001)*** -0.01
  Methadone Prog Rate -0.53 (-0.54,-0.51)*** -41.14 -0.57 (-0.58,-0.55)*** -43.45 -0.51 (-0.52,-0.49)*** -39.95
  Rate of Indiv in Tx 0.09 (0.08,0.09)*** 9.42 0.05 (0.04,0.05)*** 5.13 0.02 (0.02,0.03)*** 2.02
  % of res w/Medicaid 0.2 (0.2,0.2)*** 22.14 0.17 (0.17,0.17)*** 18.53 0.14 (0.13,0.14)*** 15.03
Time 1.22 (1.15,1.28)*** 238.72 1.86 (1.79,1.92)*** 542.37
Medicaid Cov * Time -1.05 (-1.1,-0.99)*** -65.01
*=p<0.05
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 6: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables and time
Model 7: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables, time and interaction term
***=p<0.0001
**=p<0.001
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Table 2A.6: Model Building Summary Using Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Methadone, Combined 1998-2008, N=260,425
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered -0.68 (-0.75,-0.60)*** -49.09 -0.61 (-0.69,-0.53)*** -45.66 -0.96 (-1.04,-0.88)*** -61.71 -0.98 (-1.06,-0.9)*** -62.47 1.34 (1.19,1.49)*** 281.90
Male -0.07 (-0.15,0.01) -6.76 -0.04 (-0.12,0.04) -3.92 -0.03 (-0.1,0.05) -2.96 -0.11 (-0.19,-0.04)* -10.42
Race
  Black 0.17 (0.07,0.27)** 18.53 0.06 (-0.03,0.16) 6.18 0.07 (-0.03,0.17) 7.25 0.1 (0.004,0.2)* 10.52
  Other Race -0.24 (-0.38,-0.11)** -21.34 0 (-0.12,0.13) 0.00 -0.13 (-0.26,0.005)* -12.19 -0.61 (-0.74,-0.48)*** -45.66
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.62 (-0.73,-0.51)*** -46.21 -0.65 (-0.76,-0.54)*** -47.80 -0.65 (-0.75,-0.54)*** -47.80 -0.1 (-0.22,0.01) -9.52
HS Education -0.07 (-0.15,0.02) -6.76 -0.1 (-0.18,-0.03)* -9.52 -0.1 (-0.17,-0.02)* -9.52 -0.14 (-0.22,-0.07)** -13.06
Married 0.1 (0.01,0.19)* 10.52 0.1 (0.01,0.18)* 10.52 0.12 (0.03,0.2)* 12.75 0.06 (-0.02,0.15) 6.18
Employed 0.19 (0.11,0.27)*** 20.92 0.13 (0.05,0.2)* 13.88 0.16 (0.05,0.28)* 17.35 -0.02 (-0.13,0.09) -1.98
Unstably Housed 0.15 (0.07,0.24)** 16.18 0.18 (0.1,0.26)*** 19.72 0.19 (0.11,0.27)*** 20.92 0.2 (0.12,0.28)*** 22.14
Age
  <18 0.27 (0.11,0.43)* 31.00 -0.15 (-0.31,0.01) -13.93 -0.16 (-0.32,0.01) -14.79 -0.16 (-0.33,0)* -14.79
  18-24 0.25 (0.14,0.37)*** 28.40 0.09 (-0.02,0.2) 9.42 0.1 (-0.01,0.21) 10.52 0.02 (-0.09,0.13) 2.02
  25-34 0.2 (0.1,0.3)** 22.14 0.1 (-0.001,0.2)* 10.52 0.1 (0.001,0.21)* 10.52 0.16 (0.06,0.26)* 17.35
  35-44 0.17 (0.06,0.27)* 18.53 0.1 (-0.01,0.2) 10.52 0.1 (-0.001,0.2)* 10.52 0.15 (0.05,0.25)* 16.18
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.27 (-0.38,-0.16)*** -23.66 -0.33 (-0.44,-0.22)*** -28.11 -1.12 (-1.23,-1)*** -67.37
  Detox -2.75 (-2.87,-2.62)*** -93.61 -2.78 (-2.91,-2.66)*** -93.80 -3.43 (-3.56,-3.3)*** -96.76
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.73 (-1.02,-0.44)*** -51.81 -0.8 (-1.1,-0.51)*** -55.07 -0.71 (-1.01,-0.41)*** -50.84
Psych Problems 0.33 (0.25,0.42)*** 39.10 0.31 (0.23,0.4)*** 36.34 0.01 (-0.07,0.09) 1.01
Drug Use
  Heroin -0.79 (-1.37,-0.22)* -54.62 -0.76 (-1.32,-0.19)* -53.23 -0.19 (-0.75,0.36) -17.30
  Non-rx Methadone -0.62 (-1.11,-0.12)* -46.21 -0.58 (-1.08,-0.07)* -44.01 -0.41 (-0.91,0.08) -33.63
  Cocaine 0.11 (0.01,0.2)* 11.63 0.09 (-0.01,0.18) 9.42 0.18 (0.09,0.27)*** 19.72
  Synthetic Opioids -0.71 (-1.28,-0.15)* -50.84 -0.66 (-1.22,-0.1)* -48.31 -0.51 (-1.06,0.04) -39.95
  Benzodiazepines 0.01 (-0.21,0.23) 1.01 0.04 (-0.18,0.26) 4.08 0.07 (-0.14,0.29) 7.25
  Any Opioids 0.56 (-0.02,1.14) 75.07 0.52 (-0.05,1.1) 68.20 0.34 (-0.22,0.91) 40.49
Ttl # of Drugs Used
0 0.71 (-0.01,1.43)* 103.40 0.65 (-0.06,1.37) 91.55 0.8 (0.12,1.48)* 122.55
1 -0.07 (-0.18,0.03) -6.76 -0.12 (-0.23,-0.02)* -11.31 0.22 (0.12,0.32)*** 24.61
2 0.06 (-0.04,0.16) 6.18 0.01 (-0.09,0.11) 1.01 0.25 (0.15,0.35)*** 28.40
3 (ref) ref ref ref ref ref ref
IDU 0.29 (0.13,0.45)** 33.64 0.3 (0.14,0.46)** 34.99 0.23 (0.08,0.38)* 25.86
Health Insurance Type
  Medicaid 0.11 (-0.04,0.26) 11.63 -0.03 (-0.18,0.11) -2.96
  Medicare 0.82 (0.67,0.98)*** 127.05 0.54 (0.39,0.69)*** 71.60
  No Insurance 0.27 (0.17,0.38)*** 31.00 0.16 (0.06,0.26)* 17.35
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance 0.14 (-0.05,0.34) 15.03 -0.2 (-0.38,-0.01)* -18.13
  Retirement/Pension 0.03 (-0.14,0.21) 3.05 -0.3 (-0.46,-0.13)** -25.92
  Other Income Source 0.28 (0.15,0.42)*** 32.31 -0.24 (-0.38,-0.1)** -21.34
  No Income -0.09 (-0.21,0.02) -8.61 -0.52 (-0.64,-0.4)*** -40.55
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0002 (-0.0002,-0.0001)*** -0.02
  Methadone Prog Rate -0.04 (-0.11,0.03) -3.92
  Rate of Indiv in Tx 0.22 (0.2,0.25)*** 24.61
  % of res w/Medicaid 0.08 (0.07,0.09)*** 8.33
   SABG -0.08 (-0.08,-0.07)*** -7.69




Model 1 Model 2 Model 3 Model 4 Model 5
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered -0.64 (-0.67,-0.61)*** -47.32 -0.62 (-0.65,-0.59)*** -46.21 -0.94 (-0.97,-0.91)*** -60.94 -0.95 (-0.98,-0.92)*** -61.33 1.27 (1.22,1.33)*** 256.09
Male -0.03 (-0.06,-0.005)* -2.96 0.04 (0.01,0.07)* 4.08 0.05 (0.02,0.07)* 5.13 -0.03 (-0.06,-0.001)* -2.96
Race
  Black 0.09 (0.06,0.13)*** 9.42 0.04 (0,0.08)* 4.08 0.05 (0.02,0.09)* 5.13 0.09 (0.05,0.12)*** 9.42
  Other Race -0.06 (-0.11,-0.01)* -5.82 0.16 (0.11,0.21)*** 17.35 0.05 (0.001,0.1)* 5.13 -0.39 (-0.44,-0.34)*** -32.29
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.77 (-0.81,-0.73)*** -53.70 -0.78 (-0.82,-0.74)*** -54.16 -0.76 (-0.8,-0.72)*** -53.23 -0.16 (-0.2,-0.12)*** -14.79
HS Education -0.13 (-0.16,-0.1)*** -12.19 -0.14 (-0.17,-0.11)*** -13.06 -0.14 (-0.17,-0.11)*** -13.06 -0.14 (-0.16,-0.11)*** -13.06
Married 0.16 (0.13,0.2)*** 17.35 0.09 (0.05,0.12)*** 9.42 0.08 (0.05,0.11)*** 8.33 0.04 (0.01,0.07)* 4.08
Employed 0.18 (0.15,0.21)*** 19.72 0.1 (0.07,0.13)*** 10.52 0.09 (0.04,0.13)** 9.42 -0.16 (-0.2,-0.11)*** -14.79
Unstably Housed 0.19 (0.15,0.22)*** 20.92 0.14 (0.11,0.17)*** 15.03 0.16 (0.13,0.19)*** 17.35 0.16 (0.13,0.19)*** 17.35
Age
  <18 0.26 (0.2,0.32)*** 29.69 -0.15 (-0.21,-0.09)*** -13.93 -0.2 (-0.26,-0.14)*** -18.13 -0.18 (-0.24,-0.12)*** -16.47
  18-24 0.38 (0.33,0.42)*** 46.23 0.15 (0.11,0.19)*** 16.18 0.14 (0.1,0.19)*** 15.03 0.04 (0,0.08)* 4.08
  25-34 0.31 (0.28,0.35)*** 36.34 0.14 (0.1,0.18)*** 15.03 0.14 (0.1,0.18)*** 15.03 0.13 (0.09,0.17)*** 13.88
  35-44 0.2 (0.16,0.24)*** 22.14 0.1 (0.07,0.14)*** 10.52 0.1 (0.06,0.14)*** 10.52 0.09 (0.05,0.12)*** 9.42
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.33 (-0.37,-0.29)*** -28.11 -0.38 (-0.42,-0.34)*** -31.61 -1.07 (-1.11,-1.02)*** -65.70
  Detox -2.75 (-2.8,-2.7)*** -93.61 -2.79 (-2.84,-2.74)*** -93.86 -3.36 (-3.41,-3.31)*** -96.53
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.75 (-0.87,-0.64)*** -52.76 -0.76 (-0.88,-0.65)*** -53.23 -0.61 (-0.72,-0.49)*** -45.66
Psych Problems 0.33 (0.3,0.36)*** 39.10 0.32 (0.29,0.35)*** 37.71 0.04 (0.01,0.07)* 4.08
Drug Use
  Heroin -0.44 (-0.62,-0.26)*** -35.60 -0.44 (-0.62,-0.27)*** -35.60 -0.13 (-0.3,0.04) -12.19
  Non-rx Methadone -0.23 (-0.43,-0.04)* -20.55 -0.23 (-0.42,-0.03)* -20.55 -0.26 (-0.45,-0.07)* -22.89
  Cocaine -0.04 (-0.08,0)* -3.92 -0.04 (-0.08,-0.01)* -3.92 0.13 (0.09,0.16)*** 13.88
  Synthetic Opioids -0.28 (-0.46,-0.1)* -24.42 -0.32 (-0.5,-0.14)** -27.39 -0.21 (-0.39,-0.04)* -18.94
  Benzodiazepines -0.08 (-0.17,0) -7.69 -0.04 (-0.12,0.05) -3.92 0.06 (-0.02,0.14) 6.18
  Any Opioids 0.25 (0.06,0.44) 28.40 0.29 (0.1,0.47)* 33.64 0.14 (-0.04,0.32) 15.03
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
0 -0.38 (-0.62,-0.14)* -31.61 -0.33 (-0.57,-0.09)* -28.11 -0.3 (-0.53,-0.07)* -25.92
1 -0.16 (-0.2,-0.12)*** -14.79 -0.17 (-0.21,-0.13)*** -15.63 0.11 (0.07,0.15)*** 11.63
2 0.02 (-0.02,0.05) 2.02 0 (-0.04,0.04) 0.00 0.11 (0.08,0.15)*** 11.63
3 (ref) ref ref ref ref ref ref
IDU 0.25 (0.19,0.31)*** 28.40 0.25 (0.19,0.31)*** 28.40 0.27 (0.21,0.32)*** 31.00
Health Insurance Type
  Medicaid 0.2 (0.14,0.26)*** 22.14 0.12 (0.07,0.18)*** 12.75
  Medicare 0.76 (0.7,0.82)*** 113.83 0.57 (0.51,0.62)*** 76.83
  No Insurance 0.31 (0.27,0.35)*** 36.34 0.28 (0.24,0.32)*** 32.31
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance 0 (-0.07,0.07) 0.00 -0.34 (-0.41,-0.27)*** -28.82
  Retirement/Pension -0.08 (-0.15,-0.01)* -7.69 -0.38 (-0.44,-0.32)*** -31.61
  Other Income Source 0.22 (0.17,0.28)*** 24.61 -0.24 (-0.29,-0.19)*** -21.34
  No Income -0.17 (-0.22,-0.13)*** -15.63 -0.58 (-0.63,-0.54)*** -44.01
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income '-0.0002 (-0.0002,-0.0002)*** -0.02
  Methadone Prog Rate -0.07 (-0.1,-0.05)*** -6.76
  Rate of Indiv in Tx 0.21 (0.2,0.22)*** 23.37
  % of res w/Medicaid 0.08 (0.07,0.08)*** 8.33
   SABG -0.07 (-0.08,-0.07)*** -6.76
Table 2A.8: Model Building Summary Using Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Methadone, 2008, N=162,242
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 1 Model 2 Model 3 Model 4 Model 5




Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered 1.03 (1.02,1.04)*** 179.13 0.94 (0.93,0.95)*** 156.00 0.72 (0.71,0.74)*** 105.44 0.7 (0.69,0.71)*** 101.38 0.41 (0.39,0.42)*** 50.68
Male -0.04 (-0.05,-0.03)*** -3.92 0.08 (0.07,0.1)*** 8.33 0.03 (0.02,0.04)*** 3.05 0.05 (0.04,0.06)*** 5.13
Race
  Black 0.16 (0.15,0.18)*** 17.35 0.13 (0.11,0.14)*** 13.88 0.11 (0.09,0.12)*** 11.63 -0.03 (-0.04,-0.01)** -2.96
  Other Race -0.19 (-0.21,-0.17)*** -17.30 -0.17 (-0.2,-0.15)*** -15.63 -0.23 (-0.25,-0.21)*** -20.55 -0.09 (-0.11,-0.07)*** -8.61
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.31 (-0.32,-0.29)*** -26.66 -0.33 (-0.35,-0.31)*** -28.11 -0.4 (-0.42,-0.39)*** -32.97 -0.28 (-0.29,-0.26)*** -24.42
HS Education -0.08 (-0.09,-0.07)*** -7.69 -0.07 (-0.08,-0.06)*** -6.76 -0.02 (-0.04,-0.01)*** -1.98 0.003 (-0.01,0.01) 0.30
Married 0.02 (0.004,0.03)* 2.02 -0.01 (-0.02,0.01) -1.00 0.02 (0.01,0.04)** 2.02 0.08 (0.07,0.09)*** 8.33
Employed -0.01 (-0.02,0.003) -1.00 0.04 (0.02,0.05)*** 4.08 0.08 (0.06,0.1)*** 8.33 0.07 (0.05,0.09)*** 7.25
Unstably Housed -0.16 (-0.17,-0.14) -14.79 -0.18 (-0.19,-0.17)*** -16.47 -0.22 (-0.24,-0.21)*** -19.75 -0.03 (-0.04,-0.01)*** -2.96
Age
  <18 0.77 (0.75,0.79)*** 115.98 0.54 (0.51,0.56)*** 71.60 0.72 (0.7,0.74)*** 105.44 0.6 (0.58,0.63)*** 82.21
  18-24 0.21 (0.19,0.23)*** 23.37 0.18 (0.16,0.2)*** 19.72 0.19 (0.18,0.21)*** 20.92 0.17 (0.15,0.18)*** 18.53
  25-34 0.1 (0.09,0.12)*** 10.52 0.08 (0.07,0.1)*** 8.33 0.07 (0.05,0.08)*** 7.25 0.05 (0.04,0.07)*** 5.13
  35-44 0.04 (0.02,0.05)*** 4.08 0.01 (0,0.03) 1.01 0.01 (-0.004,0.03) 1.01 -0.01 (-0.02,0.01) -1.00
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.01 (-0.02,0.01) -1.00 0.005 (-0.01,0.02) 0.50 -0.2 (-0.22,-0.19)*** -18.13
  Detox -0.32 (-0.34,-0.31)*** -27.39 -0.24 (-0.26,-0.22)*** -21.34 -0.18 (-0.2,-0.16)*** -16.47
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.99 (-1.03,-0.96)*** -62.84 -0.89 (-0.93,-0.86)*** -58.93 -0.75 (-0.79,-0.71)*** -52.76
Psych Problems 0.73 (0.72,0.74)*** 107.51 0.5 (0.49,0.51)*** 64.87 0.48 (0.47,0.49)*** 61.61
Drug Use
  Heroin 0.19 (0.13,0.24)*** 20.92 0.12 (0.06,0.17)*** 12.75 0.01 (-0.04,0.06) 1.01
  Non-rx Methadone 0.3 (0.24,0.37)*** 34.99 0.19 (0.12,0.25)*** 20.92 0.08 (0.01,0.14)* 8.33
  Cocaine 0.12 (0.11,0.14)*** 12.75 0.08 (0.06,0.09)*** 8.33 -0.06 (-0.07,-0.04)*** -5.82
  Synthetic Opioids 0.15 (0.1,0.2)*** 16.18 0.03 (-0.03,0.08) 3.05 0.02 (-0.03,0.07) 2.02
  Benzodiazepines 0.08 (0.05,0.11)*** 8.33 0.06 (0.03,0.08)** 6.18 -0.03 (-0.06,-0.01)* -2.96
  Any Opioids -0.03 (-0.08,0.03) -2.96 0.09 (0.03,0.14)* 9.42 -0.04 (-0.09,0.02) -3.92
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
0 0.25 (0.22,0.28)*** 28.40 0.21 (0.18,0.24)*** 23.37 0.03 (-0.002,0.06) 3.05
1 0.25 (0.24,0.27)*** 28.40 0.23 (0.22,0.25)*** 25.86 0.16 (0.14,0.18)*** 17.35
2 0.06 (0.04,0.07)*** 6.18 0.07 (0.05,0.08)*** 7.25 0.01 (-0.003,0.03) 1.01
3 (ref) ref ref ref ref ref ref
IDU -0.05 (-0.07,-0.02)** -4.88 -0.07 (-0.09,-0.04)*** -6.76 -0.01 (-0.04,0.01) -1.00
Health Insurance Type
  Medicaid 0.78 (0.76,0.8)*** 118.15 0.8 (0.78,0.82)*** 122.55
  Medicare 1.18 (1.15,1.2)*** 225.44 1.17 (1.15,1.19)*** 222.20
  No Insurance 1.15 (1.14,1.16)*** 215.82 1.18 (1.17,1.2)*** 225.44
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.1 (-0.13,-0.07)*** -9.52 -0.09 (-0.12,-0.06)*** -8.61
  Retirement/Pension 0.01 (-0.01,0.04) 1.01 -0.07 (-0.1,-0.05)*** -6.76
  Other Income Source -0.03 (-0.05,-0.01)* -2.96 -0.13 (-0.15,-0.11)*** -12.19
  No Income -0.06 (-0.08,-0.04)*** -5.82 -0.24 (-0.25,-0.22)*** -21.34
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (0.0001,0.0001)*** -0.01
  Methadone Prog Rate -0.04 (-0.04,-0.03)*** -3.92
  Rate of Indiv in Tx 0.06 (0.06,0.06)*** 6.18
  % of res w/Medicaid -0.01 (-0.01,-0.01)*** -1.00
   SABG 0.01 (0.01,0.01)*** 1.01
*=p<0.05
Table 2A.9: Model Building Summary Using Multiple Imputation Sample for Treatment Wait Time and Medicaid Coverage of Methadone, 2008, N=2,034,778
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered 0.8 (0.72,0.88)*** 123.36 0.86 (0.78,0.94)*** 136.32 0.78 (0.7,0.869)*** 118.15 0.72 (0.63,0.81)*** 105.44 -0.91 (-1.23,-0.59)*** -59.75
Male 0.03 (-0.06,0.12) 3.05 0.1 (0.01,0.1903)* 10.52 0.19 (0.1,0.28)*** 20.92 0.1 (0.01,0.19)* 10.52
Race
  Black 0.23 (0.13,0.33)*** 25.86 0.37 (0.27,0.4749)*** 44.77 0.36 (0.26,0.47)*** 43.33 0.02 (-0.08,0.12) 2.02
  Other Race -0.41 (-0.57,-0.25)*** -33.63 -0.43 (-0.59,-0.2737)*** -34.95 -0.44 (-0.61,-0.28)*** -35.60 -0.51 (-0.68,-0.35)*** -39.95
  White (ref) ref ref ref ref ref ref 0 (0,0) 0.00
Hispanic -0.34 (-0.5,-0.18)*** -28.82 -0.39 (-0.55,-0.2383)*** -32.29 -0.34 (-0.49,-0.18)*** -28.82 -0.16 (-0.33,0)* -14.79
HS Education -0.18 (-0.27,-0.09)** -16.47 -0.21 (-0.3,-0.1222)*** -18.94 -0.18 (-0.27,-0.09)*** -16.47 -0.18 (-0.27,-0.09)*** -16.47
Married 0.01 (-0.08,0.11) 1.01 0.01 (-0.08,0.1089) 1.01 0.05 (-0.05,0.14) 5.13 0.08 (-0.01,0.17) 8.33
Employed 0.33 (0.24,0.42)*** 39.10 0.23 (0.13,0.3188)*** 25.86 0.43 (0.3,0.56)*** 53.73 0.37 (0.24,0.49)*** 44.77
Unstably Housed -0.05 (-0.14,0.04) -4.88 -0.13 (-0.22,-0.035)* -12.19 -0.11 (-0.2,-0.01)*** -10.42 0.04 (-0.06,0.13) 4.08
Age
  <18 0.79 (0.61,0.97)*** 120.34 0.85 (0.67,1.0403)*** 133.96 0.99 (0.79,1.19)*** 169.12 1.63 (1.43,1.82)*** 410.39
  18-24 0.08 (-0.08,0.23) 8.33 0.03 (-0.13,0.1855) 3.05 0.11 (-0.05,0.27) 11.63 0.34 (0.19,0.5)*** 40.49
  25-34 0.15 (0.01,0.29)* 16.18 0.13 (-0.01,0.2728) 13.88 0.17 (0.03,0.31)* 18.53 0.21 (0.07,0.35)* 23.37
  35-44 0.18 (0.05,0.32)* 19.72 0.17 (0.03,0.3031)* 18.53 0.19 (0.06,0.33)* 20.92 0.24 (0.11,0.37)** 27.12
  >44 (ref) ref ref ref ref ref ref 0 (0,0) 0.00
Tx Program Type
  Outpatient -0.43 (-0.55,-0.315)*** -34.95 -0.42 (-0.54,-0.3)*** -34.30 -0.55 (-0.66,-0.43)*** -42.31
  Detox -2.2 (-2.35,-2.0486)*** -88.92 -2.18 (-2.33,-2.03)*** -88.70 -2.31 (-2.46,-2.16)*** -90.07
  Rehab (ref) ref ref ref ref 0 (0,0) 0.00
Enrolled in MAT -1.06 (-1.48,-0.6426)*** -65.35 -1.06 (-1.48,-0.65)*** -65.35 -0.84 (-1.23,-0.45)*** -56.83
Psych Problems -0.08 (-0.19,0.0266) -7.69 -0.16 (-0.27,-0.04)* -14.79 -0.03 (-0.14,0.08) -2.96
Drug Use
  Heroin -0.61 (-1.36,0.1459) -45.66 -0.56 (-1.3,0.19) -42.88 -1.12 (-1.85,-0.39)* -67.37
  Non-rx Methadone -0.17 (-1.23,0.9006) -15.63 -0.21 (-1.27,0.84) -18.94 -0.2 (-1.21,0.81) -18.13
  Cocaine 0.14 (0.04,0.2525)* 15.03 0.2 (0.09,0.31)** 22.14 -0.1 (-0.2,0) -9.52
  Synthetic Opioids -0.32 (-1.02,0.381) -27.39 -0.25 (-0.95,0.44) -22.12 -0.35 (-1.03,0.32) -29.53
  Benzodiazepines -0.06 (-0.46,0.3368) -5.82 -0.05 (-0.44,0.34) -4.88 -0.43 (-0.81,-0.04)* -34.95
  Any Opioids 1.17 (0.42,1.9265)* 222.20 1.05 (0.3,1.79)* 185.77 1.06 (0.33,1.79)* 188.64
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
0 -0.85 (-1.18,-0.5224)*** -57.26 -0.72 (-1.05,-0.39)*** -51.32 -1.06 (-1.38,-0.74)*** -65.35
1 0.68 (0.56,0.807)*** 97.39 0.71 (0.58,0.83)*** 103.40 0.2 (0.07,0.32)* 22.14
2 0.22 (0.1,0.3327)** 24.61 0.24 (0.13,0.36)*** 27.12 0.09 (-0.02,0.2) 9.42
3 (ref) ref ref ref ref ref ref
IDU -0.53 (-0.73,-0.3384)*** -41.14 -0.54 (-0.74,-0.34)*** -41.73 -0.34 (-0.53,-0.15)** -28.82
Health Insurance Type
  Medicaid 0.08 (-0.12,0.29) 8.33 0.07 (-0.13,0.27) 7.25
  Medicare -0.79 (-0.96,-0.63)*** -54.62 -0.09 (-0.28,0.1) -8.61
  No Insurance 0.06 (-0.08,0.2) 6.18 0.5 (0.36,0.64)*** 64.87
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance 0.45 (0.24,0.67)*** 56.83 0.43 (0.22,0.63)*** 53.73
  Retirement/Pension 0.57 (0.36,0.78)*** 76.83 0.8 (0.59,1)*** 122.55
  Other Income Source 0.37 (0.21,0.53)*** 44.77 0.43 (0.28,0.59)*** 53.73
  No Income 0.23 (0.1,0.37)** 25.86 0.27 (0.14,0.4)*** 31.00
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income 0.0005 (0.0004,0.0006)*** 0.05
  Methadone Prog Rate -0.75 (-0.85,-0.66)*** -52.76
  Rate of Indiv in Tx 0.13 (0.01,0.25)* 13.88
  % of res w/Medicaid 0.61 (0.57,0.64)*** 84.04
*=p<0.05
Table 2A.10: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Methadone, 1998, N=29,500
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered 0.79 (0.74,0.83)*** 119.66 0.87 (0.82,0.92)*** 138.69 0.84 (0.79,0.89)*** 131.64 0.81 (0.76,0.86)*** 124.79 -0.26 (-0.43,-0.08)* -22.89
Male 0.09 (0.04,0.14)** 9.42 0.15 (0.1,0.2)*** 16.18 0.22 (0.17,0.27)*** 24.61 0.13 (0.08,0.18)*** 13.88
Race
  Black 0.24 (0.18,0.29)*** 27.12 0.2 (0.14,0.25)*** 22.14 0.2 (0.14,0.25)*** 22.14 -0.09 (-0.14,-0.03)* -8.61
  Other Race -0.17 (-0.26,-0.09)*** -15.63 -0.25 (-0.34,-0.16)*** -22.12 -0.23 (-0.32,-0.15)*** -20.55 -0.31 (-0.4,-0.22)*** -26.66
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.16 (-0.24,-0.07)** -14.79 -0.14 (-0.23,-0.06)** -13.06 -0.09 (-0.18,-0.01)* -8.61 0.16 (0.07,0.25)** 17.35
HS Education -0.08 (-0.13,-0.03)* -7.69 -0.06 (-0.11,-0.01)* -5.82 -0.03 (-0.08,0.02) -2.96 -0.01 (-0.06,0.04) -1.00
Married 0.02 (-0.03,0.08) 2.02 -0.04 (-0.09,0.01) -3.92 -0.01 (-0.06,0.04) -1.00 -0.03 (-0.08,0.02) -2.96
Employed 0.27 (0.22,0.32)*** 31.00 0.15 (0.1,0.2)*** 16.18 0.21 (0.14,0.28)*** 23.37 0.19 (0.12,0.26)*** 20.92
Unstably Housed 0 (-0.05,0.05) 0.00 0.04 (-0.01,0.09) 4.08 0.06 (0.01,0.11)* 6.18 0.14 (0.09,0.2)*** 15.03
Age
  <18 0.6 (0.5,0.7)*** 82.21 0.67 (0.56,0.77)*** 95.42 0.77 (0.66,0.88)*** 115.98 1.52 (1.42,1.63)*** 357.22
  18-24 0.07 (-0.02,0.15) 7.25 0.07 (-0.02,0.15) 7.25 0.13 (0.04,0.21)* 13.88 0.51 (0.42,0.59)*** 66.53
  25-34 0.03 (-0.05,0.11) 3.05 0.15 (0.07,0.23)** 16.18 0.15 (0.08,0.23)*** 16.18 0.39 (0.32,0.47)*** 47.70
  35-44 0.01 (-0.06,0.09) 1.01 0.1 (0.02,0.17)* 10.52 0.08 (0.01,0.16)* 8.33 0.3 (0.22,0.37)*** 34.99
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.28 (-0.35,-0.22)*** -24.42 -0.22 (-0.29,-0.16)*** -19.75 -0.39 (-0.45,-0.33)*** -32.29
  Detox -1.87 (-1.95,-1.79)*** -84.59 -1.79 (-1.87,-1.71)*** -83.30 -1.73 (-1.81,-1.65)*** -82.27
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.87 (-1.09,-0.65)*** -58.10 -0.97 (-1.19,-0.76)*** -62.09 -0.77 (-0.98,-0.57)*** -53.70
Psych Problems -0.18 (-0.24,-0.12)*** -16.47 -0.23 (-0.29,-0.17)*** -20.55 -0.14 (-0.2,-0.08)*** -13.06
Drug Use
  Heroin 0.44 (0.07,0.81)* 55.27 0.57 (0.2,0.94)* 76.83 0.29 (-0.07,0.64) 33.64
  Non-rx Methadone -0.11 (-0.67,0.45) -10.42 -0.11 (-0.67,0.45) -10.42 -0.33 (-0.87,0.21) -28.11
  Cocaine 0.11 (0.05,0.16)** 11.63 0.11 (0.05,0.17)** 11.63 -0.18 (-0.24,-0.12)*** -16.47
  Synthetic Opioids 0.1 (-0.25,0.45) 10.52 0.13 (-0.22,0.48) 13.88 0.08 (-0.26,0.42) 8.33
  Benzodiazepines 0.25 (0.03,0.48) 28.40 0.19 (-0.03,0.41) 20.92 -0.18 (-0.4,0.03) -16.47
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
  Any Opioids 0.32 (-0.05,0.7) 37.71 0.21 (-0.16,0.58) 23.37 0.01 (-0.35,0.37) 1.01
Ttl # of Drugs Used
0 0.25 (0.08,0.43)* 28.40 0.32 (0.15,0.5)** 37.71 -0.21 (-0.38,-0.04)* -18.94
1 0.79 (0.72,0.86)*** 120.34 0.79 (0.72,0.86)*** 120.34 0.26 (0.2,0.33)*** 29.69
2 0.31 (0.25,0.37)*** 36.34 0.32 (0.26,0.39)*** 37.71 0.13 (0.06,0.19)*** 13.88
3 (ref) ref ref ref ref ref ref
IDU -0.6 (-0.71,-0.49)*** -45.12 -0.61 (-0.72,-0.5)*** -45.66 -0.28 (-0.39,-0.18)*** -24.42
Health Insurance Type
  Medicaid 0.08 (-0.04,0.19) 8.33 0.06 (-0.05,0.16) 6.18
  Medicare -0.71 (-0.81,-0.62)*** -50.84 0.02 (-0.09,0.13) 2.02
  No Insurance 0.15 (0.07,0.23)** 16.18 0.52 (0.44,0.59)*** 68.20
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance 0.24 (0.12,0.36)*** 27.12 0.32 (0.2,0.43)*** 37.71
  Retirement/Pension 0.51 (0.4,0.62)*** 66.53 0.68 (0.57,0.79)*** 97.39
  Other Income Source 0.14 (0.05,0.23) 15.03 0.21 (0.12,0.29)*** 23.37
  No Income 0.09 (0.01,0.16)* 9.42 0.2 (0.13,0.27)*** 22.14
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income 0.0003 (0.0003,0.0004)*** 0.03
  Methadone Prog Rate -0.8 (-0.85,-0.75)*** -55.07
  Rate of Indiv in Tx 0.16 (0.09,0.22)*** 17.35
  % of res w/Medicaid 0.51 (0.49,0.53)*** 66.53
*=p<0.05
Table 2A.11: Model Building Summary Using Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Methadone, 1998, N=98,183
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Methadone Covered 0.70 (0.69,0.71)*** 101.23 0.7 (0.69,0.72)*** 101.38 0.51 (0.5,0.52)*** 66.53 0.45 (0.44,0.47)*** 56.83 0.35 (0.33,0.37)*** 41.91
Male 0.15 (0.13,0.16)*** 16.18 0.19 (0.18,0.21)*** 20.92 0.17 (0.16,0.19)*** 18.53 0.21 (0.2,0.23)*** 23.37
Race
  Black 0.04 (0.02,0.06)*** 4.08 0.01 (-0.01,0.02) 1.01 -0.03 (-0.04,-0.01)** -2.96 -0.14 (-0.16,-0.13)*** -13.06
  Other Race -0.33 (-0.35,-0.31)*** -28.11 -0.14 (-0.16,-0.12)*** -13.06 -0.15 (-0.17,-0.13)*** -13.93 0.08 (0.06,0.1)*** 8.33
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.17 (-0.2,-0.15)*** -15.63 -0.36 (-0.39,-0.34)*** -30.23 -0.36 (-0.38,-0.34)*** -30.23 -0.39 (-0.41,-0.36)*** -32.29
HS Education -0.08 (-0.09,-0.07)*** -7.69 -0.09 (-0.1,-0.08)*** -8.61 -0.09 (-0.1,-0.07)*** -8.61 -0.06 (-0.08,-0.05)*** -5.82
Married 0.09 (0.08,0.11)*** 9.42 0.02 (0.01,0.04)* 2.02 0.02 (0,0.03)* 2.02 -0.06 (-0.07,-0.04)*** -5.82
Employed 0.11 (0.1,0.13)*** 11.63 0.1 (0.09,0.12)*** 10.52 0.22 (0.2,0.24)*** 24.61 0.14 (0.12,0.16)*** 15.03
Unstably Housed 0.13 (0.12,0.15)*** 13.88 0.04 (0.02,0.05)*** 4.08 0.01 (-0.01,0.02) 1.01 -0.03 (-0.05,-0.02)*** -2.96
Age
  <18 0.65 (0.63,0.68)*** 91.55 0.57 (0.54,0.6)*** 76.83 0.62 (0.59,0.65)*** 85.89 0.53 (0.51,0.56)*** 69.89
  18-24 0.43 (0.41,0.45)*** 53.73 0.37 (0.34,0.39)*** 44.77 0.4 (0.38,0.42)*** 49.18 0.4 (0.37,0.42)*** 49.18
  25-34 0.38 (0.36,0.4)*** 46.23 0.38 (0.36,0.4)*** 46.23 0.41 (0.39,0.43)*** 50.68 0.38 (0.36,0.4)*** 46.23
  35-44 0.22 (0.2,0.24)*** 24.61 0.23 (0.21,0.25)*** 25.86 0.26 (0.24,0.28)*** 29.69 0.23 (0.21,0.25)*** 25.86
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.64 (-0.66,-0.62)*** -47.27 -0.69 (-0.71,-0.67)*** -49.84 -0.99 (-1.01,-0.97)*** -62.84
  Detox -1.84 (-1.86,-1.82)*** -84.12 -1.9 (-1.93,-1.88)*** -85.04 -2.03 (-2.05,-2.01)*** -86.87
  Rehab (ref) 0 (0,0) 0.00 0 (0,0) 0.00 0 (0,0) 0.00
Enrolled in MAT -0.1 (-0.15,-0.05)** -9.52 -0.09 (-0.14,-0.03)* -8.61 -0.1 (-0.16,-0.05)** -9.52
Psych Problems -0.13 (-0.15,-0.12)*** -12.19 -0.18 (-0.2,-0.16)*** -16.47 -0.02 (-0.04,-0.01)* -1.98
Drug Use
  Heroin -0.14 (-0.25,-0.03)* -13.06 -0.03 (-0.13,0.08) -2.96 0.11 (0,0.22)* 11.63
  Non-rx Methadone -0.14 (-0.31,0.04) -13.06 -0.08 (-0.25,0.09) -7.69 -0.2 (-0.38,-0.03)* -18.13
  Cocaine 0.09 (0.07,0.11)*** 9.42 0.08 (0.07,0.1)*** 8.33 -0.03 (-0.05,-0.02)** -2.96
  Synthetic Opioids 0.21 (0.1,0.31)*** 23.37 0.25 (0.15,0.35)*** 28.40 0.14 (0.04,0.24)* 15.03
  Benzodiazepines 0.12 (0.05,0.18)** 12.75 0.09 (0.03,0.16)* 9.42 -0.14 (-0.2,-0.07)*** -13.06
  Any Opioids 0.13 (0.02,0.24)* 13.88 0.02 (-0.09,0.13) 2.02 -0.01 (-0.12,0.1) -1.00
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
0 0.07 (0.04,0.11)** 7.25 0.05 (0.02,0.09)* 5.13 0.08 (0.04,0.12)*** 8.33
1 0.16 (0.14,0.18)*** 17.35 0.17 (0.15,0.19)*** 18.53 0.09 (0.07,0.11)*** 9.42
2 -0.03 (-0.05,-0.02)** -2.96 -0.03 (-0.05,-0.02)** -2.96 -0.06 (-0.07,-0.04)*** -5.82
3 (ref) ref ref ref ref ref ref
IDU 0.12 (0.09,0.15)*** 12.75 0.11 (0.08,0.14)*** 11.63 0.17 (0.14,0.2)*** 18.53
Health Insurance Type
  Medicaid 0.27 (0.24,0.3)*** 31.00 0.02 (-0.01,0.05) 2.02
  Medicare 0.25 (0.22,0.28)*** 28.40 -0.07 (-0.1,-0.04)*** -6.76
  No Insurance 0.04 (0.02,0.06)*** 4.08 -0.01 (-0.03,0.01) -1.00
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.25 (-0.28,-0.22)*** -22.12 0.09 (0.06,0.12)*** 9.42
  Retirement/Pension 0.36 (0.33,0.39)*** 43.33 0.11 (0.08,0.15)*** 11.63
  Other Income Source -0.13 (-0.15,-0.1)*** -12.19 0.08 (0.05,0.1)*** 8.33
  No Income 0.21 (0.19,0.23)*** 23.37 -0.06 (-0.08,-0.03)*** -5.82
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)* -0.01
  Methadone Prog Rate -0.13 (-0.13,-0.12)*** -12.19
  Rate of Indiv in Tx -0.13 (-0.14,-0.13)*** -12.19
  % of res w/Medicaid 0.11 (0.11,0.12)*** 11.63
*=p<0.05
Table 2A.12: Model Building Summary Using Multiple Imputation Sample for Treatment Wait Time and Medicaid Coverage of Methadone, 1998, N=1,364,735
Model 1: Unadjusted association between Medicaid coverage of methadone and wait time for substance use treatment
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of methadone, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5







2006, N=1,914,338 2008, N=2,016,672
2006, individuals in 24 
states N=883,207
2008, individuals in 24 states 
N=968,237
2008, individuals in 24 
states, no missing, 
N=320,656
2006, individuals in 24 states, 
BS sample, N=24,100
2008, individuals in 24 states, BS 
sample, N=25,700
2006, individuals in 24 states, 
MI sample, N=4,258,996
2008, individuals in 24 states, MI 
sample, N=4,698,055
2006-2008 combined, no 
missing, N=561,413
2006-2008 combined, BS sample, 
N=25,300
Figure 2B.1:  Analytic Sample, Treatment Wait Time and Medicaid Coverage of Buprenorphine
2006, individuals in 24 




Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=649,612 N=320,694
n ( %) n ( %)
Medicaid Coverage of Buprenorphine*** 644921 (99%) 250675 (78%)
   missing n=0 n=0
Male*** 422089 (65%) 219679 (69%)
   missing n=203 n=0
Race
  White*** 396201 (64%) 215265 (67%)
  Black*** 124540 (20%) 72914 (23%)
  Other Race*** 95713 (16%) 32515 (10%)
   missing n=33158 n=0
Hispanic*** 117021 (19%) 34008 (11%)
   missing n=31598 n=0
HS Education*** 389981 (61%) 210126 (66%)
   missing n=11805 n=0
Married*** 73956 (19%) 67037 (21%)
   missing n=253124 n=0
Employed*** 155065 (24%) 104298 (33%)
   missing n=8980 n=0
Unstably housed*** 259992 (41%) 143422 (45%)
   missing n=11604 n=0
Age
   <18*** 67587 (10%) 26259 (8%)
  18-24*** 120578 (19%) 62089 (19%)
  25-34 166420 (26%) 81816 (26%)
  35-44*** 147584 (23%) 74996 (23%)
  >45*** 147442 (23%) 75534 (24%)
   missing n=1 n=0
Program Type
  Outpatient*** 439175 (68%) 188000 (59%)
  Detox*** 108337 (17%) 77886 (24%)
  Rehab*** 102008 (16%) 54808 (17%)
   missing n=92 n=0
Patient receiving MAT*** 46070 (7%) 16254 (5%)
   missing n=31758 n=0
Psych Problems*** 146690 (26%) 73249 (23%)
   missing n=91483 n=0
Drug use reported at admit
  Heroin*** 101536 (16%) 40347 (13%)
      missing n=0 n=0
  Non prescription Methadone*** 4684 (1%) 1836 (1%)
      missing n=0 n=0
  Synthetic opioids*** 56031 (9%) 28286 (8%)
      missing n=0 n=0
Table 2B.1 Comparison of Characteristics of Cases with Missing Data on Any Variables 
Compared to Cases with No Missing Data, Treatment Wait Time and Medicaid 
Coverage of Buprenorphine Analysis, 2008
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Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Any opiates*** 148021 (23%) 63890 (20%)
      missing n=0 n=0
  Cocaine/Crack*** 151756 (23%) 78415 (24%)
      missing n=0 n=0
  Benzodiazepine 16211 (3%) 7947 (2%)
      missing n=0 n=0
# of subs reported at admit
1*** 292681 (45%) 152040 (47%)
                                  2*** 249214 (38%) 103316 (32%)
3*** 83256 (13%) 65336 (20%)
      missing n=0 n=0
IDU*** 85288 (14%) 32155 (10%)
      missing n=24452 n=0
Client Insurance Type
  Medicaid 27822 (17%) 47002 (15%)
  Medicare*** 8401 (5%) 19701 (6%)
  No insurance*** 103905 (62%) 213149 (66%)
  Private Insurance*** 27331 (16%) 40842 (13%)
      missing n=201085 n=0
Primary Source of Income
  Public Assistance*** 8645 (3%) 17863 (6%)
  Retirement/Pension* 21426 (8%) 26258 (8%)
  Other Income*** 41029 (16%) 31787 (10%)
  No income*** 102646 (40%) 118490 (37%)
  Salary*** 81587 (32%) 126296 (39%)
      missing n=394279 n=0
Continuous variables
Days Waiting to Enter Treatment*** 8.74 (65.48) 6.29 (22.66)
Per capita Income*** $41,746 ($5,144) $41,470 ($4,853)
Rate of bupe programs/10K pop*** 7.22 (3.08) 7.57 (6.26)
Rate of individuals in tx/1M pop*** 17.55 (10.65) 18.94 (14.91)
Percent of residents rec'v Medicaid*** 21.17 (6.53) 17.8 (5.24)






Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=643,460 N=240,769
n ( %) n ( %)
Medicaid Coverage of Buprenorphine*** 562599 (87%) 120297 (50%)
   missing n=0 n=0
Male*** 421756 (66%) 165786 (69%)
   missing n=247 n=0
Race
  White*** 410625 (65%) 157930 (66%)
  Black*** 125140 (20%) 60977 (25%)
  Other Race*** 100594 (16%) 21862 (9%)
   missing n=7101 n=0
Hispanic*** 110260 (17%) 28788 (12%)
   missing n=31598 n=0
HS Education*** 387201 (61%) 154228 (64%)
   missing n=11152 n=0
Married*** 81091 (20%) 53924 (22%)
   missing n=241524 n=0
Employed*** 176582 (28%) 86187 (36%)
   missing n=9344 n=0
Unstably housed*** 258626 (42%) 108643 (45%)
   missing n=21471 n=0
Age
   <18*** 60925 (9%) 18416 (8%)
  18-24*** 122551 (19%) 44871 (19%)
  25-34** 161976 (25%) 59751 (25%)
  35-44*** 164008 (25%) 62825 (26%)
  >45*** 134000 (21%) 54906 (23%)
   missing n=0 n=0
Program Type
  Outpatient*** 431927 (67%) 140729 (58%)
  Detox*** 108712 (17%) 60553 (25%)
  Rehab*** 102765 (16%) 39487 (16%)
   missing n=92 n=0
Patient receiving MAT*** 40406 (7%) 14459 (6%)
   missing n=46243 n=0
Psych Problems*** 126746 (25%) 50654 (21%)
   missing n=144268 n=0
Drug use reported at admit
  Heroin*** 96815 (15%) 34283 (14%)
      missing n=0 n=0
  Non prescription Methadone 3541 (1%) 1371 (1%)
      missing n=0 n=0
  Synthetic opioids*** 38095 (6%) 14831 (6%)
      missing n=0 n=0
Table 2B.2 Comparison of Characteristics of Cases with Missing Data on Any Variables 
Compared to Cases with No Missing Data, Treatment Wait Time and Medicaid 
Coverage of Buprenorphine Analysis, 2006
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Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Any opiates*** 128273 (20%) 47089 (20%)
      missing n=0 n=0
  Cocaine/Crack*** 164331 (26%) 66898 (28%)
      missing n=0 n=0
  Benzodiazepine*** 10867 (2%) 4658 (2%)
      missing n=0 n=0
# of subs reported at admit
1*** 276960 (43%) 116408 (48%)
                                  2*** 259462 (40%) 79896 (33%)
3*** 82470 (13%) 44465 (18%)
      missing n=0 n=0
IDU*** 84036 (14%) 24133 (10%)
      missing n=24551 n=0
Client Insurance Type
  Medicaid 38141 (18%) 36277 (15%)
  Medicare*** 11934 (6%) 10503 (4%)
  No insurance*** 134063 (63%) 161765 (67%)
  Private Insurance 28811 (14%) 32224 (13%)
      missing n=430511 n=0
Primary Source of Income
  Public Assistance*** 10634 (4%) 14773 (6%)
  Retirement/Pension*** 18455 (8%) 19472 (8%)
  Other Income*** 38623 (16%) 24009 (10%)
  No income*** 84673 (35%) 78022 (32%)
  Salary*** 90401 (37%) 104493 (43%)
      missing n=400674 n=0
Continuous variables
Days Waiting to Enter Treatment*** 8.39 (59.05) 6.75 (28.4)
Per capita Income*** $38,791 ($4,585) $38,625 ($4,792)
Rate of bupe programs/10K pop*** 5.31 (2.12) 6.49 (4.05)
Rate of individuals in tx/1M pop*** 14.41 (10.41) 18.41 (16.32)
Percent of residents rec'v Medicaid*** 19.9 (6.54) 16.38 (4.85)








Individuals in States with Medicaid Coverage of Buprenorphine 16607 (66%)
Male 17405 (69%)
Race
  White 16744 (66%)
  Black 6031 (24%)
  Other Race 2525 (10%)
Hispanic 2845 (11%)
HS Education 16307 (64%)
Married 5463 (22%)
Employed 8748 (35%)
Unstably housed 11322 (45%)
Age
  <18 2006 (8%)
  18-24 4838 (19%)
  25-34 6304 (25%)
  35-44 6292 (25%)
  >45 5860 (23%)
Program Type
  Outpatient 14803 (59%)
  Detox 6130 (24%)
  Rehab 4367 (17%)
Patient receiving MAT 1341 (5%)
Psych Problems 5564 (22%)
Drug use reported at admit
  Heroin 3348 (13%)
  Non prescription Methadone 130 (1%)
  Cocaine/Crack 6562 (26%)
  Synthetic opioids 1788 (7%)
  Benzodiazepine 533 (2%)
  Any Opioids 4937 (20%)






  Medicaid 3746 (15%)
  Medicare 1428 (6%)
  No insurance 16779 (66%)
  Private Insurance 3347 (13%)
Primary Source of Income
  Public Assistance 1406 (6%)
  Retirement/Pension 2108 (8%)
  Other Income 2458 (10%)
  No income 8741 (35%)
  Salary 10587 (42%)
Continuous variables Mean (SD)
Days Waiting to Enter Treatment 6.39 (25.2)
Per Capita Income $40,255 ($5,027)
Rate of buprenorphine programs/10K pop 7.11 (5.46)
Rate of individuals in tx/1M pop 18.75 (15.55)
Percent of residents rec'v Medicaid 17.19 (5.10)
SABG 43.86 (29.77)
Table 2B.3: Descriptive Characteristics of Bootstrapped Listwise Deletion Sample for 
Treatment Wait Time and Medicaid Coverage of Methadone, Combined 1998-2008 
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Medicaid Coverage No Medicaid Coverage
N=16,607 N=8,693
n ( %) n ( %)
Male 11411 (69%) 5994 (69%)
Race
  White*** 10226 (62%) 6518 (75%)
  Black*** 4466 (27%) 1565 (18%)
  Other Race*** 1915 (12%) 610 (7%)
Hispanic*** 1766 (11%) 1079 (12%)
HS Education* 10624 (64%) 5683 (65%)
Married*** 3367 (20%) 2096 (24%)
Employed 5744 (35%) 3004 (35%)
Unstably housed*** 7634 (46%) 3688 (42%)
Age
  <18*** 1413 (9%) 593 (7%)
  18-24* 3114 (19%) 1724 (20%)
  25-34*** 3825 (23%) 2479 (29%)
  35-44* 4210 (25%) 2082 (24%)
  >45*** 4045 (24%) 1815 (21%)
Program Type
  Rehab*** 2413 (15%) 1954 (22%)
  Outpatient*** 10924 (66%) 3879 (45%)
  Detox*** 3270 (20%) 2860 (33%)
Patient receiving MAT*** 1149 (7%) 192 (2%)
Psych Problems** 3548 (21%) 2016 (23%)
Drug use reported at admit
  Heroin*** 2996 (18%) 352 (4%)
  Non prescription Methadone 78 (<1%) 52 (1%)
  Any opiates*** 3816 (23%) 1121 (13%)
  Cocaine/Crack* 4398 (26%) 2164 (25%)
  Synthetic opioids*** 971 (6%) 817 (9%)
  Benzodiazepine*** 240 (1%) 293 (3%)
# of subs reported at admit
                                               1** 8113 (49%) 4055 (47%)
2*** 5641 (34%) 2544 (29%)
3*** 2853 (17%) 2094 (24%)
IDU* 1606 (10%) 928 (11%)
Client Insurance Type
  Medicaid*** 2997 (18%) 749 (9%)
  Medicare*** 1053 (6%) 375 (4%)
  No insurance*** 10221 (62%) 6558 (75%)
  Private Insurance*** 2336 (14%) 1011 (12%)
Primary Source of Income
  Public Assistance*** 1097 (7%) 309 (4%)
  Retirement/Pension*** 1610 (10%) 498 (6%)
  Other Income*** 1739 (10%) 719 (8%)
  No income*** 4918 (30%) 3823 (44%)
  Salary*** 7243 (44%) 3344 (38%)
Continuous variables
Days Waiting to Enter Treatment*** 7.5 (27.2) 4.3 (20.7)
Per capita Income*** $42,582 ($3,831) $35,810 ($3,925)
Rate of buprenorphine programs/10K pop*** 8.2 (6.0) 5.1 (3.3)
Rate of individuals in tx/1M pop*** 22.7 (17.6) 11.1 (4.8)




Table 2B.4: Comparison of Characteristics of Bootstrapped Listwise Deletion Sample by 
Medicaid Coverage of Buprenorphine, Combined 2006-2008
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe covered 0.56 (0.48,0.65)*** 75.07 0.6 (0.52,0.68)*** 82.21 0.51 (0.43,0.6)*** 66.53 0.49 (0.41,0.58)*** 63.23 1.28 (1.16,1.41)*** 259.66 1.3 (1.17,1.43)*** 266.93 1.49 (1.34,1.64)*** 343.71
Male -0.05 (-0.13,0.03) -4.88 -0.06 (-0.15,0.02) -5.82 -0.08 (-0.17,0.002)* -7.69 -0.1 (-0.19,-0.02)* -9.52 -0.1 (-0.19,-0.02)* -9.52 -0.1 (-0.19,-0.02)* -9.52
Race
   Black -0.04 (-0.13,0.06) -3.92 -0.07 (-0.18,0.03) -6.76 -0.07 (-0.17,0.03) -6.76 -0.19 (-0.3,-0.09)** -17.30 -0.19 (-0.3,-0.09)** -17.30 -0.2 (-0.3,-0.09)** -18.13
  Other Race -0.63 (-0.78,-0.49) -46.74 0.14 (-0.01,0.29) 15.03 0.11 (-0.04,0.26) 11.63 0.04 (-0.1,0.18) 4.08 0.04 (-0.1,0.18) 4.08 0.03 (-0.11,0.17) 3.05
  White (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Hispanic 0.18 (0.03,0.33)*** 19.72 -0.68 (-0.83,-0.54)*** -49.34 -0.67 (-0.81,-0.52)*** -48.83 -0.29 (-0.43,-0.15)*** -25.17 -0.29 (-0.43,-0.15)*** -25.17 -0.3 (-0.44,-0.16)*** -25.92
HS Education 0.04 (-0.05,0.13) 4.08 0.09 (0,0.17) 9.42 0.09 (0,0.18)* 9.42 0.15 (0.06,0.23)** 16.18 0.15 (0.06,0.23)** 16.18 0.16 (0.07,0.25)** 17.35
Married 0.05 (-0.05,0.15) 5.13 -0.03 (-0.13,0.07) -2.96 0.01 (-0.09,0.1) 1.01 -0.02 (-0.12,0.07) -1.98 -0.03 (-0.12,0.07) -2.96 -0.02 (-0.12,0.07) -1.98
Employed -0.19 (-0.27,-0.1)*** -17.30 -0.3 (-0.38,-0.21)*** -25.92 -0.44 (-0.56,-0.31)*** -35.60 -0.5 (-0.62,-0.38)*** -39.35 -0.49 (-0.61,-0.38)*** -38.74 -0.49 (-0.61,-0.37)*** -38.74
Unstably Housed -0.08 (-0.16,0.01) -7.69 -0.04 (-0.12,0.04) -3.92 -0.05 (-0.13,0.04) -4.88 -0.09 (-0.17,0)* -8.61 -0.09 (-0.17,0)* -8.61 -0.07 (-0.16,0.02) -6.76
Age
  <18 0.59 (0.41,0.77)*** 80.40 0.37 (0.19,0.55)*** 44.77 0.36 (0.16,0.55)** 43.33 0.24 (0.05,0.43)* 27.12 0.24 (0.05,0.43)* 27.12 0.24 (0.05,0.43)* 27.12
  18-24 0.5 (0.38,0.63)*** 64.87 0.36 (0.23,0.48)*** 43.33 0.35 (0.22,0.48)*** 41.91 0.35 (0.22,0.47)*** 41.91 0.34 (0.22,0.47)*** 40.49 0.37 (0.24,0.49)*** 44.77
  25-34 0.45 (0.34,0.57)*** 56.83 0.4 (0.29,0.52)*** 49.18 0.39 (0.27,0.5)*** 47.70 0.39 (0.27,0.5)*** 47.70 0.39 (0.27,0.5)*** 47.70 0.4 (0.28,0.51)*** 49.18
  35-44 0.21 (0.1,0.32)** 23.37 0.22 (0.11,0.33)** 24.61 0.19 (0.08,0.31)** 20.92 0.2 (0.09,0.31)** 22.14 0.2 (0.09,0.31)** 22.14 0.21 (0.1,0.32)** 23.37
  >44 (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.001 (-0.109,0.108) 0.07 -0.01 (-0.12,0.1) -1.00 -0.2 (-0.31,-0.09)** -18.13 -0.2 (-0.31,-0.09)** -18.13 -0.19 (-0.3,-0.08)** -17.30
  Detox -1.2 (-1.32,-1.07)*** -69.88 -1.22 (-1.34,-1.1)*** -70.48 -1.71 (-1.84,-1.58)*** -81.91 -1.7 (-1.83,-1.57)*** -81.73 -1.68 (-1.81,-1.55)*** -81.36
  Rehab (ref) ref ref ref ref ref ref ref ref ref ref
Enrolled in MAT 0.08 (-0.12,0.29) 8.33 0.03 (-0.18,0.24) 3.05 -0.11 (-0.31,0.1) -10.42 -0.11 (-0.31,0.09) -10.42 -0.13 (-0.33,0.07) -12.19
Psych problems 0.12 (0.03,0.22)* 12.75 0.14 (0.04,0.23)* 15.03 0.17 (0.08,0.26)** 18.53 0.17 (0.08,0.26)** 18.53 0.19 (0.09,0.28)*** 20.92
Drug Use
  Heroin 0.18 (-0.28,0.63) 19.72 0.26 (-0.2,0.72) 29.69 0.51 (0.05,0.96)* 66.53 0.51 (0.05,0.96)* 66.53 0.54 (0.09,0.99)* 71.60
  Non-rx Methadone -0.57 (-1.1,-0.03)* -43.45 -0.54 (-1.07,-0.01)* -41.73 -0.42 (-0.95,0.1) -34.30 -0.43 (-0.95,0.1) -34.95 -0.42 (-0.95,0.1) -34.30
  Cocaine 0.06 (-0.04,0.16) 6.18 0.07 (-0.03,0.17) 7.25 -0.07 (-0.17,0.04) -6.76 -0.07 (-0.18,0.03) -6.76 -0.06 (-0.16,0.04) -5.82
  Synthetic Opioids 0.04 (-0.4,0.49) 4.08 0.14 (-0.31,0.59) 15.03 0.25 (-0.19,0.7) 28.40 0.26 (-0.19,0.7) 29.69 0.28 (-0.17,0.72) 32.31
  Benzodiazepines 0 (-0.27,0.27) 0.00 0.03 (-0.24,0.31) 3.05 -0.14 (-0.4,0.13) -13.06 -0.15 (-0.41,0.12) -13.93 -0.17 (-0.44,0.1) -15.63
  Any Opioids -0.07 (-0.54,0.41) -6.76 -0.13 (-0.6,0.35) -12.19 -0.48 (-0.95,-0.01)* -38.12 -0.48 (-0.95,-0.01)* -38.12 -0.5 (-0.97,-0.04)* -39.35
Ttl # of Drugs Used
1 -0.13 (-0.26,-0.01)* -12.19 -0.12 (-0.24,0) -11.31 -0.2 (-0.32,-0.08)* -18.13 -0.21 (-0.33,-0.08)* -18.94 -0.2 (-0.32,-0.08)* -18.13
2 0.05 (-0.06,0.17) 5.13 0.06 (-0.05,0.18) 6.18 0.03 (-0.09,0.14) 3.05 0.03 (-0.09,0.14) 3.05 0.03 (-0.08,0.15) 3.05
3 (ref) ref ref ref ref ref ref ref ref ref ref
IDU -0.1 (-0.24,0.04) -9.52 -0.11 (-0.25,0.03) -10.42 0.05 (-0.08,0.19) 5.13 0.06 (-0.08,0.2) 6.18 0.04 (-0.1,0.17) 4.08
Health Insurance Type
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
  Medicaid 0.4 (0.24,0.56)*** 49.18 0.11 (-0.06,0.27) 11.63 0.1 (-0.06,0.27) 10.52 0.1 (-0.07,0.26) 10.52
  Medicare 0.43 (0.24,0.63)*** 53.73 0.58 (0.39,0.77)*** 78.60 0.58 (0.39,0.77)*** 78.60 0.6 (0.41,0.79)*** 82.21
  No insurance 0.34 (0.22,0.46)*** 40.49 0.29 (0.16,0.41)*** 33.64 0.28 (0.16,0.41)*** 32.31 0.27 (0.15,0.4)*** 31.00
  Private Insurance (ref) ref ref ref ref ref ref ref ref
Primary Income
  Public Asstistance -0.55 (-0.75,-0.35)*** -42.31 -0.52 (-0.72,-0.33)*** -40.55 -0.52 (-0.71,-0.33)*** -40.55 -0.52 (-0.71,-0.33)*** -40.55
  Retirement/Pension -0.2 (-0.38,-0.02)* -18.13 -0.28 (-0.45,-0.1)* -24.42 -0.27 (-0.44,-0.1)* -23.66 -0.24 (-0.41,-0.07)* -21.34
  Other Income Source -0.38 (-0.54,-0.23)*** -31.61 -0.42 (-0.58,-0.27)*** -34.30 -0.42 (-0.57,-0.26)*** -34.30 -0.39 (-0.54,-0.23)*** -32.29
  No Income -0.23 (-0.36,-0.11)** -20.55 -0.41 (-0.53,-0.29)*** -33.63 -0.4 (-0.52,-0.27)*** -32.97 -0.39 (-0.52,-0.27)*** -32.29
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)*** 0.01 -0.0001 (-0.0001,-0.0001)*** 0.01 -0.0001 (-0.0001,-0.0001)*** 0.01
  Bupe Prog Rate 0.06 (0.04,0.08)*** 6.18 0.06 (0.05,0.08)*** 6.18 0.06 (0.05,0.08)*** 6.18
  Rate of Indiv in Tx 0.01 (0,0.01)** 1.01 0.01 (0,0.01)* 1.01 0.004 (-0.002,0.01) 0.42
  % of res w/Medicaid 0.1 (0.09,0.11)*** 10.52 0.1 (0.09,0.11)*** 10.52 0.1 (0.09,0.11)*** 10.52
  SABG 0.01 (0.01,0.01)*** 1.01 0.01 (0.01,0.01)*** 1.01 0.01 (0.01,0.01)*** 1.01
Time -0.06 (-0.15,0.04) -5.82 0.25 (0.1,0.39)* 28.40
Medicaid Cov * Time -0.49 (-0.67,-0.31)*** -38.74
Table 2B.5: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, Combined 2006-2008 Analysis, N=25,300
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
**=p<0.001
*=p<0.05
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 6: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables and time




Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe covered 0.56 (0.54,0.58)*** 75.33 0.59 (0.58,0.61)*** 80.40 0.45 (0.43,0.46)*** 56.83 0.44 (0.43,0.46)*** 55.27 1.35 (1.33,1.38)*** 285.74 1.37 (1.34,1.4)*** 293.54 1.54 (1.51,1.57)*** 366.46
Male -0.08 (-0.1,-0.06)*** -7.69 -0.07 (-0.09,-0.06)*** -6.76 -0.06 (-0.08,-0.05)*** -5.82 -0.06 (-0.08,-0.05)*** -5.82 -0.06 (-0.08,-0.05)*** -5.82 -0.06 (-0.08,-0.05)*** -5.82
Race
   Black -0.07 (-0.09,-0.05)*** -6.76 -0.06 (-0.08,-0.04)*** -5.82 -0.08 (-0.1,-0.05)*** -7.69 -0.21 (-0.23,-0.19)*** -18.94 -0.21 (-0.24,-0.19)*** -18.94 -0.21 (-0.23,-0.19)*** -18.94
  Other Race -0.63 (-0.66,-0.6)*** -46.74 0.15 (0.12,0.18)*** 16.18 0.13 (0.1,0.16)*** 13.88 0.07 (0.04,0.09)*** 7.25 0.07 (0.04,0.1)*** 7.25 0.07 (0.04,0.09)*** 7.25
  White (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Hispanic 0.15 (0.12,0.18)*** 16.18 -0.71 (-0.73,-0.68)*** -50.84 -0.71 (-0.74,-0.68)*** -50.84 -0.39 (-0.42,-0.36)*** -32.29 -0.39 (-0.42,-0.36)*** -32.29 -0.4 (-0.43,-0.37)*** -32.97
HS Education -0.09 (-0.1,-0.07)*** -8.61 -0.08 (-0.1,-0.06)*** -7.69 -0.05 (-0.07,-0.04)*** -4.88 -0.01 (-0.03,0.01) -1.00 -0.01 (-0.03,0.01) -1.00 -0.01 (-0.03,0.01) -1.00
Married 0.03 (0.01,0.05)* 3.05 0.02 (-0.003,0.04) 2.02 0.04 (0.02,0.06)*** 4.08 0.04 (0.02,0.06)** 4.08 0.03 (0.02,0.05)** 3.05 0.04 (0.02,0.06)** 4.08
Employed -0.001 (-0.02,0.02) 0.00 -0.11 (-0.13,-0.09)*** -10.42 -0.17 (-0.2,-0.14)*** -15.63 -0.23 (-0.25,-0.2)*** -20.55 -0.22 (-0.25,-0.2)*** -19.75 -0.21 (-0.24,-0.19)*** -18.94
Unstably Housed -0.02 (-0.04,-0.001)* -1.98 0.02 (0.001,0.04)* 2.02 0.004 (-0.01,0.02) 0.00 -0.02 (-0.04,-0.004)* -1.98 -0.02 (-0.04,0)* -1.98 -0.01 (-0.02,0.01) -1.00
Age
  <18 0.4 (0.36,0.43)*** 49.18 0.15 (0.11,0.19)*** 16.18 0.15 (0.11,0.19)*** 16.18 0.03 (-0.01,0.06) 3.05 0.03 (-0.01,0.06) 3.05 0.01 (-0.03,0.05) 1.01
  18-24 0.34 (0.31,0.36)*** 40.49 0.21 (0.19,0.24)*** 23.37 0.2 (0.18,0.23)*** 22.14 0.17 (0.15,0.2)*** 18.53 0.17 (0.15,0.2)*** 18.53 0.18 (0.15,0.2)*** 19.72
  25-34 0.27 (0.25,0.3)*** 31.00 0.2 (0.18,0.23)*** 22.14 0.17 (0.15,0.2)*** 18.53 0.14 (0.12,0.17)*** 15.03 0.14 (0.12,0.17)*** 15.03 0.14 (0.12,0.17)*** 15.03
  35-44 0.13 (0.11,0.16)*** 13.88 0.11 (0.09,0.14)*** 11.63 0.09 (0.07,0.12)*** 9.42 0.09 (0.07,0.11)*** 9.42 0.09 (0.07,0.11)*** 9.42 0.09 (0.07,0.11)*** 9.42
  >44 (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.05 (-0.07,-0.03)*** -4.88 -0.06 (-0.09,-0.04)*** -5.82 -0.31 (-0.33,-0.29)*** -26.66 -0.31 (-0.33,-0.28)*** -26.66 -0.29 (-0.32,-0.27)*** -25.17
  Detox -1.39 (-1.42,-1.36)*** -75.09 -1.4 (-1.43,-1.38)*** -75.34 -1.93 (-1.96,-1.91)*** -85.49 -1.93 (-1.95,-1.9)*** -85.49 -1.9 (-1.92,-1.87)*** -85.04
  Rehab (ref) ref ref ref ref ref ref ref ref ref ref
Enrolled in MAT 0.05 (0.01,0.09)* 5.13 0.04 (-0.01,0.08) 4.08 -0.08 (-0.12,-0.04)** -7.69 -0.08 (-0.12,-0.04)*** -7.69 -0.1 (-0.14,-0.05)*** -9.52
Psych problems 0.03 (0.01,0.05)* 3.05 0.05 (0.03,0.07)*** 5.13 0.12 (0.1,0.14)*** 12.75 0.13 (0.11,0.15)*** 13.88 0.13 (0.11,0.15)*** 13.88
Drug Use
  Heroin -0.48 (-0.57,-0.38)*** -38.12 -0.43 (-0.52,-0.34)*** -34.95 -0.24 (-0.33,-0.15)*** -21.34 -0.24 (-0.33,-0.15)*** -21.34 -0.23 (-0.32,-0.14)*** -20.55
  Non-rx Methadone -0.46 (-0.57,-0.36)*** -36.87 -0.45 (-0.56,-0.35)*** -36.24 -0.38 (-0.48,-0.27)*** -31.61 -0.38 (-0.48,-0.28)*** -31.61 -0.38 (-0.48,-0.27)*** -31.61
  Cocaine -0.01 (-0.03,0.01) -1.00 -0.02 (-0.04,0) -1.98 -0.1 (-0.12,-0.07)*** -9.52 -0.1 (-0.12,-0.08)*** -9.52 -0.1 (-0.12,-0.08)*** -9.52
  Synthetic Opioids -0.52 (-0.61,-0.43)*** -40.55 -0.47 (-0.56,-0.38)*** -37.50 -0.42 (-0.5,-0.33)*** -34.30 -0.42 (-0.51,-0.33)*** -34.30 -0.41 (-0.5,-0.32)*** -33.63
  Benzodiazepines 0.09 (0.04,0.15)** 9.42 0.13 (0.07,0.18)*** 13.88 -0.09 (-0.15,-0.04)** -8.61 -0.1 (-0.15,-0.04)*** -9.52 -0.12 (-0.17,-0.06)*** -11.31
  Any Opioids 0.54 (0.44,0.63)*** 71.60 0.5 (0.4,0.59)*** 64.87 0.25 (0.16,0.34)*** 28.40 0.26 (0.16,0.35)*** 29.69 0.24 (0.14,0.33)*** 27.12
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.29 (-0.32,-0.27)*** -25.17 -0.28 (-0.31,-0.26)*** -24.42 -0.35 (-0.37,-0.32)*** -29.53 -0.35 (-0.37,-0.32)*** -29.53 -0.35 (-0.38,-0.33)*** -29.53
2 -0.01 (-0.03,0.01) -1.00 -0.01 (-0.03,0.02) -1.00 -0.05 (-0.07,-0.02)*** -4.88 -0.05 (-0.07,-0.02)*** -4.88 -0.05 (-0.07,-0.03)*** -4.88
3 (ref) ref ref ref ref ref ref ref ref ref ref
IDU 0.06 (0.03,0.09)*** 6.18 0.05 (0.02,0.07)* 5.13 0.11 (0.08,0.14)*** 11.63 0.11 (0.08,0.14)*** 11.63 0.11 (0.08,0.14)*** 11.63
Health Insurance Type
  Medicaid 0.58 (0.54,0.61)*** 78.60 0.32 (0.28,0.35)*** 37.71 0.31 (0.28,0.35)*** 36.34 0.3 (0.27,0.33)*** 34.99
  Medicare 0.47 (0.43,0.52)*** 60.00 0.57 (0.53,0.61)*** 76.83 0.57 (0.53,0.61)*** 76.83 0.58 (0.54,0.62)*** 78.60
  No insurance 0.43 (0.41,0.46)*** 53.73 0.36 (0.34,0.39)*** 43.33 0.36 (0.34,0.39)*** 43.33 0.35 (0.32,0.37)*** 41.91
  Private Insurance (ref) ref ref ref ref ref ref ref ref
Primary Income
  Public Asstistance -0.28 (-0.32,-0.24)*** -24.42 -0.38 (-0.42,-0.34)*** -31.61 -0.38 (-0.42,-0.34)*** -31.61 -0.38 (-0.42,-0.34)*** -31.61
  Retirement/Pension -0.17 (-0.21,-0.14)*** -15.63 -0.31 (-0.35,-0.27)*** -26.66 -0.3 (-0.34,-0.27)*** -25.92 -0.28 (-0.32,-0.25)*** -24.42
  Other Income Source -0.26 (-0.29,-0.22)*** -22.89 -0.26 (-0.29,-0.23)*** -22.89 -0.26 (-0.29,-0.22)*** -22.89 -0.23 (-0.26,-0.2)*** -20.55
  No Income -0.14 (-0.17,-0.12)*** -13.06 -0.36 (-0.39,-0.34)*** -30.23 -0.35 (-0.38,-0.33)*** -29.53 -0.34 (-0.37,-0.32)*** -28.82
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)*** 0.01 -0.0001 (-0.0001,-0.0001)*** 0.01 -0.0001 (-0.0001,-0.0001)*** 0.01
  Bupe Prog Rate 0.06 (0.05,0.06)*** 6.18 0.06 (0.06,0.06)*** 6.18 0.06 (0.06,0.06)*** 6.18
  Rate of Indiv in Tx 0.01 (0.01,0.01)*** 1.01 0.01 (0.01,0.01)*** 1.01 0.004 (0.002,0.005)*** 0.50
  % of res w/Medicaid 0.1 (0.1,0.1)*** 10.52 0.11 (0.1,0.11)*** 11.63 0.1 (0.1,0.11)*** 10.52
  SABG 0.01 (0.01,0.01)*** 1.01 0.01 (0.01,0.01)*** 1.01 0.01 (0.01,0.01)*** 1.01
Time -0.06 (-0.08,-0.04)*** -5.82 0.22 (0.19,0.25)*** 24.61
Medicaid Cov * Time -0.45 (-0.49,-0.41)*** -36.24
Table 2B.6: Model Building Summary Using Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, Combined 2006-2008, N=561,413
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
*=p<0.05
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 6: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level variables and time





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 0.11 (0.03,0.20)* 11.63 0.11 (0.03,0.2)* 11.63 -0.17 (-0.26,-0.07)** -15.63 -0.17 (-0.26,-0.08)** -15.63 1.82 (1.59,2.04)*** 517.19
Male -0.06 (-0.14,0.02) -5.82 -0.01 (-0.09,0.07) -1.00 -0.01 (-0.09,0.07) -1.00 -0.03 (-0.11,0.05) -2.96
Race
  Black -0.06 (-0.15,0.04) -5.82 -0.09 (-0.19,0.01) -8.61 -0.1 (-0.19,-0.001)* -9.52 -0.24 (-0.33,-0.14)*** -21.34
  Other Race -0.64 (-0.78,-0.51)* -47.27 0.17 (0.03,0.3)* 18.53 0.11 (-0.03,0.24) 11.63 0.13 (-0.002,0.26)* 13.88
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.22 (0.09,0.36)*** 24.61 -0.74 (-0.87,-0.61)*** -52.29 -0.77 (-0.9,-0.64)*** -53.70 -0.49 (-0.61,-0.36)*** -38.74
HS Education -0.15 (-0.24,-0.07)* -13.93 -0.14 (-0.22,-0.05)* -13.06 -0.12 (-0.21,-0.04)* -11.31 -0.08 (-0.16,-0.0003)* -7.69
Married 0.02 (-0.07,0.12) 2.02 -0.04 (-0.13,0.05) -3.92 -0.03 (-0.12,0.06) -2.96 0.01 (-0.08,0.1) 1.01
Employed -0.06 (-0.14,0.03) -5.82 -0.21 (-0.3,-0.12)*** -18.94 -0.38 (-0.5,-0.27)*** -31.61 -0.43 (-0.54,-0.31)*** -34.95
Unstably Housed 0.07 (-0.01,0.15) 7.25 0.11 (0.03,0.19)* 11.63 0.09 (0.01,0.17)* 9.42 -0.1 (-0.18,-0.02)* -9.52
Age
  <18 0.04 (-0.12,0.21) 4.08 -0.27 (-0.44,-0.1)* -23.66 -0.27 (-0.45,-0.09)* -23.66 -0.05 (-0.23,0.12) -4.88
  18-24 0.19 (0.07,0.3)* 20.92 0.09 (-0.03,0.21) 9.42 0.07 (-0.06,0.19) 7.25 0.07 (-0.05,0.19) 7.25
  25-34 0.19 (0.08,0.29)** 20.92 0.15 (0.04,0.26)* 16.18 0.12 (0.01,0.23)* 12.75 0.12 (0.02,0.23)* 12.75
  35-44 0.11 (0.01,0.22)* 11.63 0.06 (-0.05,0.16)*** 6.18 0.03 (-0.08,0.14) 3.05 0.05 (-0.05,0.16) 5.13
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient 0.22 (0.12,0.33)*** 24.61 0.22 (0.12,0.33)*** 24.61 -0.08 (-0.18,0.02) -7.69
  Detox -1.23 (-1.35,-1.11)*** -70.77 -1.23 (-1.35,-1.12) -70.77 -1.63 (-1.75,-1.51)*** -80.41
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.18 (-0.37,0.02) -16.47 -0.18 (-0.37,0.01) -16.47 -0.15 (-0.34,0.04) -13.93
Psych Problems 0.06 (-0.03,0.15) 6.18 0.09 (0,0.18)* 9.42 0.22 (0.13,0.31)*** 24.61
Drug Use
  Heroin -0.21 (-0.64,0.22) -18.94 -0.25 (-0.67,0.18) -22.12 -0.57 (-0.98,-0.16)* -43.45
  Non-rx Methadone -0.93 (-1.41,-0.44)** -60.54 -0.86 (-1.34,-0.37)** -57.68 -0.88 (-1.35,-0.41)** -58.52
  Cocaine -0.02 (-0.12,0.08) -1.98 -0.01 (-0.11,0.09) -1.00 -0.13 (-0.23,-0.04)* -12.19
  Synthetic Opioids -0.62 (-1.03,-0.2)* -46.21 -0.66 (-1.07,-0.25)* -48.31 -0.77 (-1.17,-0.37)** -53.70
  Benzodiazepines -0.14 (-0.38,0.1) -13.06 -0.09 (-0.33,0.15) -8.61 -0.31 (-0.54,-0.08)* -26.66
  Any Opioids 0.6 (0.17,1.04)* 82.21 0.66 (0.23,1.1)* 93.48 0.68 (0.26,1.1)* 97.39
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.36 (-0.47,-0.24)*** -30.23 -0.34 (-0.46,-0.23)*** -28.82 -0.52 (-0.63,-0.41)*** -40.55
2 -0.05 (-0.16,0.05) -4.88 -0.06 (-0.16,0.05) -5.82 -0.19 (-0.3,-0.09)** -17.30
3 (ref) ref ref ref ref ref ref
IDU -0.08 (-0.22,0.06) -7.69 -0.1 (-0.24,0.04) -9.52 0.002 (-0.13,0.13) 0.00
Health Insurance Type
  Medicaid 0.48 (0.34,0.63)*** 61.61 0.21 (0.06,0.36)* 23.37
  Medicare 0.61 (0.42,0.79)*** 84.04 0.76 (0.58,0.94)*** 113.83
  No Insurance 0.4 (0.28,0.52)*** 49.18 0.36 (0.24,0.48)*** 43.33
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.35 (-0.54,-0.17)** -29.53 -0.56 (-0.75,-0.38)*** -42.88
  Retirement/Pension -0.42 (-0.59,-0.24)*** -34.30 -0.58 (-0.75,-0.41)*** -44.01
  Other Income Source -0.49 (-0.64,-0.34)*** -38.74 -0.57 (-0.72,-0.42)*** -43.45
  No Income -0.28 (-0.4,-0.16)*** -24.42 -0.38 (-0.5,-0.27)*** -31.61
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0002 (-0.0002,-0.0002)*** -0.02
  Bupe Prog Rate 0.16 (0.14,0.19)*** 17.35
  Rate of Indiv in Tx -0.02 (-0.03,-0.02)*** -1.98
  % of res w/Medicaid 0.17 (0.16,0.19)*** 18.53
   SABG 0.01 (0.01,0.01)*** 1.01
**=p<0.001
*=p<0.05
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
***=p<0.0001
Table 2B.7: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2008, N=25,700
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 1 Model 2 Model 3 Model 4 Model 5
Model 1 Model 2 Model 3 Model 4 Model 5
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 0.03 (0.003,0.05)* 3.04 0.04 (0.02,0.07)** 4.08 -0.13 (-0.15,-0.1)*** -12.19 -0.14 (-0.16,-0.11)*** -13.06 1.6 (1.54,1.66)*** 395.30
Male -0.06 (-0.09,-0.04)*** -5.82 -0.06 (-0.08,-0.04)*** -5.82 -0.06 (-0.08,-0.03)*** -5.82 -0.06 (-0.09,-0.04)*** -5.82
Race
  Black 0.001 (-0.03,0.03) 0.10 0.01 (-0.02,0.04) 1.01 -0.002 (-0.03,0.03) -0.2 -0.15 (-0.18,-0.12)*** -13.93
  Other Race -0.58 (-0.62,-0.54)*** -44.01 0.2 (0.16,0.24)*** 22.14 0.18 (0.14,0.22)*** 19.72 0.21 (0.17,0.24)*** 23.37
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.16 (0.13,0.2)*** 17.35 -0.65 (-0.69,-0.61)*** -47.80 -0.66 (-0.7,-0.62)*** -48.31 -0.42 (-0.46,-0.39)*** -34.30
HS Education -0.12 (-0.14,-0.09)*** -11.31 -0.1 (-0.12,-0.08)*** -9.52 -0.08 (-0.11,-0.06)*** -7.69 -0.06 (-0.08,-0.04)*** -5.82
Married 0.01 (-0.02,0.04) 1.01 -0.01 (-0.04,0.01) -1.00 0.01 (-0.02,0.03) 1.01 0.002(-0.02,0.03) 0.00
Employed 0.01 (-0.01,0.04) 1.01 -0.1 (-0.12,-0.07)*** -9.52 -0.22 (-0.25,-0.18)*** -19.75 -0.27 (-0.31,-0.24)*** -23.66
Unstably Housed 0.07 (0.05,0.1)*** 7.25 0.12 (0.09,0.14)*** 12.75 0.12 (0.09,0.14)*** 12.75 -0.04 (-0.06,-0.02)* -3.92
Age
  <18 0.24 (0.19,0.29)*** 27.12 -0.01 (-0.06,0.04) -1.00 -0.01 (-0.06,0.04) -1.00 0.02 (-0.03,0.07) 2.02
  18-24 0.32 (0.28,0.35)*** 37.71 0.2 (0.16,0.23)*** 22.14 0.19 (0.16,0.23)*** 20.92 0.14 (0.11,0.17)*** 15.03
  25-34 0.26 (0.23,0.29)*** 29.69 0.18 (0.15,0.21)*** 19.72 0.16 (0.13,0.19)*** 17.35 0.14 (0.11,0.17)*** 15.03
  35-44 0.15 (0.12,0.18)*** 16.18 0.11 (0.08,0.14)*** 11.63 0.1 (0.07,0.13)*** 10.52 0.08 (0.05,0.11)*** 8.33
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient 0.1 (0.07,0.12)*** 10.52 0.09 (0.06,0.12)*** 9.42 -0.19 (-0.22,-0.16)*** -17.30
  Detox -1.27 (-1.31,-1.24)*** -71.92 -1.27 (-1.3,-1.24)*** -71.92 -1.64 (-1.67,-1.6)*** -80.60
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.29 (-0.35,-0.24)*** -25.17 -0.29 (-0.35,-0.24)*** -25.17 -0.23 (-0.28,-0.18)*** -20.55
Psych Problems 0.07 (0.05,0.1)*** 7.25 0.1 (0.07,0.12)*** 10.52 0.21 (0.18,0.23)*** 23.37
Drug Use
  Heroin -0.18 (-0.3,-0.06)* -16.47 -0.12 (-0.24,0)* -11.31 -0.28 (-0.4,-0.17)*** -24.42
  Non-rx Methadone -0.35 (-0.49,-0.21)*** -29.53 -0.34 (-0.47,-0.2)*** -28.82 -0.48 (-0.61,-0.35)*** -38.12
  Cocaine 0.07 (0.05,0.1)*** 7.25 0.07 (0.04,0.1)*** 7.25 -0.08 (-0.11,-0.05)*** -7.69
  Synthetic Opioids -0.51 (-0.63,-0.4)*** -39.95 -0.46 (-0.58,-0.35)*** -36.87 -0.5 (-0.61,-0.39)*** -39.35
  Benzodiazepines 0.04 (-0.03,0.11) 4.08 0.05 (-0.02,0.12) 5.13 -0.19 (-0.26,-0.13)*** -17.30
  Any Opioids 0.55 (0.43,0.67)*** 73.33 0.5 (0.38,0.62)*** 64.87 0.37 (0.25,0.49)*** 44.77
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
0 -1.57 (-5.67,2.54) -79.20 -1.53 (-5.63,2.56) -78.35 -2.22 (-6.2,1.76) -89.14
1 -0.2 (-0.23,-0.17)*** -18.13 -0.19 (-0.22,-0.16)*** -17.30 -0.39 (-0.42,-0.35)*** -32.29
2 0.03 (0.001,0.06)* 3.05 0.03 (0.004,0.07)*** 3.05 -0.07 (-0.1,-0.04)*** -6.76
3 (ref) ref ref ref ref ref ref
IDU -0.02 (-0.06,0.02) -1.98 -0.03 (-0.07,0.01) -2.96 0.13 (0.09,0.17)*** 13.88
Health Insurance Type
  Medicaid 0.48 (0.43,0.52)*** 61.61 0.25 (0.2,0.29)*** 28.40
  Medicare 0.34 (0.29,0.39)*** 40.49 0.49 (0.44,0.54)*** 63.23
  No Insurance 0.39 (0.35,0.42)*** 47.70 0.39 (0.36,0.42)*** 47.70
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.31 (-0.36,-0.25)*** -26.66 -0.46 (-0.51,-0.4)*** -36.87
  Retirement/Pension -0.2 (-0.25,-0.15)*** -18.13 -0.33 (-0.38,-0.28)*** -28.11
  Other Income Source -0.33 (-0.37,-0.29)*** -28.11 -0.41 (-0.45,-0.36)*** -33.63
  No Income -0.24 (-0.27,-0.2)*** -21.34 -0.38 (-0.42,-0.35)*** -31.61
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0002 (-0.0002,-0.0002)*** -0.2
  Bupe Prog Rate 0.15 (0.14,0.16)*** 16.18
  Rate of Indiv in Tx -0.02 (-0.02,-0.02)*** -1.98
  % of res w/Medicaid 0.16 (0.15,0.16)*** 17.35
   SABG 0.01 (0.01,0.01)*** 1.01
Table 2B.8: Model Building Summary Using Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2008, N=320,656
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates




Model 1 Model 2 Model 3 Model 4 Model 5
Model 1 Model 2 Model 3 Model 4 Model 5
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Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 0.44 (0.43,0.45)*** 54.94 0.48 (0.47,0.49)*** 61.61 0.36 (0.35,0.37)*** 43.33 0.45 (0.44,0.46)*** 56.83 0.35 (0.34,0.36)*** 41.91
Male -0.01 (-0.02,-0.01)** -1.00 0.08 (0.07,0.08)*** 8.33 0.002 (-0.004,0.01) 0.20 0.01 (0.01,0.02)*** 1.01
Race
  Black -0.11 (-0.11,-0.1)*** -10.42 -0.07 (-0.08,-0.06)*** -6.76 -0.11 (-0.12,-0.11)*** -10.42 -0.14 (-0.15,-0.13)*** -13.06
  Other Race -0.3 (-0.31,-0.29)*** -25.92 -0.27 (-0.28,-0.27)*** -23.66 -0.23 (-0.24,-0.23)*** -20.55 -0.12 (-0.13,-0.12)*** -11.31
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.4 (-0.4,-0.39)*** -32.97 -0.26 (-0.27,-0.25)*** -22.89 -0.26 (-0.27,-0.26)*** -22.89 -0.17 (-0.18,-0.17)*** -15.63
HS Education -0.05 (-0.06,-0.04)*** -4.88 -0.04 (-0.05,-0.04)*** -3.92 -0.01 (-0.02,-0.01)*** -1.00 -0.01 (-0.02,-0.003)* -1.00
Married 0.05 (0.04,0.05)*** 5.13 0.01 (0.001,0.02)* 1.01 0.07 (0.06,0.07)*** 7.25 0.07 (0.07,0.08)*** 7.25
Employed -0.002 (-0.01,0.005) -0.20 0.02 (0.02,0.03)*** 2.02 0.01 (0.003,0.02)* 1.01 0.03 (0.02,0.04)*** 3.05
Unstably Housed -0.15 (-0.15,-0.14)*** -13.93 -0.13 (-0.13,-0.12)*** -12.19 -0.13 (-0.14,-0.12)*** -12.19 -0.04 (-0.04,-0.03)*** -3.92
Age
  <18 0.69 (0.67,0.7)*** 99.37 0.27 (0.26,0.28)*** 31.00 0.47 (0.46,0.49)*** 60.00 0.33 (0.31,0.34)*** 39.10
  18-24 0.3 (0.29,0.3)*** 34.99 0.2 (0.19,0.21)*** 22.14 0.21 (0.2,0.22)*** 23.37 0.15 (0.14,0.16)*** 16.18
  25-34 0.21 (0.2,0.22)*** 23.37 0.14 (0.13,0.15)*** 15.03 0.12 (0.11,0.13)*** 12.75 0.07 (0.07,0.08)*** 7.25
  35-44 0.09 (0.09,0.1)*** 9.42 0.05 (0.04,0.05)*** 5.13 0.04 (0.03,0.05)*** 4.08 0.02 (0.01,0.03)*** 2.02
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.2 (-0.21,-0.2)*** -18.13 -0.27 (-0.28,-0.26)*** -23.66 -0.34 (-0.35,-0.34)*** -28.82
  Detox -0.67 (-0.67,-0.66)*** -48.83 -0.75 (-0.76,-0.74)*** -52.76 -0.88 (-0.89,-0.87)*** -58.52
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.54 (-0.55,-0.53)*** -41.73 -0.54 (-0.55,-0.53)*** -41.73 -0.47 (-0.48,-0.46)*** -37.50
Psych Problems 0.83 (0.82,0.83)*** 129.33 0.65 (0.65,0.66)*** 91.55 0.62 (0.61,0.63)*** 85.89
Drug Use
  Heroin 0.03 (0.005,0.06)* 3.05 -0.002 (-0.03,0.03) -0.20 -0.04 (-0.06,-0.01)* -3.92
  Non-rx Methadone 0 (-0.03,0.04) 0.00 -0.03 (-0.06,0.003) -2.96 -0.02 (-0.05,0.02) -1.98
  Cocaine 0.04 (0.03,0.05)*** 4.08 -0.001 (-0.01,0.01) -0.10 -0.04 (-0.04,-0.03)*** -3.92
  Synthetic Opioids -0.05 (-0.07,-0.02)** -4.88 -0.04 (-0.06,-0.01)* -3.92 -0.04 (-0.07,-0.02)** -3.92
  Benzodiazepines 0.02 (-0.001,0.04) 2.02 0.03 (0.01,0.05)* 3.05 0.01 (-0.01,0.03) 1.01
  Any Opioids 0.05 (0.02,0.07)* 5.13 0.05 (0.02,0.08)** 5.13 0.05 (0.02,0.07)** 5.13
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.04 (-0.05,-0.03)*** -3.92 -0.03 (-0.04,-0.02)*** -2.96 -0.01 (-0.02,-0.001)* -1.00
2 -0.11 (-0.12,-0.1)*** -10.42 -0.06 (-0.07,-0.05)*** -5.82 -0.02 (-0.03,-0.01)** -1.98
3 (ref) ref ref ref ref ref ref
IDU -0.18 (-0.19,-0.17)*** -16.47 -0.17 (-0.18,-0.16)*** -15.63 -0.13 (-0.14,-0.12)*** -12.19
Health Insurance Type
  Medicaid 0.44 (0.43,0.45)*** 55.27 0.58 (0.57,0.6)*** 78.60
  Medicare 0.87 (0.86,0.89)*** 138.69 0.73 (0.71,0.74)*** 107.51
  No Insurance 0.92 (0.91,0.93)*** 150.93 0.91 (0.91,0.92)*** 148.43
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.06 (-0.07,-0.04)*** -5.82 -0.06 (-0.07,-0.04)*** -5.82
  Retirement/Pension 0.09 (0.07,0.1)*** 9.42 0.01 (-0.01,0.02) 1.01
  Other Income Source -0.13 (-0.14,-0.12)*** -12.19 -0.18 (-0.2,-0.17)*** -16.47
  No Income -0.18 (-0.19,-0.17)*** -16.47 -0.13 (-0.14,-0.12)*** -12.19
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)*** -0.01
  Bupe Prog Rate -0.08 (-0.08,-0.08)*** -7.69
  Rate of Indiv in Tx 0.04 (0.03,0.04)*** 4.08
  % of res w/Medicaid -0.06 (-0.06,-0.06)*** -5.82
   SABG 0.002 (0.002,0.002)*** 0.20
*=p<0.05
Table 2B.9: Model Building Summary Using Multiple Imputation Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2008, N=4,698,055
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 1.13 (1.05,1.21)*** 209.57 1.2 (1.12,1.28)*** 232.01 1.13 (1.04,1.21)*** 209.57 1.14 (1.05,1.23)*** 212.68 2.23 (2.09,2.36)*** 829.99
Male -0.1 (-0.19,-0.01)* -9.52 -0.08 (-0.16,0.01) -7.69 -0.06 (-0.15,0.02) -5.82 -0.07 (-0.15,0.02) -6.76
Race
  Black -0.28 (-0.38,-0.18)*** -24.42 -0.2 (-0.31,-0.09)** -18.13 -0.23 (-0.34,-0.12)*** -20.55 -0.35 (-0.45,-0.24)*** -29.53
  Other Race -0.72 (-0.86,-0.57)* -51.32 0.12 (-0.04,0.28) 12.75 0.12 (-0.03,0.28) 12.75 -0.24 (-0.39,-0.09)* -21.34
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.18 (0.02,0.34)*** 19.72 -0.72 (-0.87,-0.58)*** -51.32 -0.75 (-0.9,-0.61)*** -52.76 -0.13 (-0.27,0.01) -12.19
HS Education -0.03 (-0.12,0.06) -2.96 -0.03 (-0.12,0.06) -2.96 -0.01 (-0.09,0.08) -1.00 0.02 (-0.07,0.11) 2.02
Married 0.21 (0.11,0.31)*** 23.37 0.15 (0.06,0.25)* 16.18 0.2 (0.1,0.3)*** 22.14 0.15 (0.06,0.25)* 16.18
Employed -0.07 (-0.15,0.02) -6.76 -0.16 (-0.25,-0.07)** -14.79 -0.17 (-0.3,-0.04)* -15.63 -0.22 (-0.34,-0.09)** -19.75
Unstably Housed -0.05 (-0.13,0.04) -4.88 -0.03 (-0.11,0.06) -2.96 -0.03 (-0.12,0.05) -2.96 0.004 (-0.08,0.09) 0.36
Age
  <18 0.51 (0.33,0.69)*** 66.53 0.16 (-0.03,0.34) 17.35 0.17 (-0.04,0.37) 18.53 -0.05 (-0.25,0.14) -4.88
  18-24 0.38 (0.25,0.52)*** 46.23 0.21 (0.07,0.34)* 23.37 0.21 (0.07,0.34)* 23.37 0.11 (-0.02,0.25) 11.63
  25-34 0.23 (0.11,0.35)** 25.86 0.12 (0,0.24)* 12.75 0.08 (-0.04,0.21) 8.33 0.09 (-0.03,0.21) 9.42
  35-44 0.18 (0.07,0.3)* 19.72 0.19 (0.08,0.31)** 20.92 0.16 (0.05,0.28)* 17.35 0.17 (0.06,0.29)* 18.53
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.23 (-0.34,-0.12)*** -20.55 -0.22 (-0.34,-0.11)*** -19.75 -0.65 (-0.77,-0.53)*** -47.80
  Detox -1.52 (-1.64,-1.39)*** -78.13 -1.53 (-1.65,-1.4)*** -78.35 -2.38 (-2.52,-2.25)*** -90.74
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT 0.76 (0.54,0.97)*** 113.83 0.7 (0.49,0.92)*** 101.38 0.42 (0.21,0.63)** 52.20
Psych Problems 0.11 (0.01,0.21)* 11.63 0.11 (0.01,0.21)* 11.63 0.09 (-0.01,0.18) 9.42
Drug Use
  Heroin -1.54 (-2.02,-1.05)*** -78.56 -1.35 (-1.84,-0.87)*** -74.08 -0.77 (-1.24,-0.31)* -53.70
  Non-rx Methadone -0.02 (-0.51,0.48) -1.98 -0.03 (-0.53,0.46) -2.96 0.37 (-0.11,0.86) 44.77
  Cocaine -0.22 (-0.32,-0.12)*** -19.75 -0.2 (-0.3,-0.1)*** -18.13 -0.23 (-0.33,-0.13)*** -20.55
  Synthetic Opioids -1.04 (-1.5,-0.57)*** -64.65 -0.88 (-1.35,-0.41)** -58.52 -0.77 (-1.22,-0.32)** -53.70
  Benzodiazepines 0.1 (-0.18,0.38) 10.52 0.21 (-0.07,0.49) 23.37 0.25 (-0.02,0.53) 28.40
  Any Opioids 0.85 (0.36,1.35)** 133.96 0.69 (0.2,1.19)* 99.37 0.39 (-0.09,0.87) 47.70
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.56 (-0.68,-0.43)*** -42.88 -0.53 (-0.65,-0.41)*** -41.14 -0.42 (-0.54,-0.29)*** -34.30
2 -0.17 (-0.29,-0.05)* -15.63 -0.14 (-0.26,-0.02)* -13.06 -0.12 (-0.24,-0.01)* -11.31
3 (ref) ref ref ref ref ref ref
IDU 0.23 (0.08,0.37)* 25.86 0.19 (0.04,0.34)* 20.92 0.12 (-0.03,0.26) 12.75
Health Insurance Type
  Medicaid 0.54 (0.38,0.7)*** 71.60 0.15 (-0.01,0.3) 16.18
  Medicare 0.64 (0.43,0.86)*** 89.65 0.59 (0.38,0.8)*** 80.40
  No Insurance 0.43 (0.31,0.55)*** 53.73 0.27 (0.15,0.39)*** 31.00
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.2 (-0.4,0)* -18.13 -0.24 (-0.43,-0.05)* -21.34
  Retirement/Pension -0.14 (-0.33,0.05) -13.06 -0.26 (-0.44,-0.09)* -22.89
  Other Income Source -0.23 (-0.39,-0.07)* -20.55 -0.09 (-0.25,0.07) -8.61
  No Income -0.03 (-0.16,0.11) -2.96 -0.33 (-0.46,-0.2)*** -28.11
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0002 (-0.0002,-0.0002)*** -0.02
  Bupe Prog Rate -0.1 (-0.12,-0.07)*** -9.52
  Rate of Indiv in Tx 0.03 (0.03,0.04)*** 3.05
  % of res w/Medicaid 0.04 (0.03,0.06)*** 4.08
   SABG 0.0009 (-0.001,0.003) 0.09
*=p<0.05
Table 2B.10: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2006, N=24,100
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 1.14 (1.11,1.17)*** 212.68 1.19 (1.17,1.22)*** 228.71 1.08 (1.05,1.11)*** 194.47 1.09 (1.07,1.12)*** 197.43 2.2 (2.16,2.24)*** 802.50
Male -0.1 (-0.13,-0.07)*** -9.52 -0.09 (-0.12,-0.06)*** -8.61 -0.08 (-0.11,-0.05)*** -7.69 -0.07 (-0.1,-0.05)*** -6.76
Race
  Black -0.22 (-0.25,-0.19)*** -19.75 -0.17 (-0.2,-0.13)*** -15.63 -0.18 (-0.22,-0.15) -16.47 -0.26 (-0.3,-0.23)*** -22.89
  Other Race -0.63 (-0.67,-0.59)* -46.74 0.002 (-0.05,0.05) 0.00 -0.03 (-0.08,0.02)*** -2.96 -0.34 (-0.38,-0.29)*** -28.82
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.05 (0,0.1)*** 5.13 -0.7 (-0.74,-0.65)*** -50.34 -0.7 (-0.75,-0.66)*** -50.34 -0.16 (-0.21,-0.12)*** -14.79
HS Education -0.03 (-0.06,0)* -2.96 -0.04 (-0.07,-0.01)* -3.92 -0.01 (-0.04,0.02) -1.00 0.05 (0.02,0.08)** 5.13
Married 0.08 (0.05,0.11)*** 8.33 0.07 (0.04,0.1)*** 7.25 0.1 (0.07,0.13)*** 10.52 0.08 (0.05,0.11)*** 8.33
Employed -0.02 (-0.05,0.01) -1.98 -0.13 (-0.16,-0.1)*** -12.19 -0.11 (-0.16,-0.07)*** -10.42 -0.11 (-0.15,-0.07)*** -10.42
Unstably Housed -0.05 (-0.08,-0.03)** -4.88 -0.03 (-0.06,-0.01)*** -2.96 -0.05 (-0.08,-0.02)** -4.88 0.01 (-0.01,0.04) 1.01
Age
  <18 0.54 (0.48,0.6)*** 71.60 0.25 (0.19,0.31)*** 28.40 0.28 (0.22,0.34)*** 32.31 0.1 (0.04,0.16)* 10.52
  18-24 0.4 (0.36,0.44)*** 49.18 0.25 (0.21,0.29)*** 28.40 0.24 (0.2,0.28)*** 27.12 0.21 (0.17,0.25)*** 23.37
  25-34 0.32 (0.28,0.36)*** 37.71 0.23 (0.2,0.27)*** 25.86 0.2 (0.16,0.24)*** 22.14 0.16 (0.12,0.19)*** 17.35
  35-44 0.13 (0.1,0.17)*** 13.88 0.12 (0.09,0.16)*** 12.75 0.1 (0.06,0.13)*** 10.52 0.11 (0.08,0.15)*** 11.63
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.17 (-0.2,-0.13)*** -15.63 -0.17 (-0.21,-0.14)*** -15.63 -0.59 (-0.63,-0.55)*** -44.57
  Detox -1.51 (-1.55,-1.47)*** -77.91 -1.52 (-1.56,-1.48)*** -78.13 -2.34 (-2.38,-2.3)*** -90.37
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT 0.52 (0.46,0.59)*** 68.20 0.5 (0.43,0.56)*** 64.87 0.32 (0.26,0.39)*** 37.71
Psych Problems 0.04 (0.01,0.07)* 4.08 0.05 (0.02,0.08)* 5.13 0.1 (0.07,0.14)*** 10.52
Drug Use
  Heroin -0.96 (-1.11,-0.81)*** -61.71 -0.94 (-1.09,-0.79)*** -60.94 -0.41 (-0.56,-0.27)*** -33.63
  Non-rx Methadone -0.6 (-0.77,-0.44)*** -45.12 -0.6 (-0.77,-0.43)*** -45.12 -0.25 (-0.41,-0.09)* -22.12
  Cocaine -0.14 (-0.17,-0.11)*** -13.06 -0.15 (-0.18,-0.12)*** -13.93 -0.12 (-0.15,-0.08)*** -11.31
  Synthetic Opioids -0.46 (-0.6,-0.31)*** -36.87 -0.44 (-0.58,-0.29)*** -35.60 -0.23 (-0.37,-0.1)** -20.55
  Benzodiazepines 0.06 (-0.03,0.16) 6.18 0.14 (0.04,0.23)** 15.03 -0.003 (-0.09,0.09) -0.30
  Any Opioids 0.42 (0.27,0.57)*** 52.20 0.41 (0.26,0.56)*** 50.68 0.05 (-0.1,0.19) 5.13
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.43 (-0.47,-0.39)*** -34.95 -0.42 (-0.46,-0.38)*** -34.30 -0.3 (-0.34,-0.26)*** -25.92
2 -0.09 (-0.13,-0.05)*** -8.61 -0.09 (-0.13,-0.05)*** -8.61 -0.04 (-0.08,-0.01)* -3.92
3 (ref) ref ref ref ref ref ref
IDU 0.21 (0.16,0.25)*** 23.37 0.19 (0.14,0.24)*** 20.92 0.18 (0.13,0.23)*** 19.72
Health Insurance Type
  Medicaid 0.66 (0.61,0.71)*** 93.48 0.28 (0.23,0.33)*** 32.31
  Medicare 0.76 (0.7,0.83)*** 113.83 0.66 (0.59,0.73)*** 93.48
  No Insurance 0.52 (0.48,0.56)*** 68.20 0.26 (0.22,0.3)*** 29.69
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.23 (-0.29,-0.17)*** -20.55 -0.22 (-0.28,-0.16)*** -19.75
  Retirement/Pension -0.13 (-0.19,-0.07)*** -12.19 -0.2 (-0.26,-0.15)*** -18.13
  Other Income Source -0.13 (-0.19,-0.08)*** -12.19 -0.05 (-0.1,0)* -4.88
  No Income -0.05 (-0.09,-0.01)* -4.88 -0.26 (-0.3,-0.22)*** -22.89
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0002 (-0.0002,-0.0001)*** -0.20
  Bupe Prog Rate -0.11 (-0.12,-0.1)*** -10.42
  Rate of Indiv in Tx 0.03 (0.03,0.03)*** 3.05
  % of res w/Medicaid 0.04 (0.04,0.05)*** 4.08
   SABG -0.002 (-0.002,-0.001)*** -0.02
*=p<0.05
Table 2B.11: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2006, N=240,757
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 5: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level variables
Model 1 Model 2 Model 3 Model 4 Model 5





Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Bupe Covered 0.68 (0.67,0.68)*** 97.39 0.7 (0.69,0.7)*** 101.38 0.56 (0.56,0.57)*** 75.07 0.58 (0.57,0.59)*** 78.60 0.97 (0.96,0.98)*** 163.79
Male 0.02 (0.02,0.03)*** 2.02 0.08 (0.07,0.08)*** 8.33 0.05 (0.05,0.06)*** 5.13 0.02 (0.01,0.02)*** 2.02
Race
  Black -0.14 (-0.15,-0.14)*** -13.06 -0.11 (-0.11,-0.1)*** -10.42 -0.14 (-0.14,-0.13)*** -13.06 -0.1 (-0.11,-0.09)*** -9.52
  Other Race -0.26 (-0.27,-0.25)*** -22.89 -0.09 (-0.1,-0.08)*** -8.61 -0.11 (-0.12,-0.1)*** -10.42 0.04 (0.03,0.05)*** 4.08
  White (ref) ref ref ref ref ref ref ref ref
Hispanic -0.25 (-0.26,-0.24)*** -22.12 -0.31 (-0.32,-0.31)*** -26.66 -0.33 (-0.34,-0.32)*** -28.11 -0.21 (-0.22,-0.2)*** -18.94
HS Education 0.001 (-0.01,0.01) 0.00 0.005 (-0.002,0.01) 0.50 0.02 (0.02,0.03)*** 2.02 0.03 (0.02,0.04)*** 3.05
Married -0.02 (-0.02,-0.01)*** -1.98 -0.03 (-0.04,-0.02)*** -2.96 0.01 (0,0.02)* 1.01 0.03 (0.03,0.04)*** 3.05
Employed -0.01 (-0.01,-0.0002)* -1.00 0.04 (0.03,0.04)*** 4.08 0.08 (0.07,0.09)*** 8.33 0.13 (0.12,0.14)*** 13.88
Unstably Housed 0.03 (0.02,0.04)*** 3.05 -0.02 (-0.03,-0.01)*** -1.98 -0.04 (-0.05,-0.03)*** -3.92 0.02 (0.01,0.02)*** 2.02
Age
  <18 0.59 (0.58,0.61)*** 80.40 0.28 (0.27,0.29)*** 32.31 0.39 (0.38,0.4)*** 47.70 0.25 (0.23,0.26)*** 28.40
  18-24 0.23 (0.22,0.24)*** 25.86 0.14 (0.13,0.15)*** 15.03 0.15 (0.14,0.16)*** 16.18 0.09 (0.08,0.1)*** 9.42
  25-34 0.19 (0.18,0.2)*** 20.92 0.11 (0.1,0.12)*** 11.63 0.09 (0.09,0.1)*** 9.42 0.05 (0.04,0.06)*** 5.13
  35-44 0.09 (0.08,0.1)*** 9.42 0.05 (0.04,0.05)*** 5.13 0.04 (0.03,0.05)*** 4.08 0.02 (0.01,0.03)*** 2.02
  >44 (ref) ref ref ref ref ref ref ref ref
Tx Program Type
  Outpatient -0.39 (-0.4,-0.38)*** -32.29 -0.4 (-0.41,-0.39)*** -32.97 -0.51 (-0.52,-0.5)*** -39.95
  Detox -0.69 (-0.7,-0.68)*** -49.84 -0.7 (-0.71,-0.69)*** -50.34 -0.81 (-0.82,-0.8)*** -55.51
  Rehab (ref) ref ref ref ref ref ref
Enrolled in MAT -0.16 (-0.17,-0.15)*** -14.79 -0.16 (-0.18,-0.15)*** -14.79 -0.06 (-0.08,-0.05)*** -5.82
Psych Problems 0.58 (0.57,0.58)*** 78.60 0.53 (0.52,0.54)*** 69.89 0.37 (0.36,0.37)*** 44.77
Drug Use
  Heroin -0.19 (-0.23,-0.16)*** -17.30 -0.2 (-0.23,-0.16)*** -18.13 -0.29 (-0.32,-0.26)*** -25.17
  Non-rx Methadone -0.28 (-0.32,-0.25)*** -24.42 -0.28 (-0.32,-0.25)*** -24.42 -0.24 (-0.28,-0.2)*** -21.34
  Cocaine -0.04 (-0.05,-0.03)*** -3.92 -0.05 (-0.06,-0.05)*** -4.88 -0.11 (-0.12,-0.1)*** -10.42
  Synthetic Opioids -0.31 (-0.34,-0.28)*** -26.66 -0.29 (-0.32,-0.26)*** -25.17 -0.25 (-0.28,-0.22)*** -22.12
  Benzodiazepines 0.17 (0.15,0.2)*** 18.53 0.19 (0.17,0.22)*** 20.92 0.19 (0.17,0.21)*** 20.92
  Any Opioids 0.1 (0.07,0.14)*** 10.52 0.1 (0.07,0.14)*** 10.52 0.11 (0.08,0.14)*** 11.63
Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est Estimate (95% CI) % Diff Est
Ttl # of Drugs Used
1 -0.23 (-0.24,-0.21)*** -20.55 -0.22 (-0.23,-0.21)*** -19.75 -0.18 (-0.19,-0.17)*** -16.47
2 -0.23 (-0.24,-0.22)*** -20.55 -0.22 (-0.23,-0.21)*** -19.75 -0.1 (-0.11,-0.09)*** -9.52
3 (ref) ref ref ref ref ref ref
IDU -0.11 (-0.12,-0.1)*** -10.42 -0.13 (-0.14,-0.12)*** -12.19 0.01 (0,0.02)* 1.01
Health Insurance Type
  Medicaid 0.37 (0.36,0.38)*** 44.77 0.43 (0.42,0.45)*** 53.73
  Medicare 0.7 (0.69,0.72)*** 101.38 0.3 (0.29,0.31)*** 34.99
  No Insurance 0.5 (0.5,0.51)*** 64.87 0.46 (0.45,0.47)*** 58.41
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Assistance -0.003 (-0.02,0.01) -0.30 -0.09 (-0.1,-0.07)*** -8.61
  Retirement/Pension 0.04 (0.02,0.05)*** 4.08 0.01 (-0.01,0.02) 1.01
  Other Income Source -0.08 (-0.09,-0.07)*** -7.69 -0.09 (-0.1,-0.08)*** -8.61
  No Income -0.01 (-0.02,-0.002)*** -1.00 0.11 (0.1,0.12)*** 11.63
  Salary (ref) ref ref ref ref
State Level Variables
  Per Capita Income -0.0001 (-0.0001,-0.0001)*** -0.01
  Bupe Prog Rate -0.1 (-0.1,-0.1)*** -9.52
  Rate of Indiv in Tx -0.003 (-0.003,-0.002)*** -0.30
  % of res w/Medicaid -0.04 (-0.04,-0.04)*** -3.92
   SABG -0.002 (-0.002,-0.002)*** -0.20
**=p<0.001
*=p<0.05
Table 2B.12: Model Building Summary Using Multiple Imputation Sample for Treatment Wait Time and Medicaid Coverage of Buprenorphine, 2006, N=4,258,996
Model 1: Unadjusted association between Medicaid coverage of buprenorphine and wait time for substance use treatment
Model 2: Medicaid coverage of buprenorphine and demographic covariates
Model 3: Medicaid coverage of buprenorphine, demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of buprenorphine, demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 1 Model 2 Model 3 Model 4 Model 5
Model 1 Model 2 Model 3 Model 4 Model 5






1998 , N=1,704,606 2008 , N=2,016,672
1998 , opioid users only 
N=327,647
2008 , opioid users only 
N=511,448
1998 , opioid users in 38 
states, N=299,452
2008, opioid users in 38 
states, N=461,004
1998, opioid users in 38 
states, no missing, N=8,311
2008, opioid users in 38 
states, no missing, N=81,694
1998, opioid users in 38 states, 
no missing, BS sample, N=25,000
2008, opioid users in 38 states, 
no missing, BS sample, N=24,600
1998, opioid users in 38 states, 
MI sample, N=1,497,260
2008, opioid users in 38 states, MI 
sample, N=2,305,020
1998-2008 combined, no 
missing, N=90,005
1998-2008 combined, BS sample, 
N=25,300
Figure 3.1:  Analytic Sample for Aim 3, Utilization of MAT and Medicaid Coverage of Methadone
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Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=378828 N=81584
n ( %) n ( %)
Medicaid Coverage of Methadone*** 367225 (97%) 69986 (86%)
   missing n=0 n=0
Male*** 244451 (65%) 48852 (60%)
   missing n=62 n=0
Race
  White*** 263753 (71%) 53958 (66%)
  Black*** 53366 (14%) 22521 (28%)
  Other Race*** 54961 (15%) 5105 (6%)
   missing n=6748 n=0
Hispanic*** 61206 (17%) 5544 (7%)
   missing n=12087 n=0
HS Education 251892 (67%) 54849 (67%)
   missing n=4272 n=0
Married 53888 (20%) 15920 (20%)
   missing n=106634 n=0
Employed 69389 (19%) 15205 (19%)
   missing n=6057 n=0
Unstably housed*** 105404 (30%) 33116 (41%)
   missing n=33060 n=0
Age
   <24*** 84384 (22%) 17409 (21%)
  25-34*** 117639 (31%) 24730 (30%)
  35-44*** 90639 (24%) 20967 (26%)
  >45 86166 (23%) 18478 (23%)
   missing n=0 n=0
Program Type
  Rehab 73860 (20%) 15677 (19%)
  Non-Rehab Outpatient/Detox 304877 (81%) 65907 (81%)
   missing n=91 n=0
Patient receiving MAT*** 83094 (22%) 15360 (19%)
   missing n=2693 n=0
Psych Problems*** 79806 (32%) 22614 (28%)
   missing n=133120 n=0
Drug use reported at admit
  Heroin*** 259003 (68%) 57719 (71%)
      missing n=0 n=0
  Non prescription Methadone*** 11268 (3%) 1917 (2%)
      missing n=0 n=0
  Synthetic opioids*** 142610 (38%) 27424 (34%)
      missing n=0 n=0
  Cocaine/Crack*** 120412 (32%) 27939 (34%)
      missing n=0 n=0
Table 3.1 Comparison of Characteristics of Cases with Missing Data on Any Variables 




Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Benzodiazepine*** 28724 (8%) 6569 (8%)
      missing n=0 n=0
# of subs reported at admit
1*** 106509 (28%) 25642 (31%)
                                  2*** 133427 (35%) 27121 (33%)
3*** 138892 (37%) 28821 (35%)
      missing n=0 n=0
IDU*** 175659 (46%) 344448 (42%)
      missing n=0 n=0
Client Insurance Type
  Medicaid*** 31961 (24%) 25225 (31%)
  Medicare*** 18147 (14%) 6210 (8%)
  No insurance 70196 (53%) 42969 (53%)
  Private Insurance** 12161 (9%) 7180 (9%)
      missing n=201085 n=0
Primary Source of Income
  Public Assistance*** 21449 (10%) 6384 (8%)
  Retirement/Pension*** 8943 (4%) 10069 (12%)
  Other Income*** 52081 (24%) 10155 (12%)
  No income*** 94022 (43%) 35891 (44%)
  Salary*** 41892 (19%) 19085 (23%)
      missing n=113201 n=0
Continuous variables
Rate of methadone programs/10K pop*** 6.01 (3.08) 6.16 (3.19)
Rate of individuals in tx/1M pop*** 36.09 (21.02) 37.97 (25.0)






Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
N=291141 N=8311
n ( %) n ( %)
Medicaid Coverage of Methadone*** 270503 (93%) 6417 (77%)
   missing n=0 n=0
Male*** 193509 (67%) 5062 (61%)
   missing n=235 n=0
Race
  White*** 152899 (53%) 5739 (69%)
  Black** 71073 (25%) 1911 (23%)
  Other Race*** 65235 (23%) 661 (8%)
   missing n=1934 n=0
Hispanic*** 67199 (23%) 781 (9%)
   missing n=3077 n=0
HS Education*** 179228 (62%) 5750 (69%)
   missing n=1879 n=0
Married* 44319 (25%) 2158 (26%)
   missing n=111391 n=0
Employed*** 60065 (21%) 2725 (33%)
   missing n=5122 n=0
Unstably housed*** 59681 (31%) 3439 (41%)
   missing n=95744 n=0
Age
   <24*** 37365 (13%) 1298 (16%%)
  25-34** 91907 (32%) 2475 (30%)
  35-44 110603 (38%) 3241 (39%)
  >45*** 51266 (18%) 1297 (16%)
   missing n=0 n=0
Program Type***
  Rehab 43247 (15%) 1754 (21%)
  Non-Rehab Outpatient/Detox 247806 (85%) 6557 (79%)
   missing n=88 n=0
Patient receiving MAT*** 91660 (32%) 2085 (25%)
   missing n=606 n=0
Psych Problems*** 28858 (14%) 1962 (24%)
   missing n=87644 n=0
Drug use reported at admit
  Heroin*** 267149 (92%) 6242 (75%)
      missing n=0 n=0
  Non prescription Methadone** 5375 (2%) 195 (2%)
      missing n=0 n=0
  Synthetic opioids*** 29552 (10%) 2466 (30%)
      missing n=0 n=0
  Cocaine/Crack*** 113053 (39%) 3501 (42%)
      missing n=0 n=0
Table 3.2 Comparison of Characteristics of Cases with Missing Data on Any Variables 




Missing Data on Any 
Predictor Variable
No Missing Data on 
Any Predictor Variable
  Benzodiazepine*** 8609 (3%) 398 (5%)
      missing n=0 n=0
# of subs reported at admit
1*** 96160 (33%) 1872 (23%)
2 97206 (33%) 2793 (34%)
3*** 97775 (34%) 3646 (44%)
      missing n=0 n=0
IDU 154895 (53%) 4335 (52%)
      missing n=0 n=0
Client Insurance Type
  Medicaid*** 24913 (18%) 1239 (15%)
  Medicare*** 13780 (10%) 730 (9%)
  No insurance** 82278 (61%) 5225 (63%)
  Private Insurance*** 13997 (10%) 1117 (13%)
      missing n=201085 n=0
Primary Source of Income
  Public Assistance*** 25144 (23%) 775 (9%)
  Retirement/Pension*** 3557 (3%) 845 (10%)
  Other Income*** 30459 (27%) 1308 (16%)
  No income* 29250 (26%) 2306 (28%)
  Salary*** 22534 (20%) 3077 (37%)
      missing n=180197 n=0
Continuous variables
Rate of methadone programs/10K pop*** 5.33 (2.85) 3.37 (2.59)
Rate of individuals in tx/1M pop*** 29.84 (17.04) 12.82 (14.89)







Individuals in States with Medicaid Coverage of Methadone 21584 (85%)
Male 15172 (60%)
Race
  White 16787 (66%)
  Black 6910 (27%)
  Other Race 1603 (6%)
Hispanic 1738 (7%)
HS Education 16929 (67%)
Married 5124 (20%)
Employed 5061 (20%)
Unstably housed 10303 (41%)
Age
  <18 520 (2%)
  18-24 4841 (19%)
  25-34 7469 (30%)
  35-44 6901 (27%)
  >45 5569 (22%)
Program Type
  Rehabilitation 4854 (19%)
  Non-Rehabiltation (Outpatient and Detoxification) 20,446 (81%)
Patient receiving MAT 4883 (19%)
Psych Problems 6995 (28%)
Drug use reported at admit
  Heroin 18004 (71%)
  Non prescription Methadone 630 (2%)
  Cocaine/Crack 8869 (35%)
  Synthetic opioids 8384 (33%)
  Benzodiazepine 1926 (8%)






  Medicaid 7369 (29%)
  Medicare 2044 (8%)
  No insurance 13426 (53%)
  Private Insurance 2461 (10%)
Primary Source of Income
  Public Assistance 1967 (8%)
  Retirement/Pension 3087 (12%)
  Other Income 3206 (13%)
  No income 10770 (43%)
  Salary 6270 (25%)
Continuous variables Mean (SD)
Rate of methadone programs/10K pop 5.89 (3.24)
Rate of individuals in tx/1M pop 35.59 (25.33)
Percent of residents rec'v Medicaid 19.26 (4.65)
Table 3.3: Descriptive Characteristics of Bootstrapped Listwise Deletion 
Sample for Utilization of MAT and Medicaid Coverage of Methadone, 
Combined 1998-2008, N=25,300 
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Medicaid Coverage No Medicaid Coverage
N=21,584 N=3,716
n ( %) n ( %)
Male* 13049 (60%) 2123 (57%)
Race
  White*** 13575 (63%) 3212 (86%)
  Black*** 6548 (30%) 362 (10%)
  Other Race*** 1461 (7%) 142 (4%)
Hispanic 1463 (7%) 275 (7%)
HS Education* 14529 (67%) 2400 (65%)
Married*** 4080 (19%) 1044 (28%)
Employed*** 4207 (19%) 854 (23%)
Unstably housed*** 9021 (42%) 1282 (35%)
Age
  <24*** 4439 (21%) 922 (25%)
  25-34*** 6127 (28%) 1342 (36%)
  35-44*** 6012 (28%) 889 (24%)
  >45*** 5006 (23%) 563 (15%)
Program Type
  Rehab*** 3833 (18%) 1021 (27%)
  Non-Rehab (Outpatient/Detox)*** 17751 (82%) 2695 (73%)
Patient receiving MAT*** 4680 (22%) 203 (5%)
Psych Problems*** 5625 (26%) 1370 (37%)
Drug use reported at admit
  Heroin*** 17058 (79%) 946 (25%)
  Non prescription Methadone*** 384 (2%) 246 (7%)
  Cocaine/Crack*** 7811 (36%) 1058 (28%)
  Synthetic opioids*** 5618 (26%) 2766 (74%)
  Benzodiazepine*** 1510 (7%) 416 (11%)
# of subs reported at admit
1*** 7160 (33%) 575 (15%)
2*** 7343 (34%) 1109 (30%)
3*** 7081 (33%) 2032 (55%)
IDU*** 9716 (45%) 1081 (29%)
Client Insurance Type
  Medicaid*** 6842 (32%) 527 (14%)
  Medicare 1742 (8%) 302 (8%)
  No insurance*** 10761 (50%) 2665 (71%)
  Private Insurance*** 2239 (10%) 222 (6%)
Primary Source of Income
  Public Assistance*** 1753 (8%) 214 (6%)
  Retirement/Pension*** 2851 (13%) 236 (6%)
  Other Income*** 2896 (13%) 310 (8%)
  No income*** 8906 (41%) 1864 (50%)
  Salary*** 5178 (24%) 1092 (29%)
Medicaid Coverage No Medicaid Coverage
N=21,584 N=3,716
Continuous variables
  Rate of methadone programs/10K pop*** 6.56 1.99
  Rate of individuals in tx/1M pop*** 40.15 9.11




Table 3.4: Comparison of Characteristics of Bootstrapped Listwise Deletion Sample by 
Medicaid Coverage of Methadone, Combined 1998-2008
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 4.79*** 4.14-5.54 4.48*** 3.87-5.21 3.03*** 2.58-3.56 3.16*** 2.69-3.73 6.11*** 5.03-7.40 6.42*** 5.26-7.78 5.37*** 3.72-7.76
Male 0.66*** 0.62-0.71 0.64*** 0.59-0.68 0.65*** 0.60-0.70 0.73*** 0.68-0.79 0.733*** 0.68-0.79 0.73*** 0.68-0.79
Race
   Black 1.54*** 1.42-1.67 1.26*** 1.13-1.39 1.19* 1.07-1.31 0.88* 0.79-0.98 0.88* 0.79-0.98 0.88* 0.79-0.98
  Other Race 0.59*** 0.50-0.71 0.52*** 0.43-0.62 0.53*** 0.44-0.64 0.57*** 0.47-0.68 0.55*** 0.46-0.67 0.55*** 0.46-0.68
  White (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Hispanic 1.85*** 1.59-2.15 1.68*** 1.44-1.97 1.73*** 1.48-2.04 1.57*** 1.33-1.85 1.57*** 1.34-1.85 1.57*** 1.34-1.86
HS Education 0.90* 0.84-0.97 0.87** 0.81-0.94 0.90** 0.83-0.97 0.93 0.87-1.01 0.94 0.85-1.01 0.94 0.87-1.02
Married 1.22*** 1.13-1.32 1.27*** 1.17-1.39 1.26*** 1.15-1.37 1.19** 1.09-1.30 1.19** 1.09-1.30 1.19** 1.09-1.30
Employed 1.90*** 1.76-2.06 1.88*** 1.72-2.05 1.48*** 1.30-1.69 1.30** 1.13-1.50 1.27** 1.11-1.47 1.28** 1.11-1.47
Unstably Housed 1.03 0.96-1.10 1.16*** 1.08-1.25 1.15** 1.07-1.25 0.91* 0.85-1.00 0.92 0.85-1.00 0.92 0.85-1.00
Age
agelt24 0.32*** 0.28-0.36 0.33*** 0.29-0.38 0.33*** 0.29-0.38 0.37*** 0.32-0.42 0.37*** 0.32-0.42 0.37*** 0.32-0.42
age2534 0.53*** 0.49-0.59 0.57*** 0.51-0.62 0.54*** 0.49-0.60 0.63*** 0.56-0.70 0.62*** 0.56-0.69 0.62*** 0.56-0.69
age3544 0.70*** 0.65-0.77 0.74*** 0.68-0.81 0.72*** 0.65-0.78 0.76*** 0.70-0.84 0.76*** 0.69-0.83 0.76*** 0.69-0.83
age45ov (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Rehab 0.17*** 0.14-0.20 0.16*** 0.14-0.19 0.16*** 0.14-0.19 0.16*** 0.14-0.19 0.16*** 0.14-0.19
Psych problems 0.76*** 0.69-0.83 0.76*** 0.70-0.84 0.89* 0.80-0.97 0.90* 0.81-0.98 0.90* 0.81-0.98
Drug Use
  Heroin 5.64*** 4.77-6.62 5.75*** 4.88-6.80 6.44*** 5.41-7.66 6.42*** 5.37-7.61 6.36*** 5.36-7.60
  Non-rx Methadone 8.94*** 7.17-11.08 8.25*** 6.64-10.31 7.17*** 5.70-8.98 7.17*** 5.74-9.05 7.24*** 5.76-9.11
  Cocaine 1.34*** 1.20-1.48 1.30*** 1.16-1.45 1.22** 1.09-1.36 1.21** 1.09-1.36 1.22** 1.08-1.35
  Synthetic Opioids 3.94*** 3.39-4.58 3.90*** 3.36-4.55 3.90*** 3.32-4.57 3.94 3.36-4.63 3.97*** 3.37-4.65
  Benzodiazepines 1.30** 1.09-1.54 1.43*** 1.21-1.71 2.03*** 1.69-2.44 2.01*** 1.68-2.43 2.03*** 1.67-2.42
Ttl # of Drugs Used
1 4.18*** 3.65-4.77 4.44*** 3.88-5.09 4.35*** 3.77-4.96 4.35*** 3.81-5.01 4.39*** 3.82-5.03
2 1.99*** 1.81-2.21 2.03*** 1.83-2.24 1.97*** 1.79-2.20 1.99*** 1.80-2.22 1.99*** 1.79-2.21
3 (ref) ref ref ref ref ref ref ref ref ref ref
IDU 1.04*** 0.96-1.13 1.06 0.97-1.16 1.31*** 1.20-1.44 1.30*** 1.19-1.42 1.30*** 1.19-1.42
Health Insurance Type
  Medicaid 1.09 0.94-1.27 1.52*** 1.30-1.78 1.52*** 1.30-1.78 1.52*** 1.29-1.78
  Medicare 0.57*** 0.46-0.70 0.88 0.71-1.09 0.87 0.70-1.08 0.86 0.70-1.07
  No insurance 1.62*** 1.40-1.84 1.39*** 1.21-1.60 1.40*** 1.22-1.61 1.40*** 1.22-1.61
  Private Insurance (ref) ref ref ref ref ref ref ref ref
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Primary Income
  Public Asstistance 1.43*** 1.22-1.70 1.16 0.98-1.38 1.15 0.96-1.36 1.15 0.97-1.37
Retirement/Pension 0.72*** 0.61-0.85 0.55*** 0.46-0.65 0.55*** 0.46-0.66 0.55*** 0.46-0.66
  Other Income Source 1.07 0.92-1.24 0.93 0.80-1.10 0.92 0.78-1.08 0.92 0.79-1.08
  No Income 0.61*** 0.53-0.70 0.66*** 0.57-0.76 0.66*** 0.57-0.77 0.66*** 0.57-0.77
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.40*** 1.37-1.45 1.43*** 1.39-1.47 1.43*** 1.39-1.47
  Rate of Indiv in Tx 0.93*** 0.93-0.94 0.93*** 0.93-0.94 0.93*** 0.93-0.94
  % of res w/Medicaid 1.04*** 1.03-1.05 1.05*** 1.04-1.07 1.05*** 1.04-1.07
Time 0.73*** 0.63-0.84 0.59* 0.40-0.88
Medicaid Cov * Time 1.26 0.83-1.89
Model 5 Model 6 Model 7
*=p<0.05
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-level 
Model 6: Medicaid coverage of methadone,  demographic covariates, substance useI and treatment covariates, health insurance and income covariates, state-level 
Model 7: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level 
***=p<0.0001
**=p<0.001
Table 3.5: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Util ization of MAT and Medicaid Coverage of Methadone, Combined 1998-2008, 
N=25,300
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 4.41*** 4.10-4.75 4.22*** 3.90-4.53 2.80*** 2.59--3.05 2.94*** 2.72-3.20 5.58*** 5.04-6.13 5.81*** 5.26-6.41 4.30*** 3.61-5.18
Male 0.68*** 0.66-0.71 0.65*** 0.63-0.68 0.66*** 0.63-0.68 0.76*** 0.73-0.79 0.76*** 0.73-0.79 0.76*** 0.73-0.79
Race
   Black 1.55*** 1.49-1.63 1.23*** 1.16-1.30 1.14*** 1.08-1.21 0.89*** 0.84-0.94 0.88*** 0.83-0.93 0.88*** 0.83-0.93
  Other Race 0.63*** 0.57-0.69 0.53*** 0.48-0.58 0.55*** 0.50-0.60 0.61*** 0.55-0.67 0.60*** 0.54-0.66 0.59*** 0.54-0.66
  White (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Hispanic 1.77*** 1.63-1.91 1.65*** 1.52-1.80 1.72*** 1.58-1.87 1.51*** 1.39-1.65 1.51*** 1.39-1.65 1.51*** 1.39-1.65
HS Education 0.89*** 0.85-0.92 0.86*** 0.83-0.90 0.90*** 0.86-0.93 0.94* 0.91-0.99 0.95* 0.91-0.99 0.94* 0.91-0.99
Married 1.24*** 1.18-1.28 1.31*** 1.25-1.37 1.30*** 1.24-1.35 1.22*** 1.16-1.28 1.22*** 1.16-1.28 1.22*** 1.16-1.28
Employed 2.03*** 1.95-2.12 1.97*** 1.88-2.06 1.55*** 1.45-1.67 1.40*** 1.31-1.52 1.39*** 1.29-1.50 1.39*** 1.30-1.50
Unstably Housed 1.03 0.99-1.07 1.17*** 1.13-1.22 1.19*** 1.14-1.23 0.93** 0.89-0.97 0.93* 0.89-0.97 0.93* 0.89-0.97
Age
<24 0.36*** 0.34-0.38 0.38*** 0.35-0.40 0.38*** 0.36-0.41 0.43*** 0.40-0.47 0.44*** 0.40-0.46 0.43*** 0.40-0.46
25-34 0.56*** 0.53-0.59 0.58*** 0.56-0.62 0.58*** 0.55-0.61 0.66*** 0.63-0.70 0.66*** 0.62-0.70 0.66*** 0.63-0.70
35-44 0.70*** 0.68-0.74 0.74*** 0.71-0.78 0.73*** 0.69-0.76 0.79*** 0.75-0.82 0.77*** 0.73-0.81 0.77*** 0.73-0.81
>44 (ref) ref ref ref ref ref ref ref ref ref ref ref ref
Rehab 0.16*** 0.15-0.18 0.16*** 0.14-0.17 0.16*** 0.15-0.17 0.16*** 0.14-0.17 0.16*** 0.14-0.17
Psych problems 0.83*** 0.79-0.86 0.84*** 0.79-0.87 0.96 0.91-1.01 0.97 0.92.1.02 0.97 0.92-1.02
Drug Use
  Heroin 6.17*** 5.68-6.74 6.36*** 5.82-6.92 7.03*** 6.44-7.72 6.96*** 6.36-7.62 6.96*** 6.32-7.58
  Non-rx Methadone 7.17*** 6.33-8.06 6.69*** 5.94-7.59 6.23*** 5.50-7.07 6.23*** 5.50-7.07 6.30*** 5.54-7.12
  Cocaine 1.39*** 1.32-1.48 1.36*** 1.29-1.44 1.30*** 1.23-1.38 1.30*** 1.23-1.38 1.31*** 1.23-1.38
  Synthetic Opioids 4.10*** 3.80-4.43 4.06*** 3.75-4.39 4.10*** 3.79-4.47 4.18*** 3.83-4.52 4.18*** 3.85-4.54
  Benzodiazepines 1.30*** 1.18-1.41 1.43*** 1.31-1.57 1.97*** 1.79-2.17 1.95*** 1.78-2.16 1.97*** 1.79-2.17
Ttl # of Drugs Used
1 3.97*** 3.72-4.28 4.31*** 3.99-4.60 4.26*** 3.96-4.58 4.31*** 4.00-4.61 4.31*** 4.01-4.63
2 1.90*** 1.80-2.00 1.93*** 1.84-2.05 1.92*** 1.82-2.03 1.93*** 1.83-2.04 1.93*** 1.83-2.04
3 (ref) ref ref ref ref ref ref ref ref ref ref
IDU 0.99 0.95-1.03 1.01 0.97-1.06 1.26*** 1.20-1.32 1.25*** 1.19-1.31 1.25*** 1.19-1.31
Health Insurance Type
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
  Medicaid 0.99 0.91-1.07 1.39*** 1.28-1.52 1.39*** 1.28-1.51 1.39*** 1.27-1.51
  Medicare 0.58*** 0.52-0.64 0.90 0.81-1.01 0.90 0.80-1.00 0.89* 0.80-1.00
  No insurance 1.63*** 1.52-1.75 1.42*** 1.31-1.52 1.42*** 1.32-1.53 1.42*** 1.32-1.53
  Private Insurance (ref) ref ref ref ref ref ref ref ref
Primary Income
  Public Asstistance 1.46*** 1.35-1.60 1.26*** 1.15-1.38 1.25*** 1.14-1.37 1.26*** 1.14-1.37
  Retirement/Pension 0.84*** 0.77-0.92 0.64*** 0.59-0.71 0.65*** 0.59-0.71 0.65*** 0.59-0.71
  Other Income Source 1.07 0.99-1.16 0.98 0.90-1.06 0.97 0.89-1.05 0.97 0.89-1.06
  No Income 0.61*** 0.57-0.66 0.68*** 0.63-0.73 0.69*** 0.64-0.74 0.68*** 0.63-0.74
  Salary (ref) ref ref ref ref ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.39*** 1.37-1.40 1.40*** 1.39-1.43 1.40*** 1.39-1.43
  Rate of Indiv in Tx 0.93*** 0.93-0.94 0.93*** 0.93-0.94 0.93*** 0.93-0.94
  % of res w/Medicaid 1.04*** 1.03-1.04 1.05*** 1.04-1.06 1.05*** 1.04-1.06
Time 0.73*** 0.67-0.78 0.51*** 0.42-0.62
Medicaid Cov * Time 1.48** 1.21-1.81
*=p<0.05
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates and state-
Model 6: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level 
Model 7: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and income covariates, state-level 
***=p<0.0001
**=p<0.001
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance and income covariates
Model 7Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Table 3.6: Model Building Summary Using Listwise Deletion Sample for Util ization of MAT and Medicaid Coverage of Methadone, Combined 1998-2008, N=90,005
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 5.24*** 4.46-6.16 4.86*** 4.12-5.73 3.32*** 2.79-3.99 3.53*** 2.93-4.21 8.16*** 6.51-10.22
Male 0.68*** 0.63-0.73 0.65*** 0.61-0.70 0.65*** 0.61-0.70 0.76*** 0.71-0.82
Race
   Black 1.67*** 1.53-1.82 1.25*** 1.13-1.39 1.16* 1.04-1.30 0.86* 0.77-0.96
  Other Race 0.65*** 0.54-0.78 0.57*** 0.48-0.69 0.59*** 0.49-0.72 0.65*** 0.54-0.79
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 1.63*** 1.39-1.90 1.40*** 1.20-1.65 1.48*** 1.26-1.75 1.40*** 1.19-1.66
HS Education 0.87** 0.81-0.94 0.84*** 0.79-0.91 0.88** 0.81-0.95 0.92* 0.85-1.00
Married 1.26*** 1.16-1.37 1.34*** 1.23-1.46 1.31*** 1.20-1.43 1.22*** 1.12-1.34
Employed 2.05*** 1.88-2.23 1.97*** 1.81-2.17 1.63*** 1.41-1.88 1.52*** 1.31-1.78
Unstably Housed 1.13** 1.05-1.21 1.30*** 1.20-1.40 1.28*** 1.18-1.39 0.97 0.89-1.06
Age
agelt24 0.38*** 0.34-0.43 0.40*** 0.35-0.46 0.39*** 0.35-0.45 0.43*** 0.34-0.49
age2534 0.57*** 0.51-0.62 0.57*** 0.52-0.63 0.55*** 0.50-0.62 0.62*** 0.55-0.69
age3544 0.69*** 0.63-0.75 0.70*** 0.64-0.77 0.69*** 0.63-0.76 0.76*** 0.69-0.83
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.20*** 0.17-0.23 0.19*** 0.17-0.23 0.20*** 0.17-0.23
Psych problems 0.84** 0.77-0.92 0.85** 0.78-0.94 1.02 0.93-1.13
Drug Use
  Heroin 5.47*** 4.63-6.45 5.53*** 4.68-6.55 6.05*** 5.08-7.22
  Non-rx Methadone 7.24*** 5.74-9.06 6.62*** 5.24-8.32 6.17*** 4.88-7.86
  Cocaine 1.36*** 1.22-1.52 1.32*** 1.18-1.48 1.25*** 1.11-1.40
  Synthetic Opioids 3.67*** 3.16-4.27 3.56*** 3.06-4.15 3.78*** 3.22-4.45
  Benzodiazepines 1.04 0.86-1.25 1.16 0.96-1.40 1.62*** 1.33-1.98
Ttl # of Drugs Used
1 3.86*** 3.35-4.41 4.10*** 3.56-4.69 3.94*** 3.42-4.52
2 1.95*** 1.76-2.16 1.97*** 1.78-2.20 1.92*** 1.72-2.13
3 (ref) ref ref ref ref ref ref
IDU 0.94 0.86-1.03 0.96 0.88-1.05 1.26*** 1.14-1.38
Health Insurance Type
  Medicaid 0.94 0.81-1.11 1.36** 1.15-1.61
  Medicare 0.51*** 0.41-0.63 0.86 0.68-1.08
  No insurance 1.57*** 1.36-1.82 1.40*** 1.21-1.63
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Asstistance 1.39** 1.17-1.66 1.19 0.98-1.43
  Retirement/Pension 0.84* 0.70-0.99 0.65*** 0.54-0.78
  Other Income Source 1.20* 1.02-1.41 1.06 0.93-1.26
  No Income 0.68*** 0.59-0.78 0.75** 0.64-0.88
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.42*** 1.38-1.46
  Rate of Indiv in Tx 0.93*** 0.93-0.94




Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health 
Model 2 Model 3 Model 4 Model 5Model 1
Table 3.7: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Util ization of MAT and Medicaid 
Coverage of Methadone, 2008, N=24,600
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates




OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
Methadone covered 4.72*** 4.34-5.12 4.39*** 4.03-4.78 3.00*** 2.74-3.30 3.19*** 2.90-3.50 8.00*** 7.08-8.99
Male 0.67*** 0.65-0.70 0.64*** 0.62-0.67 0.64*** 0.62-0.67 0.75*** 0.72-0.78
Race
   Black 1.72*** 1.64-1.80 1.30*** 1.23-1.38 1.22*** 1.15-1.29 0.86*** 0.81-0.91
  Other Race 0.56*** 0.51-0.62 0.47*** 0.42-0.52 0.49*** 0.44-0.54 0.56*** 0.50-0.62
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 2.01*** 1.84-2.18 1.88*** 1.72-2.05 1.95*** 1.80-2.15 1.75*** 1.60-1.92
HS Education 0.88*** 0.84-0.91 0.85*** 0.82-0.89 0.88*** 0.85-0.92 0.94* 0.90-0.98
Married 1.26*** 1.21-1.32 1.32*** 1.27-1.39 1.31*** 1.24-1.37 1.23*** 1.18-1.30
Employed 2.05*** 1.97-2.16 1.97*** 1.88-2.08 1.51*** 1.40-1.63 1.40*** 1.30-1.53
Unstably Housed 1.13*** 1.08-1.17 1.27*** 1.22-1.32 1.27*** 1.21-1.32 0.93* 0.89-0.98
Age
agelt24 0.39*** 0.36-0.41 0.41*** 0.38-0.44 0.41*** 0.38-0.44 0.43*** 0.40-0.47
age2534 0.59*** 0.56-0.63 0.61*** 0.58-0.65 0.60*** 0.57-0.64 0.66*** 0.62-0.70
age3544 0.69*** 0.66-0.73 0.71*** 0.680.75 0.70*** 0.66-0.73 0.76*** 0.72-0.80
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.19*** 0.17-0.21 0.18*** 0.17-0.20 0.19*** 0.18-0.21
Psych problems 0.84*** 0.81-0.89 0.85*** 0.81-0.90 1.02 0.96-1.07
Drug Use
  Heroin 5.42*** 4.96-5.97 5.53*** 5.06-6.10 6.05*** 5.51-6.69
  Non-rx Methadone 7.54*** 6.62-8.53 6.96*** 6.14-7.91 6.49*** 5.67-7.37
  Cocaine 1.35*** 1.28-1.44 1.32*** 1.25-1.41 1.26*** 1.19-1.35
  Synthetic Opioids 3.63*** 3.36-3.97 3.60*** 3.29-3.90 3.78*** 3.44-4.12
  Benzodiazepines 1.14* 1.03-1.25 1.26*** 1.14-1.39 1.79*** 1.60-1.98
Ttl # of Drugs Used
1 3.82*** 3.54-4.11 4.10*** 3.78-4.40 3.94*** 3.64-4.25
2 1.86*** 1.75-1.97 1.90*** 1.78-2.00 1.84*** 1.73-1.95
3 (ref) ref ref ref ref ref ref
IDU 0.92** 0.88-0.97 0.94* 0.90-0.99 1.23*** 1.18-1.30
Health Insurance Type
  Medicaid 0.98 0.90-1.07 1.35*** 1.23-1.48
  Medicare 0.59*** 0.53-0.66 0.93 0.82-1.05
  No insurance 1.60*** 1.49 1.38*** 1.28-1.50
  Private Insurance (ref) ref 1.74 ref ref
Primary Income
  Public Asstistance 1.35*** 1.23-1.48 1.19** 1.07-1.31
  Retirement/Pension 0.76*** 0.69-0.83 0.59*** 0.53-0.65
  Other Income Source 1.04 0.95-1.13 0.95 0.87-1.04
  No Income 0.61*** 0.56-0.65 0.68*** 0.63-0.75
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.43*** 1.41-1.46
  Rate of Indiv in Tx 0.93*** 0.93-0.93




Table 3.8: Model Building Summary Using Listwise Deletion Sample for Util ization of MAT and Medicaid Coverage of 
Methadone 2008, N=81,694
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health 
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health 
Model 1 Model 2 Model 3 Model 4 Model 5
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 2.79* 2.73-2.84 2.72*** 2.66-2.78 1.95*** 1.91-2.00 1.97*** 1.93-2.01 2.59*** 2.54-2.65
Male 0.75*** 0.75-0.76 0.73*** 0.73-0.74 0.76*** 0.75-0.76 0.79*** 0.79-0.80
Race
   Black 1.22*** 1.21-1.23 1.12*** 1.10-1.12 1.06*** 1.05-1.07 1.05*** 1.04-1.07
  Other Race 1.16*** 1.15-1.18 1.16*** 1.14-1.17 1.12*** 1.10-1.13 1.11*** 1.09-1.12
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 1.49*** 1.47-1.51 1.30*** 1.28-1.31 1.27*** 1.26-1.29 1.27*** 1.25-1.28
HS Education 0.90*** 0.89-0.90 0.89*** 0.88-0.89 0.90*** 0.90-0.91 0.91*** 0.91-0.92
Married 1.09*** 1.08-1.10 1.14*** 1.13-1.15 1.16*** 1.15-1.17 1.13*** 1.12-1.14
Employed 1.77*** 1.76-1.79 1.73*** 1.71-1.74 1.67*** 1.64-1.69 1.57*** 1.56-1.60
Unstably Housed 0.61*** 0.60-0.61 0.68*** 0.67-0.68 0.68*** 0.68-0.69 0.64*** 0.63-0.64
Age
agelt24 0.38*** 0.37-0.38 0.44*** 0.43-0.44 0.45*** 0.44-0.45 0.48*** 0.48-0.49
age2534 0.55*** 0.55-0.56 0.58*** 0.58-0.59 0.58*** 0.58-0.59 0.63*** 0.62-0.63
age3544 0.66*** 0.65-0.66 0.70*** 0.69-0.71 0.70*** 0.69-0.70 0.74*** 0.74-0.75
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.13*** 0.13-0.14 0.13*** 0.13-0.14 0.13*** 0.13-0.14
Psych problems 0.99 0.99-1.00 0.98** 0.98-0.99 1.08*** 1.08-1.09
Drug Use
  Heroin 5.64*** 5.57-5.73 5.58*** 5.51-5.68 6.55*** 6.46-6.66
  Non-rx Methadone 6.69*** 6.53-6.79 6.55*** 6.45-6.72 6.75*** 6.62-6.89
  Cocaine 1.57*** 1.55-1.58 1.54*** 1.53-1.56 1.65*** 1.63-1.66
  Synthetic Opioids 3.42*** 3.38-3.48 3.42*** 3.39-3.48 3.46*** 3.39-3.49
  Benzodiazepines 1.38*** 1.36-1.40 1.39*** 1.38-1.42 1.51*** 1.49-1.54
Ttl # of Drugs Used
1 5.05*** 5.00-5.12 5.21*** 5.12-5.25 5.10*** 5.02-5.15
2 2.25*** 2.22-2.26 2.25*** 2.23-2.27 2.18*** 2.15.2.20
3 (ref) ref ref ref ref ref ref
IDU 1.13*** 1.12-1.14 1.15*** 1.14-1.15 1.09*** 1.08-1.10
Health Insurance Type
  Medicaid 1.38*** 1.36-1.40 1.31*** 1.30-1.34
  Medicare 1.03* 1.01-1.04 0.91*** 0.90-0.93
  No insurance 1.34*** 1.32-1.35 1.19*** 1.17-1.20
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Asstistance 1.52*** 1.50-1.55 1.43*** 1.42-1.47
  Retirement/Pension 0.88*** 0.86-0.89 0.91*** 0.89-0.93
  Other Income Source 0.91*** 0.90-0.93 0.90*** 0.88-0.91
  No Income 0.83*** 0.82-0.84 0.76*** 0.75-0.77
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.003* 1.00-1.01
  Rate of Indiv in Tx 0.99*** 0.99-0.99




Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance 
Table 3.9: Model Building Summary Using Multiple Imputation Sample for Util ization of MAT and Medicaid Coverage of Methadone, 
2008, N=2,305,020
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance 
Model 1 Model 2 Model 3 Model 4 Model 5
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 4.22*** 3.84-4.65 4.48*** 4.05-4.94 3.39*** 3.05-3.80 2.75*** 2.45-3.07 2.32*** 2.06-2.62
Male 0.84*** 0.79-0.89 0.82*** 0.76-0.88 0.93 0.87-1.01 0.94 0.87-1.02
Race
   Black 0.90* 0.83-0.96 0.85** 0.78-0.93 0.76*** 0.70-0.84 0.63*** 0.56-0.69
  Other Race 0.97 0.85-1.11 0.75** 0.64-0.88 0.75** 0.64-0.89 0.78* 0.66-0.92
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.75*** 0.66-0.86 0.70*** 0.60-0.83 0.72*** 0.61-0.85 0.82* 0.69-0.96
HS Education 0.95 0.88-1.01 0.98 0.91-1.06 1.06 0.98-1.15 1.11* 1.02-1.19
Married 0.92* 0.86-0.99 1.00 0.92-1.09 1.09* 1.01-1.19 1.11* 1.02-1.20
Employed 1.57*** 1.46-1.67 1.31*** 1.22-1.42 1.51*** 1.35-1.68 1.62*** 1.44-1.81
Unstably Housed 0.43*** 0.40-0.46 0.51*** 0.47-0.55 0.55*** 0.51-0.59 0.51*** 0.47-0.55
Age
agelt24 0.26*** 0.23-0.30 0.30*** 0.26-0.35 0.35*** 0.31-0.41 0.33*** 0.29-0.39
age2534 0.50*** 0.46-0.55 0.64*** 0.57-0.71 0.70*** 0.63-0.79 0.69*** 0.62-0.77
age3544 0.66*** 0.61-0.72 0.78*** 0.71-0.86 0.82*** 0.74-0.90 0.80*** 0.72-0.89
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.02*** 0.02-0.03 0.02*** 0.02-0.03 0.02*** 0.02-0.03
Psych problems 0.84*** 0.77-0.91 0.77*** 0.70-0.85 0.75*** 0.69-0.82
Drug Use
  Heroin 23.34*** 19.79-27.68 25.28*** 21.22-29.96 22.65*** 18.99-26.82
  Non-rx Methadone 3.90*** 2.98-5.13 4.71*** 3.57-6.19 4.71*** 3.56-6.20
  Cocaine 1.60*** 1.44-1.76 1.60*** 1.45-1.77 1.54*** 1.39-1.71
  Synthetic Opioids 9.97*** 8.59-11.55 11.13*** 9.58-13.02 12.18*** 10.49-14.27
  Benzodiazepines 4.57*** 3.90-5.38 4.85*** 4.12-5.75 5.00*** 4.23-5.90
Ttl # of Drugs Used
1 7.32*** 6.49-8.27 7.69*** 6.80-8.71 7.39*** 6.55-8.40
2 2.51*** 2.28-2.74 2.66*** 2.43-2.92 2.61*** 2.38-2.86
3 (ref) ref ref ref ref ref ref
IDU 1.40*** 1.29-1.52 1.51*** 1.39-1.64 1.63*** 1.50-1.78
Health Insurance Type
  Medicaid 1.90*** 1.64-2.19 2.18*** 1.89-2.54
  Medicare 0.57*** 0.47-0.69 0.58*** 0.48-0.70
  No insurance 1.70*** 1.52-1.90 1.84*** 1.65-2.07
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Asstistance 1.97*** 1.69-2.31 2.10*** 1.79-2.45
  Retirement/Pension 1.99*** 1.71-2.33 2.27*** 1.94-2.66
  Other Income Source 1.48*** 1.30-1.69 1.51*** 1.32-1.72
  No Income 0.52*** 0.46-0.60 0.678*** 0.59-0.78
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.12* 1.04-1.20
  Rate of Indiv in Tx 1.00 0.98-1.01




Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and 
Model 1 Model 2 Model 3 Model 4 Model 5
Table 3.10: Model Building Summary Using Bootstrapped Listwise Deletion Sample for Util ization of MAT and Medicaid Coverage of 
Methadone, 1998, N=25,000
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
Model 4: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates and health insurance 
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OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 4.02*** 3.42-4.73 4.24*** 3.59-5.01 3.19*** 2.66-3.84 2.57*** 2.12-3.11 2.18*** 1.78-2.67
Male 0.84* 0.75-0.93 0.82* 0.72-0.93 0.92 0.80-1.05 0.92 0.81-1.05
Race
   Black 0.89 0.78-1.01 0.85* 0.72-0.99 0.76* 0.64-0.90 0.63*** 0.53-0.76
  Other Race 1.06 0.84-1.34 0.88 0.67-1.15 0.87 0.66-1.15 0.90 0.68-1.18
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.75* 0.59-0.94 0.66* 0.51-0.86 0.69* 0.53-0.90 0.76* 0.58-0.99
HS Education 0.95 0.85-1.08 0.96 0.84-1.09 1.04 0.91-1.20 1.08 0.94-1.24
Married 0.95 0.84-1.07 1.01 0.88-1.16 1.11 0.95-1.27 1.12 0.97-1.29
Employed 1.51*** 1.35-1.69 1.28** 1.13-1.46 1.47** 1.21-1.78 1.57*** 1.29-1.91
Unstably Housed 0.44*** 0.39-0.50 0.51*** 0.45-0.59 0.56*** 0.49-0.64 0.52*** 0.45-0.60
Age
agelt24 0.28*** 0.23-0.35 0.32*** 0.25-0.40 0.37*** 0.29-0.48 0.35*** 0.28-0.46
age2534 0.51*** 0.44-0.60 0.62*** 0.51-0.74 0.67*** 0.55-0.81 0.65*** 0.54-0.79
age3544 0.67*** 0.58-0.78 0.77* 0.65-0.91 0.80* 0.67-0.95 0.78* 0.66-0.93
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.02*** 0.01-0.03 0.02*** 0.01-0.03 0.02*** 0.01-0.03
Psych problems 0.83* 0.71-0.97 0.76* 0.65-0.90 0.75** 0.64-0.88
Drug Use
  Heroin 20.25*** 15.20-26.97 21.83*** 16.27-29.32 19.89*** 14.82-26.71
  Non-rx Methadone 4.45*** 2.82-7.01 5.15*** 3.24-8.18 5.16*** 3.23-8.22
  Cocaine 1.66*** 1.40-1.96 1.66*** 1.40-1.97 1.60*** 1.35-1.91
  Synthetic Opioids 9.15*** 7.10-11.79 10.07*** 7.76-13.09 11.02*** 8.46-14.31
  Benzodiazepines 4.37*** 3.31-5.77 4.80*** 3.60-6.39 4.85*** 3.65-6.48
Ttl # of Drugs Used
1 7.51*** 6.09-9.25 7.77*** 6.28-9.61 7.54*** 6.09-9.33
2 2.44*** 2.09-2.85 2.59*** 2.21-3.03 2.53*** 2.16-2.98
3 (ref) ref ref ref ref ref ref
IDU 1.46*** 1.28-1.68 0.45*** 1.36-1.80 1.67*** 1.44-1.92
Health Insurance Type
  Medicaid 1.70*** 1.33-2.19 1.93*** 1.50-2.49
  Medicare 0.54** 0.39-0.75 0.55** 0.40-0.76
  No insurance 1.62*** 1.33-1.95 1.73*** 1.43-2.11
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Asstistance 2.03*** 1.56-2.68 2.14*** 1.63-2.82
  Retirement/Pension 1.95*** 1.49-2.56 2.18*** 1.66-2.88
  Other Income Source 1.42* 1.13-1.78 1.43* 1.14-1.81
  No Income 0.53*** 0.42-0.67 0.68* 0.53-0.87
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 1.14* 1.01-1.29
  Rate of Indiv in Tx 0.99 0.97-1.01




Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance and 
Model 1 Model 2 Model 3 Model 4 Model 5
Table 3.11: Model Building Summary Using Listwise Deletion Sample for Util ization of MAT and Medicaid Coverage of Methadone, 
1998, N=8,311
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates




OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Methadone covered 2.38*** 2.35-2.43 2.06*** 2.02-2.09 1.45*** 1.42-1.47 1.57*** 1.53-1.59 2.69*** 2.63-2.74
Male 0.73*** 0.72-0.73 0.68*** 0.68-0.69 0.72*** 0.71-0.73 0.78*** 0.77-0.79
Race
   Black 1.09*** 1.08-1.10 1.12*** 1.10-1.13 1.03*** 1.02-1.05 1.16*** 1.15-1.18
  Other Race 1.84*** 1.82-1.87 1.62*** 1.60-1.65 1.55*** 1.53-1.59 1.48*** 1.46-1.51
  White (ref) ref ref ref ref ref ref ref ref
Hispanic 0.97*** 0.95-0.98 0.90*** 0.89-0.92 0.87*** 0.85-0.88 0.99 0.97-1.01
HS Education 0.96*** 0.95-0.96 0.93*** 0.93-0.95 0.96*** 0.95-0.97 0.93*** 0.92-0.94
Married 0.99* 0.98-1.00 1.04*** 1.03-1.05 1.12*** 1.10-1.12 1.06*** 1.05-1.08
Employed 2.12*** 2.10-2.14 2.03*** 2.01-2.05 2.83*** 2.79-2.89 1.97*** 1.94-2.01
Unstably Housed 0.48*** 0.48-0.49 0.59*** 0.58-0.60 0.59*** 0.59-0.60 0.73*** 0.72-0.74
Age
agelt24 0.30*** 0.29-0.30 0.34*** 0.34-0.35 0.38*** 0.37-0.38 0.41*** 0.40-0.42
age2534 0.45*** 0.45-0.46 0.52*** 0.51-0.52 0.53*** 0.52-0.53 0.61*** 0.60-0.62
age3544 0.64*** 0.63-0.64 0.69*** 0.68-0.70 0.70*** 0.69-0.71 0.76*** 0.76-0.77
age45ov (ref) ref ref ref ref ref ref ref ref
Rehab 0.07*** 0.07-0.07 0.07*** 0.07-0.08 0.07*** 0.07-0.07
Psych problems 0.55*** 0.55-0.56 0.58*** 0.57-0.59 0.79*** 0.78-0.80
Drug Use
  Heroin 10.18*** 9.86-10.46 9.78*** 9.52-10.11 15.03*** 14.64-15.58
  Non-rx Methadone 2.75*** 2.66-2.83 2.44*** 2.35-2.51 3.25*** 3.16-3.37
  Cocaine 2.16*** 2.13-2.19 2.16*** 2.13-2.19 2.34*** 2.31-2.37
  Synthetic Opioids 3.67*** 3.60-3.78 3.67*** 3.60-3.78 3.42*** 3.32-3.49
  Benzodiazepines 2.05*** 2.00-2.11 2.10*** 2.04-2.15 2.44*** 2.38-2.51
Ttl # of Drugs Used
1 10.18*** 9.98-10.29 9.97*** 9.85-10.16 10.38*** 10.19-10.51
2 2.83*** 2.79-2.85 2.80*** 2.77-2.84 2.92*** 2.89-2.96
3 (ref) ref ref ref ref ref ref
IDU 1.95*** 1.94-1.98 1.84*** 1.83-1.86 1.26*** 1.24-1.27
Health Insurance Type
  Medicaid 2.61*** 2.56-2.65 1.86*** 1.83-1.90
  Medicare 1.48*** 1.45-1.50 1.21*** 1.19-1.24
  No insurance 1.73*** 1.71-1.76 1.25*** 1.23-1.27
  Private Insurance (ref) ref ref ref ref
Primary Income
  Public Asstistance 1.35*** 1.33-1.38 1.05*** 1.03-1.07
  Retirement/Pension 1.63*** 1.59-1.68 1.20*** 1.17-1.23
  Other Income Source 1.07*** 1.06-1.10 0.89*** 0.87-0.90
  No Income 1.51*** 1.48-1.53 0.78*** 0.76-0.79
  Salary (ref) ref ref ref ref
State Level Variables
  Methadone Prog Rate 0.84*** 0.84-0.85
  Rate of Indiv in Tx 0.99*** 0.99-0.99




Table 3.12: Model Building Summary Using Multiple Imputation Sample for Util ization of MAT and Medicaid Coverage of 
Methadone, 1998, N=1,497,260
Model 1 Model 2 Model 3 Model 4 Model 5
Model 5: Medicaid coverage of methadone,  demographic covariates, substance use and treatment covariates, health insurance 
Model 1: Unadjusted association between Medicaid coverage of methadone and MAT use 
Model 2: Medicaid coverage of methadone and demographic covariates
Model 3: Medicaid coverage of methadone,  demographic covariates and substance use and treatment covariates
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